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Abstract  
An excessive number of calories consumed daily, in addition to a sedentary lifestyle, 
are the main causes of increasing type 2 diabetes (T2D) prevalence worldwide (LEE, 
H.K. et al., 2010). Diabetes is usually accompanied by hypertension, lipid disorders and 
obesity. The aim of this study isto show that combination exercise is effective. It will 
compare T2D and non-diabetes (ND) volunteers doing combination exercise consisting 
of resistance and cycling. The interventions are minor and fairly short consisting of 12 
episodes of exercise over 6 weeks, yet this was enough to produce measurable change 
and improvement. This included the re-categorization of two T2D volunteers to being 
ND, using normal metrics. 
Method: in each exercise session the participant should perform a combined exercise 
program consists of 30 min of resistance exercise followed by 20 min moderate 
cycling.  This is done twice a week for 6 weeks. At the beginning of each session the 
participants have to stretch-up for 11 steps of stretching, then he/she must cycle for 
five minutes to warm up.  The RE consist of 3 sets, in each set the volunteer performed 
(squat, chest, back, biceps and triceps) 10 times.  HbA1c, lipid profile, weight, BMI, 
waist and lung capacity also measured at baseline and the 12th exercise session. OGTT 
were done at the beginning, after 1st session and finally after session 12. Moreover, 
BG and HR measured before exercise, after 1st, 2ndand 3rd RE then after 10 and 20 
minutes of AE.  BP also checked before exercise after RE and then after AE. RPE were 
checked after 1st, 2nd and 3rd RE as well as after 10 and 20 minutes AE.  Blood samples 
collected at base line after these sessions (S1, S2, S4, S6, S8, S10 and S12), centrifuge 
and refrigerate the plasma to be analysed later by a commercially-available enzyme-
linked immunosorbent assay (ELISA) and by The Evidence Investigator™ Biochip Array 
technology (Randox, UK). 
Results: After just six weeks, there was a reduction in the HbA1c level for the T2D 
volunteers which is significant (P= 0.000).  Moreover, in ND the reduction was also 
significant (P= 0.000).  In T2D, the OGTT result shows that the AUC of BG for the 1st 
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OGTT was (30.55±2.5 mmol/L/h) but then decreased in the 2nd and 3rd OGTT, finally 
decreasing to (24.4±1.9 mmol/L/h). This reduction reflects a clear improvement in the 
IS in T2D. It shows that the reduction of BG in the OGTT after chronic effect of exercise 
was better than acute effect (after the first session).  Meanwhile in ND, the AUC for 
the 1st OGTT was (14.9±3.2 mmol/L/h) and although became (13.9±3.0 mmol/L/h) in 
the 2nd OGTT returned to the original in the third reading.  In the T2D group who are 
using (Metformin and SGT2-I group), their result shows elevation in GLP-1 in the 
assessment of both acute and chronic effect of the programme.  GLP-1 in this group 
was (3.9±1.5) and increased to (8.4±1.2), (P= 0.345) after S1 and then increased more 
to (11.0±0.8), (P=0.196) after 6 weeks of exercise.  
Conclusion: In T2D and ND combination exercise has a beneficial effect on HbA1c, the 
improvement was higher in T2D. The anthropometric variables (weight, waist, BMI 
and lung capacity) improved significantly as well in T2D and ND.  OGTT shows a very 
significant improvement of BG and insulin level in both groups that was higher in T2D, 
which shows that there was an improvement in insulin sensitivity.  Exercise is also 
important to improve GLP-1 secretion. Despite the range of studies on incretin 
undertaken here, still there is a need to compare the effect of exercise and different 
types of pharmacological therapy on GLP1.  This study compared the effect of exercise 
on T2D plus medication in volunteers. It has been found that within T2D group only 
Metformin and SGT2-I group was improved.  Both SGLT2 inhibitors and metformin 
have been found to affect body weight and this may explain the improvement of GLP-
1 level, suggesting an area for future investigation. Finally, exercise has different effect 
on the inflammatory markers, it shows elevation of IL-6 in T2D after 6 weeks of 
exercise.  CRP represent significant reduction after 6 weeks as well which illustrates 
that exercise has good impact in decreasing inflammation by reducing CRP.   
Moreover, there is a little published data on the effect of exercise and medication type 
on the inflammatory markers.  The present study illustrates a significant reduction in 
Cystatin C after 6 weeks within T2D group who are using (metformin and DDP4-I).  
Therefore, there is increasing concern that some medication plus exercise improve 
inflammatory markers which need further investigations.   
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Chapter 1 
1.1 Introduction 
 
Diabetes mellitus (DM) is a chronic disease characterized by chronic persistent 
hyperglycaemia (Goyal and Jialal, 2018). This hyperglycaemia accompanied with 
metabolic disorder leads to organ damage and serious complications. Type 2 diabetes 
(T2D) is a global epidemic which has increased with increasing obesity and sedentary 
life style (Goyal and Jialal, 2018).  Diabetes is usually accompanied by hypertension, 
lipid disorders and obesity. Recent studies show that a reduction in HbA1c cause 35% 
relative risk reduction for fatal/nonfatal cardiovascular disease.  Also 56% reduction 
in CVD when this reduction of HbA1c is accompanied with systolic blood pressure 
(SBP) decrease (Eeg-Olofsson et al., 2016). Moreover, 75% reduction in CVD if 
reduction of HbA1c and SBP accompanied with decrease in non-HDL level (Eeg-
Olofsson et al., 2016). Cardiovascular complications are the leading cause of morbidity 
and mortality between patients with T2D. Asian had the highest prevalence with 
kidney complications among T2D subjects (Zheng, Ley and Hu, 2018). T2D is 
considered as a serious disease, which needs immediate intervention.  This 
intervention depends on the severity of the case.  It could be either diet and exercise 
or pharmacological intervention by using oral anti-diabetic medication to control 
blood glucose levels within normal levels. It is necessary to check routinely to discover 
T2D at an early stage because identification and early treatment can prevent or 
ameliorate further complications in pre-diabetes, diabetes or metabolic disorder.  Diet 
and exercise can potentially prevent the development of T2D of many of those at risk 
or in early stages (Diabetes UK, 2018). 
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1.1.1 Research questions  
1- Are there demonstrable health differences and improvement in HbA1c after 
the six weeks exercise intervention between groups that can be attributed to 
the intervention? 
2- Does exercise improve insulin sensitivity? Do the improvements correlate 
with medication type?  
3- Does the improvement affect incretin involvement? Do the improvements 
correlate with medication type? 
4- Does exercise change the inflammatory nature of T2D? Do the improvements 
correlate with medication type? 
 
1.1.2 Aims 
The aim of the study is to investigate the effects of a combined exercise programme 
(i.e. a combination of cardio “aerobic” and resistance) on blood glucose, incretin, 
metabolic and inflammatory mediators that could control the diabetes and increase 
insulin sensitivity in T2D. The aim of this study also is to demonstrate that combination 
exercise is essential for T2D.  Moreover, it is going to compare two intervention groups 
of both T2D and ND to see if the changes in primary and secondary outcome are 
significant between the two groups.  This study is also looking for the changes in 
incretin level within T2D group to find if there is any effect of exercise on the secretion 
of this hormone. Moreover, to state the effect of different medication on this 
hormone.  
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1.1.3 Objectives 
1- Starting recruit volunteers.  
2- Apply for ethical approval.  
3- Organise for screening visit, take medical histories and decide the inclusion and 
exclusion criteria.  
4- Search to understand the insulin and oral agent medication efficacy: becoming a 
diabetes educator.  
5- Arrange to have training to learn first aid, phlebotomy, defibrillation techniques, 
oxygen administration, adrenaline administration.  
6- Prepare for visits to diabetology group to participate in clinical and academic 
discussions relating to both types of diabetes.  
7- Ensure to train for oral glucose tolerance tests (OGTT) and measuring HbA1c, 
incretin, and inflammatory mediator (using RANDOX and ELISA machine).  
8- Record metabolic parameters.  
The following section presents critically evaluated literature that relates to the field of 
study. The information is extracted from previous research studies that give useful 
information and insight on the topic of study.   A literature search was conducted by 
using electronic databases (Science direct, google scholar, Medline, Embase, Sport 
medicine, PubMed, CINAHL, Cochrane library, and Scopus) from April 2015 until 
January 2019.  This thesis will be organised in various sections under the chapters. The 
first chapter will contain introduction, the researcher will provide a background 
information on the prevalence of diabetes mellitus, NHS and global health 
expenditures, definitions, classification of diabetes diagnosis, symptoms of diabetes 
mellitus, complications, management of T2D as the main areas of chapter one.  In 
chapter two, the researcher will focus on metabolism, the thesis will focus on 
carbohydrate, fat and protein metabolism.  As well as the physiology of insulin 
production.  Chapter three is the methodology then chapter 4, 5 ,6 and 7 are is the 
main exercise programme but each one has different findings and different analysis 
and has different research questions, aim and literature review. 
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1.2 The prevalence of diabetes mellitus 
According to the International Diabetes Federation (IDF), it is estimated that globally 
more than 415 (8.4%) million people have diabetes (Einarson et al., 2018). The 
incidence of diabetes is increasing rapidly and that number is expected to increase to 
more than 642 million by 2040 (Monje, Catena and Borgnakke, 2017; Diabetes UK, 
2018).  Approximately, 90% of diabetes worldwide have T2D.  The percentage of 
individuals who have been diagnosed with T2D in the UK is approximately more than 
2.7 million, but 750,000 individuals have the symptoms but remain undiagnosed 
(Diabetes UK, 2018). T2D is a global disease, but is more common in developed 
countries. In the future, its prevalence is expected to increase in Africa, Asia, and the 
Middle East.  It is expected to increase in those countries by an estimated 50% by 2030 
(Forbes and Cooper, 2013). Globally, T2D prevalence is 90% (Zheng, Ley and Hu, 2018). 
Countries in Asia such as China and India are examples where T2D is most prevalent. 
Common risks associated with the diagnosis of T2D in such countries is genetics 
factors, unhealthy eating combined by a lack of exercise (Zheng, Ley and Hu, 2018).   
Stevens et al, found that T2D is accompanied by decrease quality of life and a 
reduction in life expectancy up to 10 years (Stevens et al., 2015). According to Aguiree 
et al., (2013) in the countries with high-income, the prevalence of people with T2D is 
about (87% to 91%), while in type 1 diabetes is (7% to 12%), and finally the prevalence 
of other types of diabetes is (1% to 3%)(Aguiree et al., 2013). 
1.3 NHS and global health spends 
In the UK, diabetes cost approximately 10% of UK NHS health expenditure, and it 
expected to rise to 17% by 2035/2036. The cost of diabetes to the NHS is over (£1.5m) 
an hour or 10% of the NHS budget for England and Wales, or more than £25,000 every 
minute on diabetes (Diabetes UK, 2018). Annually, the estimated number that spent 
on treating diabetes and its complications is £14 billion (Diabetes UK, 2018). 
Global health spends on diabetes and its complications were costed as at least £411 
billion in 2013. By 2035, the estimated number could exceed USD 627 billion (Aguiree 
et al., 2013).  
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 1.4 Definitions 
1.4.1 Diabetes mellitus 
Diabetes mellitus is a metabolic disorder of various aetiologies accompanied with 
disturbances of carbohydrate, fat and protein metabolism as well as chronic 
hyperglycaemia (elevated blood glucose).  The condition is due to defects in the 
secretion of insulin, insulin action, or both (Ozougwu et al., 2013; Kharroubi and 
Darwish, 2015; American Diabetes Association, 2018).  Diabetes is a condition in which 
glucose in the blood rises to higher levels than the normal range (4-8mmol/L).  
1.4.2 Type 2 diabetes mellitus 
T2D is a progressive metabolic disorder characterised by hyperglycaemia (Goyal and 
Jialal, 2018).   That can be due to insulin resistance (IR) in peripheral tissues, deficiency 
of insulin secretion in the pancreas (Goyal and Jialal, 2018; Kerner and Brückel, 2014; 
American Diabetes Association, 2018). This form of diabetes is not usually rapidly fatal 
because usually some endogenous insulin is still being produced by the pancreas 
(Goyal and Jialal, 2018; Kerner and Brückel, 2014).  
1.4.3 Type 1 diabetes mellitus (T1D) 
T1D specifies the progression of beta-cell destruction, which finally causes diabetes 
mellitus (Bornstein, 2018).  In this kind of diabetes, there is absolute insulin deficiency 
thus exogenous insulin is essential for survival, to prevent the development of 
ketoacidosis, coma and death. T1D occur due to autoimmune processes that lead to 
beta-cell destruction.  This accompanied with the existence of anti-GAD, islet cell or 
insulin antibodies (Kerner and Brückel, 2014; American Diabetes Association, 2018). 
1.4.4 Haemoglobin A1c (HbA1c)  
HbA1c is presenting the plasma glucose concentration over the last two to three 
months and used mmol/mol or percentage to measure it (Vijayakumar et al., 2017; 
Goyal and Jialal, 2018). 
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1.4.5 Metabolic Syndrome 
Metabolic syndrome is the term for some risk factors for both coronary heart disease 
(CHD) and T2D.  If the patient has three or more of five metabolic risk factors, they are 
considered to have metabolic syndrome (Rył et al., 2015). These risk factors are the 
following: 
a- Obesity, if the waist measurement ≥ 35 inches for women and ≥ 40 inches for 
men. 
b-  High level of triglyceride (TG). 
c- Low level of HDL cholesterol level.  
d- High blood pressure (hypertension) 
e- High level of fasting blood glucose (diabetes mellitus). 
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1.5 Classification of diabetes   
Diabetes has been classified into the following categories (Monje, Catena and 
Borgnakke, 2017; Kerner and Brückel, 2014; ADA, 2016; Goyal and Jialal, 2018): 
1. T1D. 
2. T2D. 
3. LADA (latent autoimmune diabetes in adults) is classified as type 1 diabetes. 
4. Maturity-onset diabetes of the young (MODY) 
5. Gestational diabetes. 
6. Diabetes associated with causative clinical states, diseases, drugs and/or chemicals. 
 
1.5.1 Type 1 diabetes mellitus (IDDM)  
Millions of people worldwide have been affected by T1D, which is also known as 
insulin-dependent diabetes mellitus (IDDM) and its prevalence (5-10%) of diabetes 
subjects (American Diabetes Association, 2018; Goyal and Jialal, 2018).  In this 
condition, T cell-mediated destruction of β cells in the islets of Langerhans causes 
absolute insulin deficiency, but the reason for this auto-immune destruction is not 
fully understood (American Diabetes Association, 2018; Mustonen et al., 2018; Wang 
et al., 2017; Bornstein, 2018).  It has been found that there are high levels of T cells in 
T1D accompanied with a decline in C-peptide levels (Linsley et al., 2018). This leads to 
a total lack of insulin secretion from the pancreas, causing catastrophic 
hyperglycaemia, resulting in a disturbance in the metabolism of carbohydrate, fat and 
protein, that also produces ketones leading to ketoacidosis which is rapidly fatal if 
untreated (American Diabetes Association, 2018).  This β cell destruction occurs 
rapidly in children and adolescent while it is slow in adult (American Diabetes 
Association, 2014; Goyal and Jialal, 2018).  T1D is common in adolescence and 
childhood but it can happen as well in adult even in the 80th and 90th decades of life 
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which called (LADA) (American Diabetes Association, 2018). T1D is due to genes and 
environmental factors such as viruses nevertheless, recent studies have proved that 
less hygiene correlate to incidence of autoimmune disease (Bornstein, 2018). 
 
1.5.2 Key features of T1D 
According to American Diabetes Association, (2018): 
 Treatment with insulin is essential throughout the patient’s lifetime. 
 It entails beta cell destruction, which causes complete insulin 
deficiency and lack of plasma C-peptide. 
 Patients are predisposed to ketosis. 
 Usually, the onset of the disease is acute.  
 Peak onset time is at pre-school age (4-6 years) and around puberty 
(10-14 years); however, it can occur at any age. 
 Presence of specific autoantibodies. 
  
1.5.3 Environmental factors 
Numerous environmental factors which might be aetiological and/or pathogenic in 
T1D (Wang et al., 2017; Katsarou et al., 2017). The exposure to some environmental 
factors for long periods of time causes certain variation in genes, this genetic 
predisposition is linked to the human leukocyte antigen (HLA) genes which produce 
protein that play a crucial role in immune system regulation (Adi and Gerard-Gonzalez, 
2018).  Another factors are thought to contribute to the development of T1D, and may 
comprise one or more triggers such as multivitamins deficiency especially in neonates 
who were not breast feed, vitamin D deficiency, and viral or microbial infections 
(Wang et al., 2017; Katsarou et al., 2017; Adi and Gerard-Gonzalez, 2018).  In humans, 
evidence shows that there is a higher rate of onset of the disease reported in the 
winter, while the lower rate reported at the end of spring and summer (Scobie and 
Samaras, 2012).   Basically, the presence of β-cell-directed autoantibodies associated 
with HLA alleles is the best predictor to diagnose T1D (Adi and Gerard-Gonzalez, 2018).  
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1.5.4 Pathogenesis 
It has been found that in T1D, most of the cases had an immunological association to 
disease pathogenesis (Adi and Gerard-Gonzalez, 2018).   Not all patients with T1D have 
these features (Atkinson, Eisenbarth and Michels, 2014).  There are two kinds of T1D; 
type 1A occurs due to a cell-mediated autoimmune attack on β cells (autoimmune) 
diabetes.  Some (85–95%) of patients with T1D have type 1A which show positive 
antibodies (Adi and Gerard-Gonzalez, 2018).  Type 1B (idiopathic) diabetes with no 
antibodies which have unknown etiology (Atkinson, Eisenbarth and Michels, 2014; 
American Diabetes Association, 2018; Adi and Gerard-Gonzalez, 2018). 
1.5.5 Type 2 diabetes (T2D)    
The prevalence of T2D is very high worldwide (DeFronzo et al., 2015; Goyal and Jialal, 
2018).  This type is a multifactorial disease characterised by IR, relative insulin 
deficiency and advanced beta cell deterioration, which affects insulin secretion 
(Christensen et al., 2014; DeFronzo et al., 2015; Goyal and Jialal, 2018).  T2D is a 
condition that is normally characterised by the body failing to use the available insulin, 
as produced in the pancreas (Christensen et al., 2014; DeFronzo et al., 2015). These 
pathophysiological defects cause an imbalance between the rate of glucose 
production and its disposal. The rise in the former and decline in the latter leads to 
hyperglycaemia. This is caused by a condition called IR which is due to a reduction of 
glucose disposal by peripheral tissues, mainly muscles and increased production of 
hepatic glucose (Meah and Juneja, 2015).  During the initial stages of diabetes, the 
pancreas produces extra insulin in an attempt to utilize glucose.  However, over time, 
the pancreas fails to generate sufficient insulin to keep the blood glucose at the 
recommended levels (Christensen et al., 2014; DeFronzo et al., 2015).  As such, the 
individual suffers T2D because of a lack of adequate levels of insulin. Alternatively, it 
may sometimes result from the failure of the body’s cells to react to insulin. This 
persuades the glucose to remain in the blood without being used as a source of fuel 
for the production of energy (Christensen et al., 2014; DeFronzo et al., 2015; Samour 
and King, 2012). The Insulin signalling pathway: food is consumed, the food is then 
digested in the stomach, and finally the small intestine will subsequently release 
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glucose which is transported through the blood circulation. Out of the five types of 
specific protein called glucose transporters “GLUT”, the GLUT-4 protein is considered 
the most insulin-sensitive and it is known as the insulin dependent glucose transporter 
which uptakes glucose only into the skeletal muscle and adipose tissue in cases of 
normal insulin secretion (Mann and Bellin, 2016; Codario, 2011).  Other transporters 
such as GLUT1, GLUT2 and GLUT3 are known as insulin independent glucose 
transporters, which can be found in vital organs such as pancreatic β cells, kidneys, 
brain, red blood cells (RBC) and placenta.  Therefore, GLUT2 in b cells permits glucose 
to be transported within β cells to stimulate the secretion of insulin (Mann and Bellin, 
2016). 
This pathway usually starts by a simple mechanism called simple glucose-stimulated 
insulin secretion (GSIS) where glucose is transported into the β cell and then 
metabolised to release ATP.  The ATP triggers a cascade of signals in the β cell which 
is important for glucose to stimulate insulin production. GLUT1 and GLUT3 have been 
found in recent studies to have played an essential role in β cells like GLUT2 which 
show that any mutation in the gene encoding GLUT2 does not cause a defect in the 
production of insulin (Mann and Bellin, 2016).  After food ingestion, glucose is 
transported to the β cell and converted via hormone glucokinase to glucose 6 
phosphate (G6P).  This hormone is called glucose sensor in the β cell.  In the 
mitochondria, ATP are produced via the Krebs cycle as a result of metabolised G6P. 
The ATP then binds to and closes the ATP-dependent potassium channel which 
prevents the potassium to quit the β cell and this process is called cell membrane 
depolarisation.  This depolarisation triggers voltage-gated calcium channels which 
elevate calcium influx and increase intracellular calcium concentration.  The high level 
of calcium in the cytoplasm stimulates insulin and C-peptide production (Mann and 
Bellin, 2016). This GSIS is also augmented by amino acid (AA), free fatty acid (FFA) and 
glucagon-like peptide-1(GLP-1). Insulin secretion can be stimulated also when some 
AA enters the Krebs cycle and acts as a substrate to convert G6P to then generate ATP.  
ATP then does the same process of depolarising the β cell membrane to stimulate 
insulin secretion (Mann and Bellin, 2016) . The pathway of how FFA stimulates insulin 
secretion is still unclear.  The basal insulin secretion increased along with the chronic 
elevation of FFA however this prevents the bolus insulin secretion (GSIS).  High levels 
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of lipolysis in adipose tissue elevates FFA in the circulation and causes IR and T2D 
(Mann and Bellin, 2016).   Furthermore, the pancreas stimulates insulin secretion in 
the blood stream to enhance glucose clearance from the blood stream (Mann and 
Bellin, 2016; Saltiel and Kahn, 2001).  Insulin has three target cells, skeletal muscle, 
liver and adipose tissues and each cell has insulin receptors to enable insulin to enter 
inside the cell and trigger glucose transporters e.g. GLUT4 (in the skeletal muscle and 
adipose tissue) and GLUT2 (in the liver) (Mann and Bellin, 2016; Jaldin-Fincati et al., 
2017).  Insulin-induced GLUT4 translocation from intracellular to the cell membrane 
has been found in the early 1980s (see figure 1) (Thorens and Mueckler, 2009).  The 
GLUT4 proteins are stored in intracellular vesicles of skeletal muscle and adipose 
tissue and then transferred to the cell surface in the plasma membrane as 
translocation of GLUT4 to the cell surface (Codario, 2011).  
The role of these transporters is to transport glucose on the cell membrane from the 
outside to the inside of cells to store it or use it as energy for different body functions.  
In adipose tissue, insulin stimulates glucose storage as TG and inhibits lipid breakdown 
(lipolysis).  Moreover, in the skeletal muscle and liver, insulin stimulates storage of 
glucose as glycogen, insulin stimulates protein synthesis. All these cascade to 
normalise blood glucose, however, in T2D there are some defects in this process 
starting in failure of IR which lead to hyperglycaemia (Mann and Bellin, 2016; Saltiel 
and Kahn, 2001).  In T2D, skeletal muscle cells in IR subjects are characterized by a 
lower ability to utilise extracellular glucose. The level of GLUT4 becomes low in those 
subjects, because of the impairment in their translocation to the membrane.  This is 
due to either an insulin signalling mechanism impairment or due to an accumulation 
of GLUT4 in the membrane (Navale and Paranjape, 2016).  This defect affects the 
pathway between the transporter (GLUT4) and the receptor before enhancing the 
glucose entering the cell, which causes IR (Mann and Bellin, 2016).  
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Figure 1: effect of insulin on glucose uptake 
 
There are three counter-regulatory hormones which help the body when it suffers 
from hypoglycaemia. These hormones are glucagon, adrenaline and cortisol.  
Glucagon stimulates hepatic glucose production via glycogenolysis or by production 
of glucose from AA and glycerol via gluconeogenesis (Mann and Bellin, 2016).  It also 
stimulates lipolysis and the carrying of FFA to the liver. Cortisol enhances the 
catabolism of protein to the AA which acts as a substrate for gluconeogenesis and 
impaired glucose uptake by insulin. Moreover, adrenaline inhibits insulin secretion 
directly, enhancing glycogenolysis, adipocytes lipolysis and IR (Mann and Bellin, 2016).   
In addition, the defects in incretin hormones lead to a reduction in the postprandial 
insulin release by the beta cells, as well as increased production of glucagon by the 
alpha cells (Garduno-Garcia et al., 2018; Michaliszyn et al., 2014).   Additionally, the 
renal tubular reabsorption of glucose is increased as a result of upregulation of sodium 
glucose co-transporters-2 (SGLTs-2) and a β-cell deficiency. All these factors cause 
fatigue in β-cells because of their huge workload, indicating that insulin therapy may 
be necessary for longstanding T2D (Meah and Juneja, 2015).  Recently, the effect of 
incretin has attracted a great deal of attention. In humans, the main incretin hormones 
are glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide 
(GIP) (Nauck and Meier, 2016; Fava, Dong and Wu, 2016).  Both hormones enhance 
glucose-dependent insulin secretion and are quickly deactivated by dipeptidyl 
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peptidase-4 (DPP-4); however, only GLP-1 minimises glucagon secretion (Nauck and 
Meier, 2016; Fava, Dong and Wu, 2016).  The incretins have a direct effect on the 
satiety centre, which suppresses appetite, delays gastric emptying and causes an 
increase in beta cell neogenesis as well as inhibit apoptosis. These two hormones are 
secreted from the intestinal cells in response to food intake. GLP-1 is synthesised from 
proglucagon in the l-cells of the small intestine and GIP in the k-cells of the proximal 
intestinal mucosa (Nauck and Meier, 2016; Fava, Dong and Wu, 2016).  GLP-1 levels 
are decreased in T2D patients but still they can react with this hormone (Rhee et al., 
2014; Nauck and Meier, 2016).  
By administration of exogenous GLP-1, glycaemic control can be achieved, it has an 
advantage in reducing body weight (Nino et al., 2017; Htike et al., 2017). T2D suffer 
from extreme production of hepatic glucose, although they have a high level of insulin 
(Okamoto et al., 2017). In these individuals, insulin resistance is characterised by 
increased hepatic glucose production and fasting hyperinsulinemia. It is clear that in 
T2D, the ability of insulin to suppress hepatic glucose production is minimised 
(Okamoto et al., 2017). Accordingly, inappropriate insulin secretion or the inability of 
insulin receptors to effectively respond to insulin, leads to impaired glucose 
homeostasis and T2D (Page and Johnson, 2018). Risk factors for the development of 
T2D include sedentary lifestyle, family history, obesity, high waist circumference, 
history of gestational diabetes in women, being older than 40 years and ethnicity, such 
as being of South Asian, African-Caribbean or black African descent (Stevens et al., 
2015).  
 
1.5.6 Causes of type 2 diabetes  
The pancreas is a large complex gland that is found behind the stomach, and consists 
of α, β, δ cells (Mann and Bellin, 2016; Thomas and Philipson, 2015).  The role of β cell 
in the body is to produce insulin, which transfers the glucose that is available in the 
blood to recipient cells, so that it can be used as energy in the body (Mann and Bellin, 
2016; Thomas and Philipson, 2015).  While α cells role is to produce glucagon which 
release glucose in case of hypoglycaemia.  
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According to Schwartz, et al (2016), all types of diabetes are created from defects in 
the β cell in the pancreas. This β cell impairment affects insulin production.  In this 
theory, IR only represents a primary deficiency in insulin production as well as 
approximately third this people are going to have diabetes in the future (Schwartz, et 
al, 2016).   
There are several causes of such failure, which are referred to as risk factors.  One of 
the risk factors for T2D is age. Researchers have shown that people aged 45 or older 
stand a higher chance of developing diabetes conditions. However, this age drops to 
25 in the case of Asians (Jones et al., 2012). Genetic factors also play a critical role in 
the acquisition of T2D. Studies have proven that the condition is genetically inherited; 
as such, people who have close relatives with the condition are at greater risk (Jones 
et al., 2012). Overweight and obesity also magnify the chances of contracting the 
disease (Martin-Timon et al., 2014; Hsu et al., 2015).  It is therefore advisable for 
Asians to maintain body weight within the recommended range of BMI (18.5 to 24.9 
kg/m2) by undertaking regular exercise and observing a healthy diet and lifestyle 
(Jones et al., 2012). Finally, ethnicity is a risk factor; past studies have shown that 
individuals whose origin is south Asian, black African, African-Caribbean or Chinese 
may be more likely to developed T2D (Watt et al., 2018; Diabetes UK, 2018; Ogurtsova 
et al., 2017).   
 
1.5.7 Key features of T2D  
According to (American Diabetes Association, 2016), the key features of T2D are: 
 Insulin resistance (associated with obesity); relative insulin deficiency. 
 Slow development of hyperglycaemia. 
 Risk factors: obesity, age, ethnicity, unhealthy diet, smoking and 
physical activity. 
 Cardiovascular risk factors: hypertension, dyslipidaemia and glucose 
intolerance. 
 Gestational DM. 
 Stronger genetic correlation than T1D. 
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 Strong association with CVD. 
 Risk of heart failure that is two to three times higher than in people 
without diabetes. 
 Risk of cerebrovascular disease; patients are three times more likely 
to suffer a stroke. 
 Risk of diabetic nephropathy, neuropathy, and retinopathy. 
1.5.8 Some factors associated with developing T2D 
Some factors associated with developing T2D (Kerner and Brückel, 2014; American 
Diabetes Association, 2018): 
1. Genetic syndromes: muscular dystrophy and lipodystrophic disease. 
2. Pancreatic diseases: chronic pancreatitis, post pancreatectomy and cystic fibrosis. 
3. Endocrinopathies: primary aldosteronism, Cushing syndrome, acromegaly, 
pheochromocytoma, glucagonoma and polycystic ovaries.  
4. Medication: such as thiazide diuretics, beta-blockers, glucocorticoids, phenytoin, 
nicotinic acid, catecholamines, tacrolimus, oestrogen, progesterone and 
antidepressants, especially clozapine, olanzapine and risperidone.  
5. U.S. regulators have shown that six anti-psychotic medications can increase the risk 
of impaired glucose tolerance (IGT) and diabetes: 
a. Zyprexa (olanzapine) 
 b. Risperdal (risperidone) 
c. Clozaril (clozapine) 
d. Seroquel (quetiapine) 
5. Geodon (ziprasidone) 
e. Abilify (aripiprazol) 
6. Chemicals: Tetrachlorodibenzoparadioxin. 
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1.5.10 Gestational diabetes mellitus (GDM) 
This type of diabetes is when high blood glucose is discovered at any time during 
pregnancy and is categorised as GDM (Baz, Riveline and Gautier, 2016; Goyal and 
Jialal, 2018).  Generally, gestational diabetes occurs at 24 - 28 weeks of pregnancy 
(ADA, 2016).  During pregnancy, GDM women have a sevenfold risk of developing T2D 
for several years compared to with normal glucose tolerance (NGT) women (Baz, 
Riveline and Gautier, 2016).  It has been found that higher than 25% of women with 
GDM could have T2D in future as they developed insulin resistance before and after 
pregnancy (Baz, Riveline and Gautier, 2016; Goyal and Jialal, 2018).   
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1.6 T2D, obesity and inflammatory markers 
The progression of T2D usually preceded by large vessel atherosclerosis (Esser et al., 
2014). Both disorders are linked to abdominal obesity and the insulin-resistance 
syndrome (IRS). The IRS involves hyperinsulinemia, glucose intolerance, hypertension 
and dyslipidaemia (high triglyceride and low high-density lipoprotein [HDL]) which are 
together known as metabolic syndrome (Feijóo-Bandín et al., 2016; Esser et al., 2014). 
The pathogenesis of obesity-related IR and T2D involves the activation of the immune 
system and a chronic inflammation process. Inflammatory markers are considered as 
risk factors for the progress of T2D and its macrovascular complications (Esser et al., 
2014). In case of obesity, liver, muscle, pancreas and adipose tissue are all sites of 
inflammation. It has been considered that T2D is an inflammatory disease (Esser et al., 
2014).  Thus, in the management of T2D the anti-inflammatory therapies might play 
important role in the prevention of the disease (Esser et al., 2014). Chapter 8 shows 
more information about inflammatory markers.  
 
1.7 Glycosylated proteins (AGE products, and their receptors RAGE) 
AGE is defined as Advanced Glycation End-products while RAGE is defined as the 
Receptor of Advanced Glycation End-products. The hypothesis of AGE formation, 
suggests that glucose binds to chemically sensitive amino acid protein which 
accelerate chemical modification of this proteins to form AGE during hyperglycaemia 
which contributes to the pathogenesis of diabetic complications such as 
atherosclerosis, nephropathy, neuropathy and retinopathy (Singh et al., 2014; 
Yamagishi, Fukami and Matsui, 2015).    RAGE can be produced in most of the body 
cells to induce inflammation.  The RAGE pathway cooperates with cytokines, 
lipopolysaccharides, oxidised low-density lipoprotein (LDL), and glucose activated 
cellular response.   RAGE facilitated persistent cell stimulation is crucial in diabetes 
and its complications, tumour growth, autoimmune and infectious inflammatory 
diseases (Singh et al., 2014).  The creation of advanced glycation end-products (AGEs) 
is associated with failure in glycaemic control.  In renal failure patients, chronic 
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inflammation will elevate oxidative stress (OS) level which will cause rapid AGE 
formation and the kidney unable to eliminate it (Singh et al., 2014).  Anti-AGE policies 
may have a key role in the treatment of diabetic patients. Numerous of possible drug 
candidates such as AGE inhibitors have been stated recently (Saleh, 2015). There is 
evidence to show in diabetes that glycation of haemoglobin and production of Hb-AGE 
stimulate cellular OS to release potent oxidants. This causes oxidative damage to 
endothelial cell and produces inflammatory response. These inflammatory mediators 
play crucial role in the progression of atherogenesis and the diabetic vascular 
complications (Saleh, 2015). High production of AGEs has a crucial role and underlies 
the pathophysiology of chronic diabetic complications (Piperi et al., 2015). AGEs in the 
mitochondrial cause production of high amount of reactive oxygen species (ROS).  The 
AGEs are responsible for activating the RAGE. The latter has a negative effect of 
damaging intracellular cells and increasing the level of cytosolic ROS. Also, it activates 
the nuclear factor kappaB (NF-Κb), increases the level of cytokines and stimulates the 
endoplasmic reticulum to cause oxidative stress (Piperi et al. 2015; Pinto-Junior et al. 
2018). Recent findings have demonstrated a link between regulating AGE/RAGE and 
microRNAs in complicated micro and macrovascular complications for persons 
suffering from diabetes.  These studies argued the rule of miRNAs as novel therapeutic 
agents in the complications of diabetes (Piperi et al., 2015). Moreover, AGEs IR by 
decreasing content of GLUT-4 protein (Pinto-Junior et al., 2018). 
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1.8 Diagnosis 
It is very important to do routine checks for blood sugar, blood pressure, and lipid in 
those patients who are at high risk of developing diabetes.  The earlier patients are 
diagnosed, the greater the information will help in managing diabetes properly and 
avoid complications. If impaired fasting glucose (IFG) or impaired glucose tolerance 
(IGT) is discovered early, this could help in diabetic onset delay or prevention 
(Christensen B et al., 2014). Impaired fasting glucose (IFG) or impaired glucose 
tolerance (IGT) are the cases when the blood glucose level is higher than normal but 
still not reach the level of T2D.  Individuals with IFG or IGT (see table 1) are known as 
pre-diabetic, and they have a high risk to develop T2D. In people with IFG or IGT, it is 
valuable to have pharmacological and lifestyle interventions to minimize the risk of 
progression to T2D. Lifestyle interventions is also beneficial in preventing other 
chronic disease not only T2D (Stevens et al., 2015). During the last decade, the diabetic 
diagnostic tests have been improved.  Table 1 demonstrates the diagnostic criteria 
according to the American Diabetes Association (ADA) (Vijayakumar et al., 2017): 
 Fasting glucose ≥ 7.0 mmol/L (126 mg/dL) is generally diagnostic of diabetes 
mellitus.  
 2h Post oral glucose tolerance test (OGTT) ≥200 mg/dL (11.1 mmol/L). 
 HbA1c ≥6.5% (48 mmol/mol). 
 
Prediabetes was defined as HbA1c levels between 5.7 and 6.4%, FPG (100 - 125 
mg/dL), or 2h post OGTT (140 - 199 mg/dL) according to American Diabetes 
Association (ADA) criteria (Vijayakumar et al., 2017).  
 Normal Pre diabetes Diabetes  
 
HbA1c < 5.7% 
< 39 mmol/mol 
 
5.7 % -6.4% 
(39-46 mmol/mol) 
 ≥ 6.5% 
≥ 48 mmol/mol 
FBG 3.9- 5.5 mmol/l 
(70-100mg/dl) 
 5.6-6.9mmol/l (100-
125mg/dl) 
> 7.0 mmol/l (≥126 mg/dL) 
Table 1: HbA1c and FBG levels. 
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1.8.1 Impaired fasting glucose 
If the fasting glucose level is between 5.6 and 6.9 mmol/L (100– 125 mg/dL), this is 
considered as prediabetic and needs an OGTT to confirm that (Vijayakumar et al., 
2017). 
1.8.2 Oral glucose tolerance testing (OGTT) 
ADA states that, in those patients who are at risk, glucose tolerance should be checked 
if the level of glucose cannot be detected by other diagnostic tests.  An oral glucose 
tolerance test is made up of two blood tests. The first blood test is a fasting blood 
sample, after which 75 g of oral glucose solution is given as a drink, and then a further 
blood sample is taken after 2 hours to measure glucose level (American Diabetes 
Association, 2018;Christensen B et al., 2014).  
 
 
 
Normal Pre diabetes Diabetes  
 
BG < 7.8 mmol/L (140 
mg/dL) 
 7.8- 11.0 mmol/L  
(140-199 mg/dl) 
≥ 11.1 mmol/L  
(200 mg/dL)  
Table 2 Glucose level 2h post OGTT for ND, Pre-diabetes and T2D. 
  
This test is very important in high risk patients to discover diabetes at an early stage.   
In women with impaired fasting glucose, GTT is the test of choice. ADA 
recommendation is that tests should be repeated on a different day to confirm the 
result (ADA, 2016).   
1.8.3 Glycated haemoglobin levels (HbA1c) 
 HbA1c measures the quantity of glucose that is being carried by the haemoglobin in 
the body (Vijayakumar et al., 2017; Goyal and Jialal, 2018). The HbA1c measures the 
blood glucose levels for the previous two to three months. The latest recommendation 
ADA, is that the glycated haemoglobin HbA1c in a patient with diabetes is > 6.5 % (48 
mmol/mol).  A value of less than 6.5% (48 mmol/mol) does not exclude diabetes 
diagnosed using other glucose tests (see table 1) (Vijayakumar et al., 2017).  
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1.9 Symptoms of diabetes mellitus 
 
Table 3 summarises the symptoms of diabetes and the cause behind these 
symptoms according to ADA.  
 
Table 3: Symptoms of DM (American Diabetes Association, 2018) 
Symptoms  Due to 
Polyuria Osmotic diuresis associated with clearance 
of glucose from blood. 
Polydipsia Water loss from polyuria. 
Tiredness/lethargy Reduced ability to utilise glucose 
Weight loss Breakdown of protein & fat as alternative 
energy source. 
Genital itching Local effect of glucose that excreted in the 
urine. 
Blurred vision. Change of shape of lens due to 
hyperglycemia.  
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1.9 Complications 
Acute complications of T1D are hyperglycaemic hyperosmolar nonketotic coma, 
Ketoacidosis, and hypoglycaemia which is rare in T2D (Tiwari, 2013).  Chronic 
complications are divided into microvascular and macrovascular disorders, which 
increase morbidity and mortality of the disease (Siersma et al., 2017; Li et al., 2018; 
Goyal and Jialal, 2018). 
 In insulin-sensitive tissues such as liver, muscle, and heart, high fatty-acid flux leads 
to oxidative damage, while in noninsulin-sensitive tissues such as kidney, eye, and 
nervous system are affected by high level of blood glucose and fatty acid levels which 
resulted in ROS-induced diabetic complications (Tiwari, 2013; Sharma, 2015; Hecker 
and Wagner, 2017).  
 
Table 4:  Chronic complications 
Macrovascular Microvascular 
Atherosclerotic diseases Nephropathy  
Ischemic heart disease  Neuropathy  
Stroke Retinopathy 
Peripheral Vascular Disease PVD 
 
 
Protein glycation and production of advanced glycation end products (AGEs) play a 
significant role in the diabetic complications as explained above in section (1.7) as well 
as some other diseases like osteoporosis, aging and rheumatoid arthritis (Singh et al., 
2014). During diabetes and inflammation, RAGE, the development of receptors is 
enhanced in certain cells.  When AGEs and RAGE Interact on macrophages, this causes 
OS (explained more lately in section 5.3) (Singh et al., 2014). Microvascular and 
macrovascular are common in both T1D and T2D patients. Some of microvascular 
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complications are blindness, kidney disease, and gangrenous ischemia changes 
causing amputations (Gedebjerg et al., 2018; Kuniss et al., 2018). According to the 
quality report 2016, the prevalence of long-term complications in T2D subjects are: 
24.2% neuropathy, 0.7% amputation, 8.2% retinopathy, 0.4% blindness, 12.5% 
nephropathy and 0.6% dialysis (Kuniss et al., 2018).  Diabetes complications presented 
in one-third of recently diagnosed T2D patients (Gedebjerg et al., 2018). 
1.9.1 Microvascular complications  
 1.9.1.1 Diabetic nephropathy  
Diabetic nephropathy is a condition that results to the damage of the kidney due to 
elevation of BG. As such, the damaged kidney becomes ‘leaky’ and allows large 
amounts of protein to be discharged to urine. This condition can advance and become 
severe and cause kidney failure. Diabetic nephropathy is a major cause of kidney 
disease in a majority of patients that requires renal replacement, and also linked to 
cardiovascular mortality (O'Brien, Patrick and Caro, 2003; Valmadrid et al., 2000).  The 
oxidation of protein produces carbonyls of the existence of OS (Tiwari, 2013; Hecker 
and Wagner, 2017). The higher production of this carbonyls play a crucial role in the 
pathogenesis of nephropathy among diabetes patients (Tiwari, 2013; Hecker and 
Wagner, 2017). Diabetic nephropathy consists of two types, microalbuminuria and 
macroalbuminuria. Uncontrolled diabetes and high blood pressure causes diabetic 
nephropathy, which needs pharmacological treatment and protein diet restriction 
(Tiwari, 2013).  When the extracellular glucose level is increased to (30 mmol/l), the 
production of intracellular ROS increases also and recruit podocyte apoptosis and 
podocyte depletion. It concludes that podocyte apoptosis/depletion is the early 
leading cause of diabetic nephropathy in murine T2D models (Wada and Makino, 
2013). Three major pathways showing abnormality of intracellular metabolism have 
been identified in the progress of diabetic nephropathy are formation of AGE 
products, stimulation of polyol and PKC (protein kinase C) pathways, and glomerular 
hyperfiltration which induce intra-glomerular hypertension (Wada and Makino, 2013). 
Furthermore, recent studies show that the inflammation pathways play significant 
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roles in the development of diabetic nephropathy (Yap, Frankel and Tam, 2017). These 
studies support the development of new therapeutic agents (Yap, Frankel and Tam, 
2017; Wada and Makino, 2013).  High concentration of protein in urine leads to renal 
impairment and chronic kidney disease, which could finally cause end stage renal 
disease.  Tight glycaemic and blood pressure control will decreased renal perfusion 
pressure, which assists in the prevention of renal disease (Pugliese and Porta, 2018).  
Screening for diabetic nephropathy in T2D should be at diagnosis and then annually 
(Handelsman et al., 2015).  
1.9.1.2 Diabetic retinopathy 
Diabetic retinopathy is the term for disorders of the retina which occur as a result of 
diabetes mellitus. When diabetic retinopathy occurs, the resulting changes are in 
retinal blood vessels.  There are two main types of retinopathy: non-proliferative and 
proliferative. In non-proliferative retinopathy, which is the more common, capillaries 
behind the eye swell and form pouches. Non-proliferative retinopathy varies between 
mild, moderate, and severe, depending on the numbers of blood vessels that have 
been blocked (ADA, 2016). In some cases, after several years of developing 
retinopathy, it is progresses to a more serious form (proliferative retinopathy). Here, 
the damage of the blood vessels increases which leads to a complete blockage of the 
vessel. As a result, new blood vessels start growing in the retina responded to that 
closure.  Diabetic retinopathy is a chronic progressive threatening disease of the 
retinal microvasculature associated with the persistent high blood glucose levels and 
other conditions associated with diabetes mellitus e.g. hypertension (Ghanchi et al., 
2012).  However, retinopathy rates are higher among: people with T1D and in people 
with longer duration of diabetes (American Diabetes Association, 2018).  Uncontrolled 
blood glucose can also cause cataracts, glaucoma and occlusion of retinal artery and 
retinal vein (American Diabetes Association, 2018).   In T2D who are using an oral 
hypoglycaemic agent or who control their blood sugar on life style changes alone, 
about 60 % of them develop retinopathy after 15 years (Singh et al., 2014). AGEs had 
a critical effect in loss of lens transparency by glycation of eye lens protein which cause 
cataract. Cataract is a major cause of blindness in developed and developing countries. 
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In diabetes mellitus patients the progression of cataract is increased. It is 
recommended to consume low AGEs-content food to delay the development of 
cataract (Singh et al., 2014). Diabetic retinopathy screening in T2D should be at 
diagnosis and then annually, if it is negative retinopathy should be checked every 2 
years (Handelsman et al., 2015). 
 
 1.9.1.3 Diabetic neuropathy 
Diabetic peripheral neuropathy is a common diabetes complication which increases 
the rate of morbidity and mortality (Malone, 2016; Hussain and Adrian, 2017). In 
hospitalized diabetes patients, 30% have peripheral neuropathy (Malone, 2016).  
Furthermore, in diabetes patients, 60-70% of them have developed mild to severe 
peripheral neuropathy (Habibur Rahman et al., 2016). The symptoms of neuropathy 
are paraesthesia, striking pain, numbness, or weakness in the feet and hands and 
finally sensory loss (Malone, 2016). Approximately 1 in 10 people with diabetes 
develop a foot ulcer, which can cause a serious infection (Diabetes UK, 2018).  
Furthermore, diabetic neuropathy causes ulceration of lower limbs, reduced healing 
of wounds which result in gangrene, and subsequently the need for amputation 
(Hussain and Adrian, 2017). Tight glycaemic control, and good foot care may greatly 
lower the risk of these outcomes (Pemayun et al., 2015; Hussain and Adrian, 2017). 
There are various causes for lower extremity amputation such as HbA1c ≥ 8%, 
peripheral arterial disease, hypertension, and hypertriglyceridemia. Immediate 
treatment of comorbidities like hypertriglyceridemia and hypertension are essential 
to minimize risk of amputation (Pemayun et al., 2015). In diabetes, the mitochondria 
abnormalities and mitochondria associated OS are susceptible to ROS which cause 
damage for mitochondrial DNA and nuclear DNA which lead to diabetes neuropathy 
(Sandireddy et al., 2014).  Deregulation of fission and fusion proteins that control the 
number and the shape of mitochondria cause damage of the cell functions and might 
result in degeneration (Ramesh et al., 2012). In T2D, OS leads to numerous adverse 
effects on cells physiology e.g. lipid peroxidation. This lipid peroxidation results in 
neural disorders (Ramesh et al., 2012). Basically, OS has been shown to have a role in 
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the pathogenesis of diabetic neuropathy in animal models.  Some clinical trials show 
that the administration of α-lipoic-acid “antioxidant” leads to an improvement in the 
nerve conduction velocity and minimize neuropathic symptoms (Ramesh et al., 2012). 
Moreover, AGEs might damage nerve fibres because of their effect on matrix 
metalloproteinases. The neuropathy screening should be started after 5 years after 
diagnosis of T1D and then annually, while in T2D it should be at diagnosis and then 
annually (Handelsman et al., 2015).   
 
1.9.2 Macrovascular complications   
Macrovascular complications manifest as cardiovascular disease (CVD) such as 
peripheral vascular disease (PVD), stroke, and coronary heart disease (CHD) (Chawla 
et al., 2016). The main causes of CVD are coronary atherosclerosis, and metabolic 
syndrome in people who have T2D. It has been reported that hyperglycaemia, is 
associated with a high risk of new cardiovascular events (Chawla et al., 2016).  OS is 
due to T2D affects the cell physiology such as lipid peroxidation (Tiwari, 2013; Ramesh 
et al., 2012). In T2D, atherosclerosis and cardiomyopathy result from IR while FFA 
causes an increment of mitochondrial ROS; also, ROS inactivates anti-atherosclerosis 
enzyme but lipids are the main targets (Chawla et al., 2016). The toxic effect of 
hydroperoxides on the cell is direct or by degradation of cell by the hydroxyl radical 
which is very toxic (Tiwari, 2013).  Hydroperoxides react with copper and iron and 
produce malondialdehyde (MDA) which destroy cell membranes.  The structure of 
lipid and metabolism shows changes in diabetes patients especially those with 
vascular complications (Tiwari, 2013). Notably, in atherosclerosis cholesterol 
specifically, LDL cholesterol is the main contributor to atherosclerosis. Nevertheless, 
in T2D dyslipidaemia, TRG and VLDL have been found to be elevated with normal or 
slightly high LDL and low HDL (Rask-Madsen and King, 2013). 
In coronary atherosclerosis, plaque builds up inside the arteries, which causes 
narrowing, decreases the flow of oxygen-rich blood to the heart. The damage of the 
inner layers of the coronary arteries is due to some factors such as; high blood glucose 
level in IR or diabetes, high blood cholesterol level, high blood pressure, presence of 
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albuminuria and smoking (Chawla et al., 2016). Inflammation also worsens metabolic 
syndrome and increases the risk of CHD and heart attack (American Diabetes 
Association, 2018; Chawla et al., 2016).  A common cause for such complications is 
ROS which is a result of processes commenced and accelerated through chronic 
hyperglycemic conditions (Chawla, Chawla and Jaggi, 2016; Sandireddy et al., 2014).   
1.10 Management of type 2 diabetes mellitus  
The target of treatment in diabetes patients listed in (table 5) which shows the levels 
pf BG, blood pressure (BP) and the lipid profile.  Table 6 also states the BG level in 
pregnant women while fasting and 2h after OGTT.  
Table 5: Target of treatments as stated by (Baxter et al., 2015; Inzucchi et al., 2015;  American 
Diabetes Association, 2018) as the following: 
 Test  Level  
Blood glucose 
 
 
 
FPG < 5.6 mmol/l (70–130 mg/dL) 
 
Post-prandial (2hrs) < 7.8 mmol/l (< 180 mg/dL) 
HbA1c < 6.5% (48  mmol/mol) 
Blood pressure   
 
< 130/80 
Lipids profile 
 
 
 
 
TC < 4 mmol/l (<156mg/dl). 
LDL < 2.59 mmol/l (<100 mg/dL; <70mg/dL 
an option in those with existing 
cardiovascular disease. 
HDL Greater than 40 mg/dL for men, 
greater than 50 mg/dL for women 
TRG < 1.7 mmol/l (150 mg/dL). 
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Table 6: For Pregnant women with diabetes the BG target is (American Diabetes Association, 2018; 
NICE 2015): 
 fasting 1 hour after meals 2 hours after meals  
Blood glucose level < 5.3mmol/l < 7.8mmol/l < 6.4mmol/l 
 
Inzucchi et al., (2015) believed that, at early stage of T2D the non-pharmacological 
treatment preferred as first option for three months and then if still no improvement 
in blood glucose, the pharmacological treatment should be initiated. 
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1.10.1 Hypoglycaemic agents  
Table 7 shows the hypoglycaemic agent that used in T2D (Garber et al., 2017; Baxter et al., 2015; BNF, 2018). 
Table 7: Medication list for T2D   
Class of medication  
 
 
Examples 
 
NICE guideline 
recommendations  
 
 
Efficacy Mechanism of action 
 
Caution & 
Contraindications 
 
Side effects 
  
1-Biguanides 
 
 
Metformin 
 
Considered as the 1st 
line treatment, 
Metformin “drug of 
choice in T2D” especially 
in obese patients 
BMI>25kg/m2. The dose 
should start low, and 
increased slowly.  
1%–2% A1c 
reduction and 
had some 
benefit in TG 
reduction and 
weight loss. 
Activate AMP kinase 
and decrease hepatic 
glucose production. 
 
Caution: 
In renal impairment 
the dose should 
adjusted. It should 
be stopped if eGFR 
< 
30ml/min/1.73m2. 
 
Gastrointestinal disorder 
(diarrhoea, nausea, 
vomiting, and abdominal 
cramping), CKD, lactic 
acidosis. 
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Contraindications: 
Severe renal 
impairment if SrCr > 
150 micmol/L and 
eGFR <  
30ml/min/1.73m2. 
Ketoacidosis, Heart 
failure, Lactic 
acidosis 
 
 
2-Suphlonylureas 
(SU) 
 
 
2ndgeneration  
Glyburide 
Gibinclamide 
Glipizide 
Gliclazide 
Glimipride 
 
 
 
Consider as 1st line 
therapy when: 
A- Metformin is not 
tolerated or C.I. 
B- Non-obese patients. 
C- Rapid response is 
required. 
1%–2% A1c 
reduction. 
Closes K ATP channels 
on b-cell plasma 
membranes and 
stimulate the 
pancreas to secrete 
more insulin. 
 
Contraindications: 
Porphyria, 
pregnancy, breast 
feeding, and severe 
hepatic impairment  
 
Hypoglycaemia, and 
weight gain. 
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Used as combination 
with Metformin in 
obese patient with 
uncontrolled DM. 
 
3- Meglitinides 
(glinides) 
 
 
 
Repaglinide 
Nateglinide 
 
Used in combination 
with Metformin in 
obese patients when 
Metformin alone failed. 
 Repaglinide can be used 
as monotherapy or in 
combination with 
Metformin. 
 Nateglinide can only 
use in combination with 
Metformin. 
 
 
0.5%–1.5% A1c 
reduction.  
Rapid acting for 
meal time 
flexibility 
Closes K ATP channels 
on b-cell plasma 
membranes and 
increase insulin 
secretion. 
 
Contraindications: 
Ketoacidosis, 
pregnancy, breast 
feeding, and severe 
hepatic impairment 
 
Hypoglycaemia, and 
weight gain.  
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4-Thiazolidinediones 
(TZD) 
 
 
Pioglitazone 
Rosiglitazone 
 
 
2nd/3rd line add to: 
A- Metformin & SU 
where insulin C.I or not 
tolerated. 
B- SU where metformin 
is not tolerated. 
C- Metformin as 
alternative to SU where 
risk of hypoglycaemia 
significant. 
 
 
0.5%–1.4% A1c 
reduction.  As 
well as both 
increase HDL-C, 
but Pioglitazone 
has more 
positive effects 
on reducing 
LDLC & TG than 
Rosiglitazone. 
Activate nuclear 
transcription factor 
PPAR-y and increase 
insulin sensitivity 
 
Contraindications: 
Pregnancy, breast 
feeding, and severe 
hepatic 
impairment, heart 
failure, bladder 
cancer, and patient 
with high risk of 
fracture.  
 
Weight gain, edema, 
heart failure, bone 
fracture, and altered 
blood lipid (increase LDL 
‘rosiglitazone’). 
 
5- Alfl- Glucosidase 
inhibitors: 
 
 
Acarbose 
Miglitol 
 
 
Consider as an 
alternative therapy in 
people who are unable 
to use other oral drugs. 
 
 
0.5%–0.8% 
reduction in A1c 
Inhibit intestinal alfa-
glucosidase enzyme 
and delay intestinal 
carbohydrate 
digestion and 
absorption.  
 
May enhance 
hypoglycaemic 
effects of insulin 
and sulphonylureas. 
Gastrointestinal disorder 
(diarrhea, flatulence). 
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6-Dipeptidyl 
Peptidase 4 
Inhibitors (DPP4-I) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sitagliptin 
Vildagliptin 
Saxagliptin 
Linagliptin 
Alogliptin 
 
 
 
 
 Inhibits DPP-4 activity, 
increasing 
postprandial active 
incretin (GLP-1,GIP) 
concentrations.  
Increase insulin 
secretion and 
decrease glucagon 
secretion (glucose 
dependent). 
 
 
 
 
 
 
Contraindications: 
Diabetic 
Ketoacidosis (DKA), 
pregnancy, breast 
feeding and renal 
impairment 
 
Angioedema/urticarial 
and other immune-
mediated dermatological 
effects, upper respiratory 
tract infection (URTI), 
Hepatotoxicity and 
gastrointestinal 
disturbance. 
 
 
 
62 
 
7-Bile acid 
sequestrants 
 
 
 
Colesevelam  
 
 
 
 Binds bile acids in 
intestinal tract, 
increasing hepatic bile 
acid production and 
(decrease hepatic 
production level and 
increase incretin level) 
 
 Constipation, increase 
triglycerides, and may 
decrease absorption of 
other medications. 
 
8-Dopamine-2 
agonists: 
 
 
 
Bromocriptine 
(quick release) 
 
  Activates 
dopaminergic 
receptors, modulates 
hypothalamic 
regulation of 
metabolism, and 
increase insulin 
sensitivity. 
 
 Dizziness/syncope, 
nausea, fatigue, and 
rhinitis. 
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9-Sodium–Glucose 
Cotransporter 2 
Inhibitors (SGLT2 I) 
 
 
 
Canagliflozin, 
Dapagliflozin, 
Empagliflozin. 
 
  Inhibit SGLT2 in the 
proximal nephron, 
blocks glucose 
reabsorption by the 
kidney, facilitates its 
excretion in the 
kidney increasing 
glucoseuria.  It is 
independent on the 
action of insulin which 
minimise 
hypoglycaemia unlike 
TZD.  
 
 Genitourinary infections, 
polyuria, volume 
depletion/hypotension, 
dizziness, increase LDL, 
and increase creatinine 
(transient). 
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10-GLP-1 receptor 
agonists 
 
Exenatide, 
liraglutide 
Albiglutide 
Lixisenatide 
Dulaglutide. 
0.5%–1.1% reduction in 
A1c 
 Activates GLP-1 
receptors, increase 
insulin secretion and 
decrease glucagon 
secretion (glucose 
dependent), slow 
gastric emptying, and 
increase satiety. 
 
Contraindications: 
Severe 
gastrointestinal 
disease, DKA. 
 
Gastrointestinal disorder 
(nausea, vomiting, and 
diarrhea), increase heart 
rate, C-cell 
hyperplasia/medullary 
thyroid tumors in 
animals, pancreatitis. 
 
11-Amylin mimetics 
 
Pramlintide 
 
  Activate amylin 
receptors, decrease 
glucagon secretion, 
slow gastric emptying 
and increase satiety.  
 
 Gastrointestinal disorder 
(nausea, and vomiting), 
hypoglycaemia unless 
insulin dose is 
simultaneously reduced. 
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1.10.2 Insulins 
 
Insulin is a peptide hormone that can be purified from bovine or porcine pancreas 
which is responsible of regulation CHO and fat metabolism, It was discovered in early 
1921 by Banting and Best (Baeshen et al., 2014; Kubota et al., 2017).  In 1982, a new 
field was developed by using genetic engineering in the production of insulin in E. coli 
and yeast which was approved by FDA and the human insulin was the first medication 
that has been produced by using recombinant DNA technology by Eli Lilly Company. 
Human insulin produced by β-cell and consists of 51 amino acid in two chain 
connected by 2 disulfide bonds (Baeshen et al., 2014).  
Insulin has different effects on the body which are listed below (Baxter et al., 2015; 
Garber et al., 2017; Inzucchi and Majumdar, 2015; Mann and Bellin, 2016): 
 Maintain blood glucose level within 4-6 mmol/l. 
 Convert glucose to glycogen in skeletal muscle (Glycogenesis). 
 Convert excess glucose to fat in adipose tissue (lipogenesis). 
 Stimulate protein synthesis.  
 Reduce new glucose output by inhibit converting of glycogen to glucose 
(glycogenolysis) and preventing breakdown of protein to energy 
(gluconeogenesis). 
 Prevent break down of fat (lipolysis). 
 
The uses of insulin could be in T1D and T2D (Baxter et al., 2015; Garber et al., 2017; 
Inzucchi and Majumdar, 2015). T2D individuals who are recommended to use insulin 
e.g. T2D who have inadequate blood glucose control on optimised oral hypoglycemic 
agents, contraindications to oral hypoglycemic agents or have recurrent symptoms of 
hyperglycaemia or unexplained weight loss. Moreover, T2D who are pregnant or 
considering pregnancy or with acute illness or recurrent infection. 
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1.10.2.1 Types of insulins 
Table 8 illustrates different types of insulins (Baxter et al., 2015; Garber et al., 2017; Inzucchi and Majumdar, 2015; BNF, 2018).  
Table 8: Insulins List. 
Insulin type  
 
Examples 
 
Company 
 
Dosage form 
 
Onset (min) 
 
Peak activity 
(hr) 
 
Duration (hr) 
 
Rapid acting 
(Analogue)  
Humalog 
(Insulin lispro) 
Lilly Vial, cartridge and 
prefilled pen 
15 min 1.5 h 2-5 h 
 
Novorapid 
(Insulin aspart) 
Novonordisk  Vial  10-20 min 1-3 h 3-5 h 
Short acting 
(Soluble) 
Actrapid Novonordisk Vial, cartridge and 
prefilled pen 
< 30 min 1.5-3.5 h 7-8 h 
 
Humilin S Lilly Vial and cartridge  30-60 min 1-6 h 6-12 h 
 
Insuman Rapid Sanofi 
Aventis 
Vial, cartridge and 
prefilled pen 
 
< 30 min 1-4 h 7-9 h 
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Intermediate acting Humulin I Lilly Vial, cartridge and 
prefilled pen 
 
½- 1 h 1-8 h 22 h 
 
Insulatard Novonordisk Vial, cartridge and 
prefilled pen 
 
<1.5 h 4-12 h 24 h 
 
Insuman Basal  Sanofi  
Aventis 
Vial, cartridge and 
prefilled pen 
< 1 h 3-4 h 11-20 h 
Long acting Lantus (Glargine) 
 
Sanofi  
Aventis 
Vial, cartridge and 
prefilled pen 
2.5 h - 24 h 
 
Levemir (Detemir) 
 
Novonordisk Cartridge 2.5 h - 24 h 
Mixture  Mixtard 30/70 or 
50/50 
Novonordisk Vial and cartridge < 30 min 2-8 h 24 h 
 Novo Mix 30 Novonordisk Cartridge and prefilled 
pen 
< 10-20 min 1-4 h 24 h 
 Humalog mix 25 or 50 Lilly Vial, cartridge and 
KwikPen 
15 min 2h 22 h 
 Insulin comb 25 Sanofi 
Aventis 
Vial, cartridge and 
prefilled pen 
30-60 min  2-4 12-19 h 
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1.10.2.2 Clinical applications of insulin: 
Insulin acts on specific receptors available on the cell membrane, the density of these 
receptors are different according to type of cell e.g. liver, muscle and adipose tissue 
have the highest density (Mann and Bellin, 2016).  Proinsulin has two chains connected 
together by C-peptide which is later separated to release insulin and C-peptide. The 
insulin contains A- and B- chains which are connected together by two sulphide bonds 
(Mann and Bellin, 2016; McCulloch, 2018).  Insulin receptor is a receptor tyrosine 
kinase (RTK), it is glycoprotein which had 2 extracellular subunits (extracellular) which 
connected to 2 transmembrane subunits (in cytoplasm) by disulphide bonds (Mann 
and Bellin, 2016; McCulloch, 2018).  Both insulin and C-peptide are co-released from 
β cell however, C-peptide only useful in clinical situation to quantity the endogenous 
insulin production in those patients who are using insulin.  Activates insulin receptors, 
which allow insulin to stimulate the glucose to transport across cell membranes which 
increase glucose disposal through use in body energy or store it as glycogen in the liver 
and skeletal muscle.  Alternatively, it is stored as TG in the adipose tissue. 
Furthermore, insulin decreases hepatic glucose production by inhibiting glucagon 
secretion (Mann and Bellin, 2016; McCulloch, 2018). The adverse effect of insulin are 
hypoglycaemia, and weight gain. 
1.10.2.3 Insulin regimens:  
Insulin regimens classified as the following:  (Diabetes UK, 2016; Scobie and Samaras, 
2012). 
1.10.2.4 Basal Bolus  
A basal-bolus injection regimen is injecting four or more injections over the day. It 
consists of an injection at each meal and one at night. This regimen is closest to the 
physiological Insulin profile, i.e. like ND. A basal-bolus regimen can be used in T1D and 
T2D. Regular self-monitoring blood glucose (SMBG) is required for this regimen. The 
role of basal insulin is to control BG levels at stable levels during fasting periods. It 
works over a relatively long period of time and therefore basal insulin will be either 
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long acting insulin or intermediate insulin. The role of bolus insulin used at meal times 
is to keep BG levels under control after each meal i.e. to stop the post-prandial rise 
that would occur despite basal dosing. Short acting insulin or rapid acting insulin used 
before meal to act quickly. Multi daily injections consist of basal (once daily of 
intermediate or long acting Insulin) and bolus (3 or more short or rapid acting insulin 
doses). 
1.10.2.5 Insulin dose adjustment: 
(Diabetes UK, 2018; Scobie and Samaras, 2012) illustrate that: 
Once daily regime: often starts with 10 units at bed time. 
Twice daily regime: 2/3 is given the morning and 1/3 in the evening depending on 
meal sizes. 
Basal Bolus regime: ½ is given at bed time with the remaining ½ split between the 3 
bolus injections.  
1.10.2.6 Injection technique: 
1- Abdominal area (fast). 
2- Arms (medium to fast) 
3- Thigh (low) 
 
1.10.2.7 Insulin pump: 
According to Diabetes UK, an insulin pump consists of rapid or short acting insulin 
which filled into a portable device attached to the body by a catheter located below 
the skin (Diabetes UK, 2016).  It is considered as a superior alternative to insulin 
injections because there is no need to inject the skin many times.  Moreover, it 
facilitates the blood glucose level control.   In the UK, there are approximately one in 
every 1,000 diabetic patient uses an insulin pump (Diabetes UK, 2018). 
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1.10.2.8 Artificial pancreas: 
Artificial pancreas (AP) idea was first established in the 1970s, it is made up with a big 
device which had limitations (Saleem et al., 2017). During the last few decades, many 
researchers have improved the (AP) or automated control system (Saleem et al., 
2017).  The idea of AP consists of an integrated closed-loop control (CLC), combining 
continuous glucose monitoring (CGM) and insulin pump (continuous subcutaneous 
insulin infusion “CSII”), which improve glycaemic control in diabetes (Breton et al., 
2012; Saleem et al., 2017). This device intended to optimize blood glucose level within 
normal range (3.9–10 mmol/L). It is also decrease blood glucose from 7.73 to 6.68 
mmol/L without increasing hypoglycemia, and this reduced variability overnight. It has 
been conclude that, this artificial pancreas shows improvement toward automated 
CLC (Breton et al., 2012). The missing feedback of glucose sensing has a fundamental 
drawback for closed loop control (Saleem et al., 2017).  Numerous ideas have been 
developed after receiving feedback in other researches such as proportional integral 
design (PID) control, fuzzy logic control and adaptive control (Saleem et al., 2017).   
Moreover, the most widely used control approach is the model predictive control 
(MPC), because it has ability to handle a wide range of scheme constraints. In essence, 
to overcome the problems of regulating insulin in AP studies is still challenging (Saleem 
et al., 2017).  Recent study shows that dual-hormone artificial pancreas had the lowest 
risk of hypoglycemia, however the differences were not significant which need further 
study to prove that  (Haidar et al., 2017).  
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Chapter 2 (Metabolism) 
2.1 introduction 
Metabolism is the term used for various biochemical reaction which provides required 
energy to the body and helps in maintaining biological functions such as, biosynthesis, 
heat generation and muscle contraction (Evans and Heather, 2016).  Energy is derived 
from carbohydrate, fat and protein, while glucose is the main source of energy in cells 
due to its solubility and fast movement which make it easy to transport (Evans and 
Heather, 2016). Anabolism is the process of storing energy from energy-rich substrate, 
while catabolism is the processes degrading substrates to biologically energy which 
used in the movement or other anabolic mechanism. Obesity is a result of imbalance 
of these pathways (Evans and Heather, 2016).   Szablewski, (2011) illustrates that 
glucose metabolism is a very important process in most physiological functions. It is 
also produced inside the body by process called gluconeogenesis in the liver and 
kidney from non-carbohydrate source. Glucose is used as a source of energy by 
catabolising and producing adenosine triphosphate (ATP) and as a source of starting 
material for biosynthetic reactions. This process is conducted in peripheral tissues 
including muscle kidney and the brain (Szablewski, 2011; Mann and Bellin, 2016).  In 
the case of low blood glucose level that may cause, seizures, loss of consciousness and 
finally death.  Glucose homeostasis is the process that normally controls blood glucose 
level around 90 mg/dl (5 mmol/l).  Insulin is the dominant glucoregulatory hormone, 
which regulates the plasma glucose concentration.  In T2D, if the glucose 
concentration is very high after meals, insulin is required to stimulate the utilisation 
of glucose to prevent hyperglycaemia (Maughan, 2013; Giugliano, Ceriello and 
Esposito, 2008; Szablewski, 2011; Mann and Bellin, 2016).  During hypoglycaemia, 
glucagon, another pancreatic glucoregulatory hormone, acts on the liver to increase 
hepatic glucose production within minutes.  Carbohydrate consumption provokes 
increases the concentration of insulin, and decreases the concentration of glucagon 
(Maughan, 2013; Szablewski, 2011). Any impairment in the regulation of hepatic 
glycogen metabolism lead to disorder in blood glucose homeostasis and are 
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significantly accompanied with metabolic disorders e.g. T2D (von Wilamowitz-
Moellendorff et al., 2013; Mann and Bellin, 2016).   
  
2.2 Carbohydrate definition  
Carbohydrates are molecular compounds consist of three elements: carbon, hydrogen 
and oxygen (Evans and Heather, 2016).  It is the main source of energy in human 
nutrition (Stylianopoulos, 2013).  Carbohydrates which called saccharide are classified 
into, simple sugars and complex carbohydrates. Simple sugar is the monosaccharide 
e.g. glucose while complex sugar consists of more than one monosaccharide such as 
disaccharides (two sugars) e.g. sucrose, polysaccharides (more than two sugars) e.g. 
starch and cellulose (Dashty, 2013). The enzyme amylase which is produced in the 
mouth, stomach and small intestine, converts starch and sugar from food into simpler 
sugars (Dashty, 2013).  Sugars commonly found in the diet are disaccharides which 
include: 
1-Sucrose commonly known as table sugar, which is hydrolysed by enzyme invertase 
(sucrase) into one mole of D-Glucose and one mole of D-Fructose. They bound 
together by (1-α to 2-β orientaion).  
2- Lactose is the milk sugar, which is divided by lactase enzyme into one galactose 
carbohydrate and one glucose carbohydrate. These are bound together by a (1-4 
glycoside bond in β orientation).  
3-Maltose which hydrolysed by maltase enzyme into (two molecules of D-Glucose), it 
is the result of starch breakdown. The link is between the first carbon atom of glucose 
and the fourth carbon of another glucose molecule (1-4 in α orientation). 
 
 
 
 
 73 
 
2.3 Carbohydrate pathway  
 To provide the primary energy fuel, carbohydrates are hydrolysed and transferred 
into the blood as glucose.  This process begins with the absorption of carbohydrates 
from the stomach wall.  Disaccharides or polysaccharides are hydrolysed in the small 
intestine by three pancreatic enzymes: amylase, maltase, invertase and also by 
lactase, which is secreted by the intestinal wall.  In the portal vein, the 
monosaccharides are absorbed and then transported to the liver.  The glucose is then 
converted to glycogen in the liver (see section 5), and primarily stored in the cells of 
the liver as well as the skeletal muscle tissue (Maughan, 2008). 
 
2.4 Carbohydrate or Glucose metabolism 
Metabolism as explained above consists of catabolism which is the produce of energy 
and anabolism which is the storage of energy (Evans and Heather, 2016). Metabolism 
pathway understanding play essential role in the management of several diseases 
such as diabetes (Evans and Heather, 2016).   The energy molecules that used in 
metabolism are consist of two groups, the first is the phosphate group which is the 
high energy e.g. adenosine triphosphate (ATP), guanosine triphosphate (GTP) and 
creatine phosphate.  The second group is the hydride ion carrier group e.g. 
nicotinamide adenine dinucleotide (NADH), Flavin adenine dinucleotide (FADH2) and 
nicotinamide adenine dinucleotide phosphate (NADPH) (Evans and Heather, 2016; 
Salway, 2016).   Glucose molecule uptake into the cell membrane by glucose 
transporters (GLUT), which is immediately phosphorylated to glucose-6-phosphate 
(G6P) by the enzyme hexokinase (liver and pancreas: glucokinase) (Evans and Heather, 
2016; Mann and Bellin, 2016).    G6P then either stored as glycogen in the muscle or 
enters glycolysis process (see figure 4) (Consitt et al., 2016).  G6P plays an essential 
role in the metabolism of carbohydrate, which can be used for glycolysis process and 
glycogen synthesis (glycogenesis), while in case of glycogen breakdown 
(glycogenolysis) and non-carbohydrate precursors (gluconeogenesis) the G6P can be 
produced (Evans and Heather, 2016; Mann and Bellin, 2016).   These will discussed 
more lately in this section.   
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Figure 2: Metabolism of carbohydrate, Protein and fat. 
2.5.1 Glycolysis (Anaerobic)  
Glycolysis is the process of glucose metabolism to obtain energy through different 
chemical reaction (Locasale, 2018).  This is the oldest biochemical pathway, it has been 
discovered at 1950s which is a pathway that represents the basic principles of 
achieving biological from metabolic biochemistry (Locasale, 2018).  Figure 2 shows 
that each molecule of glucose converted to 2 molecule of pyruvate, 2 ATP, and 2 NADH 
(Evans and Heather, 2016).  This part of the process is called anaerobic, and it occurs 
in the cytoplasm, in the presence or absence of oxygen.  After the digestion of 
carbohydrates, insulin stimulates the entering of glucose from the blood into cells for 
storage (Dashty, 2013). Glycolysis is controlled by hormonal and metabolic signals 
which stimulate insulin secretion in the pancreas and inhibit glucagon release (Evans 
and Heather, 2016).  During exercise, glucose is transferred to muscle as source of 
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energy (Dashty, 2013).  In glycolysis, Six-carbon glucose molecules are degraded to 
three-carbon pyruvate.  After that, pyruvate transport to mitochondria and 
decarboxylated to acetyl-CoA and then further metabolized to lactate (Evans and 
Heather, 2016).  By glycolysis, glucose breakdown in the muscle provides energy, while 
in liver, extra glucose is broken down to pyruvate, and then to acetyl-CoA, to be used 
in lipogenesis (lipid synthesis) (Evans and Heather, 2016).   Glycolysis is the main 
pathway providing ATP from glucose or glycogen in tissues to be used for internal body 
function or in different body movements (Evans and Heather, 2016).     
2.5.2 Krebs cycle, Aerobic (Prep Step - CoA) or tricarboxylic acid cycle 
This is a sequence of chemical reactions that are a common characteristic of aerobic 
organisms that results to release of energy from acetyl-coA oxidation obtained from 
eating carbohydrates, fats and proteins in diet.   Dashty, (2013) states that, pyruvate 
and lactate can be additionally oxidized to Carbon dioxide (CO₂) and water (H₂O) by a 
process called the Krebs’ (tricarboxylic acid) cycle in the mitochondria.  Degradation 
of glucose for releasing its energy for the anabolic pathways starts from glycolysis and 
continues to the Krebs or tricarboxylic acid (TCA) cycle in the mitochondria. It called 
aerobic because it needs oxygen to be completed.  Krebs cycle occurs in the inner 
mitochondrial membrane (see figure 3). Cells break down food such as CHO through 
multiple pathways e.g. in the glycolysis process the breakdown of glucose molecules 
releases energy, which is captured by energy carrier molecule adenosine triphosphate 
ATPs and NADH.  In this process glucose is converted to 2 pyruvate molecules in the 
mitochondria where each pyruvate is oxidised to acetyl CoA.  Acetyl CoA (2 carbon 
atom) reacts with oxaloacetic acid (4 carbon) and produce citrate (6 carbon) to then 
enter citric acid cycle.  Acetyl CoA can also be generated by break down of fats and 
amino acids. In this circular reaction part of the citric acid cycle, carbon atom is 
oxidised and release waste product carbon dioxide (CO₂).  In this way energy released 
stepwise and capture by energy carriers including 3 NADH, 2 ATP, and 1 FADH₂. 
Moreover, this citrate is again oxidised to oxaloacetic acid and combined with acetyl 
CoA to release citrate and start citric acid cycle and finally generate energy.  As it is 
explained in the beginning each glucose converted to 2 pyruvate molecules in the 
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preparatory process of Krebs cycle.  As explained each pyruvate start the process of 
Krebs cycle to release energy, from glycolysis 2 ATP, 2 NADH and extra 2 NADH from 
preparatory stage. Furthermore, in citric acid cycle there is 1 ATP, 3 NADH, and 1 
FADH₂ hence if multiple each one by 2 the result is 2 ATPs, 6 NADH, 2 FADH₂.  The net 
result is 4 ATP, 10 NADH, and 2 FADH₂.    Every NADH contain 3 ATPs, and every FADH₂ 
have 2ATPs, so 10 NADH contain 30 ATP, 2 FADH₂ contain 4 ATP and the 4 ATP that 
already in Krebs cycle.  Finally, totally 38 ATPs are released via Krebs cycle to produce 
energy inside the cells.  Acetyl CoA is the general catabolic intermediator which enter 
Krebs cycle and generate ATPs regardless of whether the starting molecule is glucose, 
fat or amino acid (Dashty, 2013;Evans and Heather, 2016).      
  
 
Figure 3: Krebs cycle 
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2.5.3 Glycogenesis 
Glycogenesis is the process of glycogen synthesis from glucose (see Figure 4), which 
happens mainly in the liver and skeletal muscle and stored there.  It is synthesised 
when the body is in a state of rest, and is activated by insulin when the glucose level 
becomes high, commonly after the consumption of carbohydrates (Dashty, 2013; 
Evans and Heather, 2016). This process will explain more in details later in (section 
2.12).  
2.5.4 Glycogenolysis 
Glycogenolysis is the breakdown of glycogen to produce glucose (see Figure 4), it 
mainly occurs in the liver, skeletal muscle and kidney. This occurs to supply glucose for 
glucose dependent tissue when the blood glucose level becomes low (Dashty, 2013; 
Evans and Heather, 2016). Generally, glycogenolysis plays crucial role when the body 
responds to the production of adrenaline and the regulation of glucose levels in the 
blood (Goff and Chen, 2016; Ward, 2014).  Any impairment in the regulation of hepatic 
glycogen metabolism lead to disorder blood glucose homeostasis and significantly 
accompanied with metabolic disorders e.g. T2D (von Wilamowitz-Moellendorff et al., 
2013).  This part will also discuss more lately in (section 2.12). 
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Figure 4: Glycogenesis and glycogenolysis  
 
2.5.5 Glycogen Storage differences between liver and muscles, and Hepatic 
and Fat and Muscle cell responses to glucose 
Glycogen is a branched glucose polymer in the form of glucose, which serves as energy 
storage during periods of nutritional sufficiency for utilisation as needed (Evans and 
Heather, 2016). Claude Bernard discovered liver glycogen in 1857 (Peter et al., 2012). 
Glycogen is the essential storage system because it allows the body to generate 
glucose quickly during both sedentary and athletic activities and maintains blood 
glucose (Jensen et al., 2011).  Glycogen is the freely stored form of glucose, present 
mainly in the muscles and the liver (Evans and Heather, 2016).  The muscles contain 
three to four times more glycogen than the liver due to the large muscle mass within 
the body. About 350 gram of glycogen stored in skeletal muscle that is enough for 
contraction of the muscle for 70 minutes, while there are about 100 gram of glycogen 
stored in the liver that is enough for body supply for about 12 hours (Evans and 
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Heather, 2016).  Glycogen metabolism is regulated by hormones such as insulin, 
glucagon and adrenaline “epinephrine” except in diabetes the insulin is exogenously 
added (Peter et al., 2012; Evans and Heather, 2016). When glucagon is released if 
hypoglycaemia is threatened, it stimulates the liver to discharge some of the stored 
glycogen to maintain blood glucose levels (Peter et al., 2012).   
2.5.6 Glycogen metabolism in the liver and muscles 
Glycogen metabolism as explained above is regulated by three hormones, insulin, 
glucagon and epinephrine (Goff and Chen, 2016). In the post prandial the glycogen 
stored mainly in the liver, while after exercise primarily in the skeletal muscle (Adeva-
Andany et al., 2016). This metabolic system consists of glycogen synthase that stores 
energy and glycogen phosphorylase which produces energy in the form of glucose 
released directly into plasma (glycolysis). Glycogen synthase is making glycogen to 
store it which activated by the anabolic hormone (insulin) (Goff and Chen, 2016; Agius, 
2015).  In this process glucose enter cells through transporters, then it will 
phosphorylate to G6P, then G6P going through isomeration to G1P and create uridine 
5ʹ-diphosphate-glucose which contribute glycogen synthesis (Adeva-Andany et al., 
2016). Glycogen phosphorylase catalyses the breakdown of glycogen to glucose to use 
it for energy, this activated by catabolic hormones glucagon and epinephrine (Goff and 
Chen, 2016). In this process glycogen is converted to G1P and then to G6P and finally 
produce glucose (Adeva-Andany et al., 2016).  Glycogen phosphorylase activity is 
regulated by allosteric mechanism and by enzyme phosphorylation and 
dephosphorylation which is reversible (Adeva-Andany et al., 2016). Liver glycogen 
phosphorylase isoenzymes have different response to regulatory process than muscle.  
The liver is responsible for glucose level regulation in the plasma (Adeva-Andany et al., 
2016; Peter et al., 2012).  The enzyme glycogen phosphorylase in the muscle is highly 
activated by AMP and by elevated glycogen level in the muscle (Adeva-Andany et al., 
2016).  The main candidates to regulate muscle glycogen synthesis are GLUT4, 
hexokinase and glycogen synthetase (Adeva-Andany et al., 2016; Peter et al., 2012).  
The liver stores glucose as glycogen, it can then break down to glucose but the liver is 
not using this for energy, it will release it to blood circulation when BG level become 
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below normal level. In the liver the enzyme glycogen phosphorylase is the isoenzyme 
of muscle phosphorylase and has different action than the one in the muscle; because 
in the liver this enzyme is sensitive to glucose molecules. After consuming a meal that 
leads to high glucose levels , the glucose acts as an allosteric inhibitor and binds to the 
special regulator known as the “allosteric”. This makes a change in the structure of 
“phosphorylase a” from an active state to an inactive state which will stop glycogen 
from breaking down to glucose (Agius, 2015).  Hence, the liver will stop producing its 
own glucose after consuming a meal.  However, in case of low BG, the liver cell is 
converted from an inactive state to an active state leading to the breakdown of 
glycogen to glucose which is then released into the blood stream (Adeva-Andany et 
al., 2016). Along the glycolytic pathway, glucose 6-phosphate is metabolized to 
pyruvate and lactate (Lavin, 2012; Evans and Heather, 2016). It has been found that 
during exercise, fatigue, impaired muscle performance and muscle glycogen depletion 
all have strong association.  Patients with Glycogen Storage Disease, had a complete 
elimination of muscle glycogen synthase which causes weakness, pain and cramps in 
the muscle as well as cramps and poor exercise performance (Xirouchaki et al., 2016).  
There are several mechanisms for fatigue during exercise yet the main reason for that 
is still unclear (Xirouchaki et al., 2016).  The hypothesis behind fatigue is the glycogen 
depletion. Different researches propose that during exercise, glycogenolysis is 
essential for energy supply and muscle contraction generally because muscle glycogen 
is important for glucose to enter glycolysis pathway (Xirouchaki et al., 2016). 
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2.5.7 Gluconeogenesis 
The good balanced between glucose utilization and endogenous glucose production 
or dietary glucose delivery is necessary for controlling normal blood glucose level (Goff 
and Chen, 2016). Glucose is produced from three different procedures: absorbed from 
the intestine after carbohydrate consumption, glycogenolysis, and gluconeogenesis 
(Giménez-Cassina et al., 2014). Carbohydrate metabolism continues even in the lack 
of dietary intake and induces the body to produce new glucose, using non-
carbohydrate sources and regulated by glucagon hormone (Giménez-Cassina et al., 
2014; Evans and Heather, 2016; Dashty, 2013).  In the case of glucose, the precursors 
are lactate, pyruvate, glycerol, and glucogenic amino acids.  This is conducted mainly 
in the liver, and to a lesser extent in the cortex of the kidneys (Evans and Heather, 
2016).     Generally, the non-carbohydrate precursor are specific amino acids (such as 
alanine), glycerol (resulting from fat breakdown) and lactate (derived from muscles) 
(Schutz, 2011).  Examples of catabolism is the breakdown of glucose “glycolysis” and 
breakdown of glycogen “glycogenlolysis”.  Anabolism process such as synthesis of 
glucose “gluconeogenesis” and the synthesis of glycogen such as “glycogenesis”.  
Gluconeogenesis is activated in the shortage of endogenous and exogenous glucose 
supply, where the body uses fats and amino acids instead of carbohydrates to produce 
glucose.   This process is vital in case of metabolic stress, such as starvation (Evans and 
Heather, 2016; Schutz, 2011).  Glycerol maintains glucose supply via this process for 
the body tissue during fasting, by activation of stored body fats (see figure 2).  This 
response will only occur if adequate ATP is available to the cell. The liver has a crucial 
role in controlling blood glucose homeostasis by balancing glucose uptake and storage 
through glycogenesis and the production of glucose through glycogenolysis and 
gluconeogenesis if BG threatens to become low (Szablewski, 2011; von Wilamowitz-
Moellendorff et al., 2013).  Thus, in the postprandial state, the liver converts glucose 
to glycogen and TG, while in the post-absorptive state, it produces glucose by 
glycogenolysis and gluconeogenesis (von Wilamowitz-Moellendorff et al., 2013).   
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2.6 Fructose metabolism 
The main source of energy in cells is glucose, as stated previously but cells can also 
utilise fructose in cases where a high amount of sucrose (glucose and fructose) have 
been ingested. The muscle, adipose tissue and kidney contain hexokinase (HK), which 
is necessary to phosphorylate fructose to produce fructose-6-phosphate (F6P) 
(Dashty, 2013).  F6P is consumed directly through the glycolysis pathway.  The liver 
however, contains only glucokinase (GK), so fructose needs to be converted first to 
glucose in the liver to complete the glycolysis pathway (Dashty, 2013).   
2.7 Pentose phosphate pathway: 
Pentose phosphate pathway (PPP) is an alternative pathway to glycolysis and TCA 
cycle for oxidation of glucose. It should be noted that no ATP are consumed or 
produced in this pathway (Evans and Heather, 2016; Arese and Gallo, 2014).  Primarily, 
glucose is oxidized by enzyme hexokinase and a molecule of ATP is utilized to produce 
G6P in the 1st process of glycolysis pathway.  PPP is the biochemical reaction that 
oxidized the G6P (6 carbon) by glucose 6 phosphate dehydrogenase (G6PDH) to 6-
phosphogluconate and generate NADPH.  The 6-phosphogluconate is converted to 
ribulose-5-phosphate (5 carbon) and CO2 and a second molecule of NADH (Evans and 
Heather, 2016; Arese and Gallo, 2014). This pathway is an important source of NADPH 
in most tissues (Kuehne et al., 2015). It is also an important source of ribulose-5-
phosphate which is used in nucleotides (DNA and RNA) and in aromatic amino acids 
synthesis. While NADPH provides energy for some anabolic reaction e.g. lipogenesis 
and also to maintain the storage of antioxidant inside the body (Evans and Heather, 
2016; Arese and Gallo, 2014). 
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2.8 Fats  
Dietary lipids are an essential source of energy. TG from ingested dietary lipids is 
absorbed by gut, emulsified by bile acid, and then hydrolysed in the intestinal lumen 
with different pancreatic lipases to release free fatty acid (FFA) and glycerol (Hussain, 
2014). Lipids are either endogenous lipids, which are synthesised within cells, or 
exogenous lipids, which are derived from dietary fat. They are categorised by their 
insolubility in water, and have a different range of biological functions.  They are 
essential in cell membranes as phospholipids, and as a major source of stored energy 
in adipose tissue as triacylglycerols (TAGs), which is known as a TG (Griffin, 2013; 
Hussain, 2014).   Serum lipids contain TG, phospholipids, cholesterol and their 
component fatty acids (FA). These serum lipids are transferred from intestine to 
peripheral liver and tissues, to be utilised and stored in macromolecular complexes of 
lipid and protein called lipoproteins (Griffin, 2013). TG is not water soluble so it needs 
to transport into the blood circulation as lipoproteins, which known as (chylomicrons).  
Lipids then release from the transporter by lipoprotein lipase (LPL) and catalysed by 
pancreatic lipase to FFA and water soluble glycerol and enter circulation (Griffin, 
2013). Obesity, T2D, and CVD diseases associated with defect of enteric lipid 
homeostasis (Song, Veenstra and Perrimon, 2014). 
2.8.1 Lipid digestion and absorption 
The average daily intake of fat in a Western diet ranges from between 50 and 100 g, 
and provides between 35–40% of total energy (Griffin, 2013). This diet contains mostly 
TG, phospholipids and cholesterol. The fat is emulsified in the stomach by the 
breakdown by lipases and is solubilised with bile salts in the duodenum. This can then 
be absorbed through the walls of the upper small intestine (Griffin, 2013).  
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2.8.2 Lipid metabolism  
Griffin (2013) illustrates that, fats play a key role in the process of energy storage.   
Once fats have been ingested, they are formed as TG. This process starts with the fat 
catabolism process that comprises of splitting FA from glycerol with the help of 
enzyme lipase.  Insulin controls the action of lipase. In the case of insulin deficiency, 
there is great accumulation of FA, which are converted in the liver to the ketone bodies 
which results in ketoacidosis (Griffin, 2013).  Any disturbances in lipid metabolism in 
adipose tissue, skeletal muscle, liver,  gut and pancreas play an essential role in the 
progress of IR, impaired glucose metabolism and T2D (Stinkens et al., 2015). Low fat 
diet help in preventing and/or reversing these disturbances in FA metabolism 
(Stinkens et al., 2015). 
 
2.8.3 Lipogenesis  
Lipogenesis is the process for the formation TG or FA which starts in the mitochondria 
(Griffin, 2013; Hussain, 2014).  FA synthesis is obtained from three sources, diet, 
adipose cells and liver.  The exogenous source produce TG which enters the circulation 
as chylomicrons, while in the liver glucose is converted to FFA and then to TG which is 
released into the circulation as very low-density lipoprotein (VLDL).  The last source is 
the adipose cells which produce TG or FFA in the circulation.  In the blood circulation, 
VLDLs interact with lipoprotein lipase (LPL) in the skeletal muscle, cardiac and adipose 
tissue, where TG used for storage or release energy (Griffin, 2013; Hussain, 2014).  
Lipogenesis is an anabolic process which obtains energy from different pathways, first 
through Krebs cycle and TCA which produces Acetyl CoA and releases ATP and the 
second pathway is PPP which releases NADPH (see figure 3) (Evans and Heather, 
2016).   
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2.8.4 Lipolysis 
Lipolysis is the process when TG, stored in adipose tissue, starts to decompose and 
release glycerol and free fatty acids, free fatty acids then enter the blood circulation, 
which is essential when the body needs more energy (Griffin, 2013).  TG consists of 
glycerol connected to 3 fatty acids by 3 ester bonds. TG can be hydrolysed through 
several steps to diglycerides and then monoglyceride and finally glycerol and FFA. 
During lipolysis, 3 water molecules are hydrolysed 3 ester bonds within TG molecules 
in the presence of 3 different enzymes. TG is hydrolysed first by enzyme adipose 
triglyceride lipase (ATL) to give diglycerides (2 ester bond and 2 FA) and one FFA. 
Moreover, this diglycerides hydrolysed by hormone sensitive lipase enzyme (HSL) to 
produce monoglyceride (1 ester bond and 1 FA) and 1 FFA. Finally, monoglyceride is 
hydrolysed by enzyme monoglyceride lipase to release glycerol and FFA (Griffin, 2013).   
In the blood stream, the free fatty acids bind to serum albumin to transfer to tissues 
(Griffin, 2013). Free fatty acids oxidized to generate ATP which take place in the 
mitochondria. FFA then degrades to acetyl-CoA that totally oxidized via Krebs cycle 
(Griffin, 2013).  Glycerol also enters the blood stream and is absorbed in the liver and 
kidney to participate in gluconeogenesis (see figure 3) and glycolysis pathway.  
Different hormones induce lipolysis such as glucagon, adrenaline, nor-adrenaline and 
growth hormone (Mann and Bellin, 2016). 
 
2.8.5 Lipoproteins 
Lipids are insoluble in water and plasma; therefore, they need to combine with a 
protein to form a lipoprotein.  Lipoprotein facilitates the transportation of lipids in the 
body (Griffin, 2013). It has spherical surface which is bounded by hydrophilic cover of 
phospholipid monolayer and has free cholesterol and is covered by a large protein, 
apolipoprotein which helps to stabilized all the structure (Hussain, 2014).   The role of 
lipoproteins is to carry endogenous lipids that are synthesized in the liver; and 
exogenous lipids, which re-synthesized in the gut from dietary fats to peripheral tissue 
(Griffin, 2013).   
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The first lipoprotein is chylomicrons which result from TRG absorption in the intestine. 
It has a large spherical structure lipoprotein and low molecular weight and it carries 
exogenous TG to tissues.  The second is very-low-density lipoprotein (VLDL), which is 
produced in the liver and released into the bloodstream to transport and supply body 
tissues with endogenous TG. The third is intermediate-density lipoprotein (IDL) which 
result from catabolism of VLDL. The fourth is Low-density lipoprotein (LDL) the final 
product of catabolism of VLDL and transfers cholesterol to the peripheral tissues. 
(Griffin, 2013). The accumulation of the cholesterol in the artery walls occurs if the 
concentration of LDL is high, which can lead to atherosclerosis.  The fifth lipoprotein 
is high-density lipoprotein (HDL) which produced from liver and intestine acts to 
transfer cholesterol from the cells to the liver for elimination.  It is very important to 
protect artery walls from atherosclerosis that can cause cardiovascular problems 
(Griffin, 2013).  
 
2.8.6 Insulin resistance and intestinal lipoprotein production 
 
The role of insulin in adipose tissue skeletal muscle cells is to induce the migration of 
the GLUT4 transporter to the cell membrane to enable uptake of glucose. Insulin 
stimulates lipoprotein lipase (LPL) to remove FFA from chylomicron and VLDL to be 
uptake by adipocytes (Mann and Bellin, 2016). In case of lipogensis, intracellular 
glucose is converted to glycerol-3-phosphate that combine and esterified with FFA to 
produce TG in adipocytes (Morgantini et al., 2014).  In the liver, excess glucose form a 
diet also enters Krebs cycle in the mitochondria and produces pyruvate, then Acetyl 
CoA, then citrate which transports to cytoplasm and is converted again to Acetyl CoA 
and this process finally produces cholesterol by enzyme HMG CoA reductase (see 
figure 3) (Mann and Bellin, 2016). Acetyl CoA can also converted to FA which combined 
to glycerol (obtained from glucose before enter Krebs cycle) to produce TG 
(Morgantini et al., 2014). This lipid (cholesterol and TG) combine in the liver to 
apoproteins phospholipids to form two kinds of lipoprotein (HDL and VLDL).  VLDL is 
responsible for transporting FA and TG to body tissues for energy or for storage in 
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adipose tissue (Arca, 2015).  VLDL also converted to LDL which is responsible for 
transportation of cholesterol to body tissue or LDL which is moved to the liver again 
to recycle and form more lipoprotein or excreted in the bile duct (Arca, 2015).  On the 
other hand, lipolysis occurs in adipocytes in case of fasting or exercise to release 
energy (Norikazu Maeda, 2017). Any defect of lipid metabolism leads to a higher level 
of fat in the body “dyslipidaemia”, obesity, insulin resistance, T2D and CVD (Hussain, 
2014).  In the IR individual there are increase of TG-rich lipoproteins level and decrease 
in HDL cholesterol level (Arca, 2015; Hussain, 2014). The release of chylomicron is 
elevated in obesity, insulin resistance and T2D (Hussain, 2014).  Different studies show 
the link between IR and dyslipidaemia (Hussain, 2014). Overproduction of VLDL is 
mainly evident in T2D (Arca, 2015). This proves that diabetes is also associated with 
high fat level not only high glucose level this will discuss more lately in (chapter 5).  
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2.9 protein  
2.9.1 Structure and function of proteins 
CHO and fat are the main source of energy.  Protein also provides some energy at 4 
kcal/g; though proteins predominant action is to act as a source of amino acids (AAs) 
and to provide essential substrate to the body (Hayamizu, 2017).  In case of starvation 
when the intake of lipid and CHO is inadequate, AAs can be used as source of energy 
(Hayamizu, 2017; Bender, 2012).  Essentially, there is no storage form of AAs like CHO 
“glycogen” or fat “TG”.  Thus, muscle protein will breakdown if necessary, to provide 
energy (Hayamizu, 2017). Protein is the second largest component of tissue, after 
water.  It makes up about 17% of the weight of an average adult (Emery, 2015). After 
ingested a protein rich meal, gastric juices containing hydrochloric acid released in the 
stomach to facilitate proteins breakdown. Stomach secrets pepsin to break the 
peptide bonds between amino acids and produce smaller protein units (Emery, 2015). 
This will transfer to small intestine where the pancreatic enzymes chymotrypsin and 
trypsin assist the breakdown of this protein as well as extra enzyme released by small 
intestine help in this process. Small intestine muscle contractions (which need ATP) 
help in mix the protein and deliver it to the site of absorption (Emery, 2015).  It will 
then transfer released amino acids (AAs) to blood circulation then to liver.  In the liver, 
some AAs used to resynthesize new protein while minimum number of AAs can 
breakdown to nitrogen (contain ammonia). Finally, the nitrogen is the end-product of 
protein metabolism, which excreted in the urine as urea (see figure 2) (Emery, 2015).   
In the liver, most AAs are deaminated and the carbon skeleton are used in two process 
ketogenesis or gluconeogenesis.  Alternatively, they are used as an energy fuel for liver 
(Bender, 2012). Some AAs convert in the liver to glucose or FAs.  This glucose is either 
stored as glycogen or used as source of energy and FAs are also either stored as TG in 
the adipose tissue or used for energy (Hayamizu, 2017; Bender, 2012). AAs can be 
used t produce purine and pyrimidine bases which are used for nucleotide synthesis 
(RNA and DNA) (Newsholme et al., 2011).  That glucose from AAs can be then 
converted to pyruvate and OAA by catabolism via Krebs cycle - these AAs that form 
pyruvate are called “glucogenic AAs”. Pyruvate and OAA are substrates for 
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gluconeogenesis and can produce glucose again in the liver and kidney (Hayamizu, 
2017; Bender, 2012). FA converted to Acetyl CoA or acetoacetate “this called 
ketogenic AAs”. Lysine and leucine are examples of AAs that produce ketogenic 
intermediate Acetyl CoA or acetoacetate.  Alanine and arginine are producing 
glucogenic intermediate. Moreover, isoleucine, phenylalanine and tyrosine produce 
both glucogenic and ketogenic precursors (Bender, 2012). Acetyl CoA or acetoacetate 
(2C) is not used as a precursor for gluconeogenesis due to the lost 2 carbon inform of 
Co2 when forming citrate (6C) in Krebs cycle.  Therefore, they are not able to increase 
OAA which can be used in gluconeogenesis.  Acetyl CoA and acetoacetate are good 
precursors for ketone synthesis or energy production in a fasting state, while in a 
feeding state can produce FA (Bender, 2012). Insulin plays major role in regulating 
metabolism of carbohydrate, lipids, and protein in different tissues (Burgos et al., 
2016). Therefore, any resistance to insulin lead to T2D.  In insulin resistance 
individuals, there is a defect of protein metabolism which prove that there are link 
between T2D and whole body protein metabolism impairment (Burgos et al., 2016).  
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2.10 Lactate 
 
Lactate and lactic acid are appear in the blood in case of anaerobic metabolism in 
absence of oxygen in the tissue to support normal metabolic demands (Consitt et al., 
2016).  In the skeletal muscles lactate produces by anaerobic glycolysis in the absence 
of oxygen.  Lactate then transports to the liver and converts to glucose.  Glucose then 
returns to the skeletal muscles and is metabolized back to lactate CO2 and H2O 
(Consitt et al., 2016). The normal plasma lactate concentration is 0.3–1.3 mmol/litre 
(Phypers and Pierce, 2006).  For many years it has been believed that lactate was only 
a waste product as a result of anaerobic exercise (Gladden, 2004). Lactate research 
started from the 19th century, when Pasteur proposed that lactate was produced by 
lack of oxygen during muscle contraction.  In 1920, Otto Meyerhof suggested that 
glycogen was a precursor of lactate.  In 1923, Hill and Lupton proposed that when 
muscle contracted the lactic acid immediately released as energy donor (Gladden, 
2004). Lactic acid was consider as the main cause of fatigue (Hermansen, 1981). 
Moreover, in the 20th century George Brooks started to discover the actual lactate’s 
role in exercise and metabolism.  In high intensity exercise, the body unable to use 
oxygen immediately to create energy and this called anaerobic mode when body 
energy begun to break down to pyruvate and then to lactate (Gladden, 2004). The 
lactate production conducted in the cytoplasm via glycolysis process after production 
the intermediate metabolite pyruvate from glucose.  Pyruvate is the end product of 
glycolysis which enters mitochondria through mitochondrial pyruvate carriers (MPC) 
(Consitt et al., 2016). In the aerobic state, pyruvate is then converted to acetyl CoA by 
pyruvate dehydrogenase (PDH) which enter the Krebs cycle. Lactic acid level is usually 
low under these conditions. While in anaerobic conditions, pyruvate is converted by 
lactate dehydrogenase (LDH) to lactic acid the only reaction that can regenerate NAD+ 
allowing further glycolysis (Consitt et al., 2016). High plasma lactate level associated 
with insulin resistance, obesity and T2D (Consitt et al., 2016). Lactate has the essential 
role in preventing glycolysis and insulin signalling which also inhibits insulin-stimulated 
glucose uptake (Consitt et al., 2016).  Research propose that the accumulation of 
lactate is due to over production of pyruvate higher than oxidation of pyruvate which 
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involving PDH role (Consitt et al., 2016). Moreover, this accumulation increased in 
hyperinsulinemia but the mechanism is not clear. PHD has been found higher in lean 
healthy subjects while in insulin resistance subjects and elderly found impaired 
(Consitt et al., 2016).  Exercise indicated to improve PHD activity especially in younger 
individuals (Consitt et al., 2016).  This study suggested that three months of endurance 
exercise improved PHD phosphorylation, which minimize lactate accumulation in 
older participants (Consitt et al., 2016).   
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2.11 Physiology of insulin production  
Insulin has a crucial role in controlling metabolism of carbohydrate, lipids, and protein 
in the body tissues (Burgos et al., 2016). Generally, β- cells stimulate insulin secretion 
when the glucose is released in circulation (Figure 5).  Thus, to remove this glucose 
from circulation and use it either in the body energy as ATP or store it as glycogen in 
the muscle or as TG in the adipose tissues (Rutter et al., 2015).  
 
Figure 5: the organs that control plasma glucose level. 
 
2.11.1 Insulin secretion in the nondiabetic individual 
In non-diabetes, the liver, while fasting, releases glucose at a rate of approximately 
(2.0 mg/kg/min) and it is responsible for the balance of glucose homeostasis by both 
glycogenolysis and gluconeogenesis (Wilding, 2014; Meah and Juneja, 2015).   The 
kidneys reabsorb most of this glucose to release it into circulation by gluconeogenesis 
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(15–55 g per day), (approximately 180 mg/dL), so that less than 0.5 g is excreted per 
day. This retained amount (known as basal glucose) is metabolised by a balanced 
secretion of basal insulin to maintain euglycaemia. During the 4.5-hour postprandial 
period, an elevation in renal glucose release (>2-fold), which cause a further bolus 
secretion of insulin (known as prandial) to control the glucose metabolism (Wilding, 
2014; Meah and Juneja, 2015).  Additional hepatic actions of insulin on adipose tissue 
and muscle to prevent the gluconeogenic substrates production (such as lactate, 
alanine, and glycerol) as well gluconeogenic energy substrates (e.g., FFAs), which lead 
to successive inhibition of hepatic glucose production HGP (Wilding, 2014)  
2.11.2 Insulin secretion in individuals with type 2 diabetes 
In T2D patients, both renal and hepatic glucose production are increased due to 
elevation in gluconeogenesis (Wilding, 2014; Meah and Juneja, 2015).  The production 
of hepatic glucose from glycogenolysis and gluconeogenesis is about 5 times higher 
(2.5 mg/kg/min), due to multiple defects. In addition, the renal threshold is in 
appropriately raised up to 240 mg/dL as a result of upregulation of SGLT-2 
transporters, which prompts the kidneys to reabsorb extreme amounts of glucose and 
leads to the existence of hyperglycaemia (Meah and Juneja, 2015). During the 4.5-
hour postprandial period, glucose production has been increased in T2D 
approximately by 30% (100 g vs 70 g) higher than healthy individuals (Wilding, 2014; 
Meah and Juneja, 2015).  In case of diabetes, gluconeogenesis has important role. 
Therefore, it has been found elevated in diabetes subjects (Wilding, 2014; Mann and 
Bellin, 2016). Insulin and catecholamines (eg, adrenaline) play important role in 
regulating renal gluconeogenesis which take place within proximal tubule cells in the 
renal cortex (Wilding, 2014; Mann and Bellin, 2016).  Insulin reduces renal 
gluconeogenesis directly, and minimizes the production of gluconeogenic substrates, 
such as lactate and glycerol which decreases glucose production into the circulation. 
On the other hand, adrenaline enhances renal gluconeogenesis, increases renal 
glucose production, increases the supply of gluconeogenic substrates, inhibits insulin 
secretion, and decreases renal glucose uptake (Wilding, 2014; Mann and Bellin, 2016). 
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2.12 Metabolism in Non-diabetes and Diabetic Individuals  
 
 As indicated in (section 2.5.3), the principal metabolic effects of insulin are glycogen 
synthesis stimulation in skeletal muscle, and liver.  Moreover, it increases glycolysis 
and minimizes gluconeogenesis in the liver (Szablewski, 2011; Griffin, 2013; Mann and 
Bellin, 2016).  Insulin also stimulates the active transport of plasma amino acids into 
muscle as well as stimulates muscle protein synthesis directly (anabolic action) while 
depressing protein breakdown.  Insulin stimulates the fatty acid synthesis (lipogenesis) 
and storage in adipose and hepatic tissues as TG. In adipose cells, insulin inhibits 
hormone-sensitive lipase activity, preventing the breakdown of the lipid (lipolysis). By 
preventing lipolysis, the free fatty acid decreased in the circulation (Szablewski, 2011; 
Griffin, 2013; Mann and Bellin, 2016).  Generally, glycogen converts to glucose to give 
energy which is required during physical activity.  On the other hand, in a sedentary 
life style, after consuming CHO if the stored glycogen in the body is already high so 
then another process called de novo lipogenesis occurs which produces fat from 
carbohydrates (Jensen et al., 2011; Ameer et al., 2014).  This process occurs in the 
cytoplasm by converting glucose through glycolysis to pyruvate as explained above in 
(section 2.5.2) which is then in mitochondria converts to Acetyl CoA and finally to FFA 
in the circulation or stores in the form of TG (3 FFA glycerol molecules) in adipocytes 
and leads to obesity (see figure 2) (Evans and Heather, 2016; Mann and Bellin, 2016).  
However, in case of doing activity this stored glycogen become less in the muscle so 
this TG stores as glycogen and then could be convert to glucose which called 
gluconeogenesis (Evans and Heather, 2016; Mann and Bellin, 2016). TG hydrolysis to 
(glycerol and FFA), glycerol converts to pyruvate and then glucose and finally glycogen 
while FFA converts to Acetyl CoA.  While in case of protein metabolism as explained 
above (section 2.9), most AAs are deaminated and the carbon skeleton are used in 
ketogenesis or gluconeogenesis process or can be used as source of energy for liver 
functions (Bender, 2012).  In the liver, via Krebs cycle 50% of AAs converts to pyruvate 
and then glucose while the other 50% converts to Acetyl CoA and then FFA or in the 
TCA cycle (Bender, 2012).  The role of insulin in fat and muscle cells is to ensure that 
the glucose transporter (GLUT4), is stimulated and delivered to the surface of the cell 
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from a location that is intracellular. In this case, insulin ensure that carbohydrate is 
stored in the body as glycogen and after consumption of a diet rich in carbohydrate, 
the blood glucose is rapidly removed from the circulation (Jensen et al., 2011; Govers, 
2014). The processes are less effective in diabetic individuals than in non-diabetic 
people. However, in insulin resistant and T2D subjects, stimulating glucose disposal by 
insulin is reduced (Jensen et al., 2011).  In T2D, if glycogen stores are full then the body 
started to synthesis De novo lipid from the glucose (Jensen et al., 2011; Ameer et al., 
2014).   
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Chapter 3 (Methodology) 
3.1 Training  
First aid, defibrillation and phlebotomy training (Collecting venous blood samples 
should be taken by using aseptic technique via the vacutainer system).  
3.2 Exercise study design 
The diabetes and exercise physiology lab (DEPL) had been established by the research 
team which had the exercise equipment with good ventilation and room temperature 
control.  The lab and equipment checked regularly for safety.  
3.3 Recruitment of volunteers 
Ethical approval had been obtained by DMU Ethics committee.  The recruitment was 
by different way, posters distributed in the diabetes awareness day, in some schools, 
on twitter, diabetic UK, and DMU official website.  Confidentiality is very important so 
all data saved securely by code and number, all volunteer sheets stored securely. 
3.4 Volunteer information sheet 
This sheet explains the whole trial to the volunteers including aim and objectives. This 
will also provide the information about what they are going to do from week one to 
week six, what kind of test, and the offer that they will get by completing six weeks. 
3.5 Volunteer health screen 
This form contains patient name, email address, contact number, and home address.  
This is also made to take the patient past medical history, medication history, physical 
activity, and family history.   Moreover, if they have any medical problem or acute 
illness to decide that they can participate or not depending on the study exclusion and 
inclusion criteria.  This form should be kept in secure place only the research team can 
access to it.     
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3.6 Volunteer consent form 
This form to confirm that the volunteers had read the volunteer information sheet and 
agree to participate in the trial as well as they can withdraw any time if they cannot 
continue in the study for some reasons.  
3.7 Confidentiality 
To make sure that the volunteer information is confidential, each volunteer 
information recorded with their initial and type of diabetes (code). Only research team 
know what that code means. 
3.8 Exercise equipment 
3.8.1 Multi-use gym machine 
This machine (Body Craft Jones Maxrack 3D Machine) is used to perform resistance 
exercise which consists of squat, chest, back, biceps, and triceps.  Each step should be 
done for ten times and then repeat all steps for three sets.   
3.8.2 Ergometer bike 
The ergometer bike (Lode, Corival Recumbent, US) is used before starting any type of 
exercise to warm up and for aerobic exercise as well (see Figure 6). 
 
 
Figure 6: Ergometer bike 
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3.8.3 AD Instruments machine (ADI) Power lab system 
ADI Analysis System (PL3516/P ADInstruments, 16 channels, Australia) (see Figure 7).  
This instrument comprises a face mask, gas mixing chamber, gas analyser (oxygen and 
carbon dioxide, long tube to connect the face mask with gas mixing chamber. It is 
important to calibrate ADI each time before the volunteer starts cycling to give 
accurate reading.  Calibration can be conducted by using bag contains (16% oxygen 
and 4% carbon dioxide). All equipment e.g. tube, face mask, nose clip, head cover 
should be cleaned after each volunteer to avoid any infection. 
 
 
Figure 7: AD Instruments machine (ADI) Power lab system 
3.8.4 HbA1c analyser machine (Quo-Test A1c reagent kit) 
Que-Test A1c reagent kit is used to measure Glycated haemoglobin (HbA1c).  By using 
finger pricking procedure (FPP) and squeeze a large drop of blood on the cartridge 
then place it into the analyser.  In approximately 5 minutes the result will appear on 
the screen as well as a print of the result (see Figure 8). 
 
 
Figure 8: HbA1c analyser machine (Quo-Test A1c reagent kit) 
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 3.8.5 Lipid profile measurement machine Cholestech LDX analyser 
Cholestech LDX analyser (Cholestech Corporation 3347 Investment Boulevard, 
Hayward, CA 94545, USA) is used to measure lipid profile (TC, HDL, LDL, and TG). It 
consists of the analyser, test cassette, optical check, tube to collect blood, and 35 µl 
fixed volume pipette.   By using Finger Print Procedure (FPP), with draw a few amount 
of blood by pipette and place it on the test strip (cartridge) and then insert the strip in 
the machine by using buttons “RUN”, “DATA” and “STOP”.  In approximately five 
minutes the result will printout (see Figure 9).   
 
 
Figure 9: Lipid profile measurement machine Cholestech LDX analyser 
3.8.6 Blood glucose monitor by Finger pricking procedure (FPP) 
This process used to measure blood glucose (BG) during the exercise sessions and the 
OGTT.  First, sterile the finger with the alcohol swab, leave it until dry.  Use the lancet 
device to prick the finger, squeeze a big drop enough to measure BG.   Insert a strip in 
the blood glucose kit (Contour, BAYER, Ontario, Canada,) place the drop of blood on 
the strip, then the result will display on the screen immediately (see Figure 10). 
 
 
Figure 10: Blood glucose monitor by finger pricking procedure (FPP) 
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3.8.7 Lactate monitoring by (FPP): 
Lactate was measured in two time points, the first one before exercise once the 
volunteer arrive and the second one immediately after the cycling has completed.  This 
is conducted by using FPP as explained above in section (8.8.6).  Insert the lactate Pro 
2 strips in the blood lactate test meter (Lactate Pro 2, Konan-cho, Amstelveen, the 
Netherlands) (see Figure 11).   
 
 
Figure 11: Lactate monitor  
3.8.8 Heart rate (HR) monitor: 
The patient wears the HR monitor (Polar) on the chest which acts as a sensor. The 
patient then checks the watch (Polar) at the following intervals: 1) at resting, 2) after 
each set of resistance exercise (RE), 3) during 20 minutes of aerobic exercise (AE) (see 
Figure 12). 
  
 
 
Figure 12: Heart rate (HR) monitor 
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3.8.9 Rate of perceived exertion (RPE) 
By using Borg scale (1976) during RE and AE.  This scale started from 6 till 20, that to 
show that the perceived level of exercise to be between very very light to maximum 
exertion (see Figure 13).  
 
Figure 13: Rate of perceived exertion (RPE) Borg scale of perceived exertion 1976 
3.8.10 Blood pressure monitor (BP) 
Arm blood pressure monitor (Omron M10-IT, Omron Healthcare Co., Ltd, Japan) is 
used to measure blood pressure of the volunteers during the exercise session.  The 
volunteer should sit on the chair and relax for 10 minutes at least to make sure the 
reading is correct. The BP set is cuffed around the arm at the same level of the heart. 
The monitor then applies pressure to the arm in order to measure the BP (see Figure 
14).  
 
 
Figure 14: Blood pressure monitor (BP) 
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3.8.11 Collection and storage of venous blood samples 
Venous blood samples should be taken by using aseptic technique via the vacutainer 
system (see Figure 15). Venous blood samples collected from each volunteer (in 
combination exercise) total 21 samples.  In the first session for OGTT, a total of four 
samples (first one before drinking the oral glucose while fasting, the second sample 
was taken after 30 minutes, the 3rd one after one hour, then finally the 4th one after 2 
hours of drinking the glucose. In the second visit which is the first exercise session a 
total of three blood samples were taken, the first one before starting exercise, the 2nd 
after resistance exercise, and the 3rd one after aerobic exercise. The following day of 
the 1st exercise session, another OGTT is conducted and another four samples are 
taken as the 1st OGTT.  In the 2nd exercise session only one sample at the beginning 
then after that blood samples have been taken on 4th, 6th, 8th, 10th, 12th, and 4 samples 
are taken in the same manner as the previous two. 
 
 
Figure 15: Collection and storage of venous blood samples 
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3.9 ELISA machine 
This machine is equipped to scan and quantify colour reactions produced when 
chromophores bond to antibodies with which the antigen of interest interacts. ELISA 
(enzyme-linked immunosorbent assay) is a plate-based assay technique designed for 
detecting and measuring peptides, proteins, hormones and antibodies.  It is used to 
analyse insulin sensitivity and incretin level (see Figure 17). The general principle of 
ELISA involves immobilizing an antigen to a solid surface and then complexed with an 
antibody that is linked to an enzyme. Detection is accomplished by assessing the 
conjugated enzyme activity via incubation with a substrate to produce a quantifiable 
product (Mercodia, 2009). A highly specific antibody-antigen interaction is the most 
important component of the detection procedure. One of the advantage of this 
method is the step where non-bound material can be easily separated from bound 
ones during the assay. This ability to wash away non-specifically bound ingredients 
makes the ELISA a great tool for quantifying specific analytics. In ELISA, various 
antigen-antibody combinations are used, always including an enzyme-labelled antigen 
or antibody, and enzyme activity is measured calorimetrically. The enzyme activity is 
measured using a substrate that changes colour when modified by the enzyme. Light 
absorption of the product formed after substrate addition is measured and converted 
to numeric values. Depending on the antigen-antibody combination, the assay is called 
a direct ELISA, indirect ELISA, sandwich ELISA, competitive ELISA (Mercodia, 2009). 
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Figure 16: Procedure of ELISA 
 
 
In the present study, insulin and incretin will be analysed using a commercially-
available enzyme-linked immunosorbent assay (ELISA) with <0.01 cross reactivity with 
pro-insulin (Mercodia AB, Uppsala, Sweden).  The Microplate Reader with a plate 
shaker (IKA® MTS 2/4 digital, Germany) and Manta Software, (Labtech LT-4000, 
Ireland) are used to read and analyse the tests.  Mercodia is a solid phase two-site 
enzyme immunoassay. It uses a direct Sandwich technique where two monoclonal 
antibodies are directed against separate antigenic elements on the insulin or incretin.  
When samples are incubated, the insulin present in the sample reacts with both the 
anti-insulin antibodies bound to the microplate wells and peroxidase-conjugated anti-
insulin antibodies. And the unbound enzymes labelled antibodies are removed with a 
simple washing step, followed by the addition of a detection agent, 3,3`,5,5`-
tetramethylbenzidine (TMB). After incubation, an acidic solution is added to bring the 
reaction to a stop and a colorimetric measurement is conducted (Mercodia, 2009). 
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Figure 17: ELISA machine and Mecrodia Kit 
 
 
 
3.9.1 The procedure of insulin as the following: 
1- Mix two enzyme conjugate solution to prepare enzyme conjugate 1X and 
also need to prepare wash buffer solution. 
2- Add 25 µl of calibrators and the samples into wells in order. 
3- Pipette 100 µl of enzyme conjugate 1X to wells. 
4- Incubate wells on the plate shaker for 1 hour at room temperature (18-25˚ 
C) and (700-900 rpm). 
5- Wash wells quick wash for 6 times. 
6- Pipette 200 µl of substrate TMB in the wells. 
7- Incubate on the bench at room temperature (18-25˚ C) for 15 minute.   
8- Add 50 µl of stop solution to the wells and shake it on the plate shaker to 
mix it for 5 seconds. 
9- Read on the ELISA machine within half an hour to see the results. 
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3.9.2 The procedure for GLP-1 as the following: 
1- Prepare wash buffer solution and prepare enzyme conjugate 1X by mixing two 
different vials of enzyme conjugate.  
2- Mix 5 ml substrate reagent A with 5 ml substrate reagent B to prepare 
substrate working solution.  
3- Add 25 µl of calibrators and the samples into wells in order.  
4- Add 50 µl of enzyme conjugate 1X to wells. 
5- Incubate wells on the plate shaker for 2 hours at room (18-25˚ C) and (700-900 
rpm). 
6- Wash wells quick wash for 6 times. 
7- Pipette 100 µl of substrate working solution into each well. 
8- Incubate on the bench in the dark for 15 minutes at room temperature (18-25˚ 
C). 
9- Use a microplate reader for chemiluminescence.  Read all visible light (glow) 
with an integration time of 1 second.   
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3.10 RANDOX Machine 
 The Evidence Investigator™ (Randox, UK) is a Multiplexing ELISA technology (see 
Figure 18).  This machine is used to measure the level of C-peptide, CRP, cystatin, 
Interleukin -6 (IL-6), Tumour Necrosis Factor α (TNF-α), leptin and resistin.  
 
 
Figure 18: RANDOX Machine 
 
 The Evidence Investigator™ consists of Metabolic Syndrome Array I and Array II. 
3.10.1 The Evidence Investigator™ Metabolic Syndrome Array I (METS I) 
The Evidence Investigator™ Biochip Array technology is used to analyse blood 
sample for different test such as for insulin, IL-6, leptin, resistin and TNF α. 
3.10.2 Reagent composition 
1. METS I DIL ASY (1 × 14ml), is thevassay diluent 20 mM Tris Buffered saline pH 
7.5 containing protein, surfactant, blocking agents and preservatives. 
2. METS I CONJ (1 × 20ml), is the conjugate 20 mM Tris buffered saline pH 7.5 
containing protein, surfactant, preservatives and assay specific antibodies 
labelled with horseradish peroxidase (HRP). 
3. METS I BIOCHIP (54 BIOCHIPS), solid-phase substrate containing discrete test 
regions of immobilised antibody.  
4. METS I CAL (9 × 1ml), 9 vials of lyophilised base material containing analytes 
for the full array.   
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5. REAG SGNL-EV840 (1 × 10ml) and LUM-EV840 PX (1 × 10ml), mixed together 
in a ratio of 1:1 and give the working Signal reagent-EV40. 
6. BUF WASH (conc) (1 × 32ml), 20 mM Tris buffered saline, pH 4.4 containing 
surfactant and preservatives.   
7. Calibrator Concentration Disc and Barcodes I. 
 
Quality control kit: this contains a number of small vials with red cover to be used as 
quality detector of the procedure. For one METS I kit we need 3 vials of control. 
 3.10.3 Procedure 
1- Prepare samples to make sure that it dissolved before you start. 
2- All materials should be equilibrated to room temperature before use. 
3- Add 1 ml of double deionised water to the 9 vials of calibrator and 3 vials of 
control and then roll for 30 minutes.  
4- The 6 Biochip carriers should be attached to the handling tray. 
5- Pipette 200 µl of assay diluent in each well (total of 54 well). 
6- Pipette 100 µl of calibrator, control, and then the samples in order. 
7- Place the handling tray to the base plate of the thermoshaker and incubate it 
for 1 hour at +37° C and 370 rpm.   
8- Mix half the quantity of washing buffer with 500 ml distilled water to use it in 
washing the well.  
9- Remove the handling tray with the 6 carriers from the thermoshaker. Discard 
the reagents and then wash with the mixture that we prepare, carry out 2 quick 
wash, tap the side of handling tray and then carry out 4 long wash each one 
stays for 2 minutes.  
10-  After the wash pipette 300 µl conjugate into each well. 
11- Place the handling tray to the base plate of thermoshaker and incubate it for 1 
hour at +37° C and 370 rpm.   
12- While waiting for that to finish prepare the mixture (working Signal reagent-
EV40) and protect from light. 
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13- Remove the handling tray with the 6 carriers from the thermoshaker. Discard 
the reagents and then wash with the mixture that we prepare, carry out 
another 2 quick wash, and 4 long wash.  
14- After washing take off the first carrier and pipette 250 µl of the mixture 
(working Signal reagent-EV40), protect the biochip from light and wait for 2 
minutes thin place it into the he Evidence Investigator™. 
15- Repeat same step to rest of 5 biochips. 
16- The image will be capture automatically by software. 
17- Finally, you can check all your result in the computer.   
3.10.4 The Evidence Investigator™ Metabolic Syndrome Array II (METS II) 
This array has the same composition and same process except two steps only: 
1- The dilution of samples with 300 µl of the diluent is required, this diluent is 
available in separate box. 
2- Washing process here is different, 6 long washes instead of 4 long washes. 
3.11 Main exercise trial 
The study will involve 2 x 2 hours exercise sessions a week for a 6 weeks period.   
3.11.1 Introduction and orientation visit 
During the first visit of the volunteer, the volunteer is normally asked to complete 
some medical and personal information forms in order to obtain their initial data. 
During this visit, the student may use the opportunity to introduce the process to 
follow and also provide an initial orientation. This would include showing the 
volunteer the equipment and letting them try resistance exercise, cycling, and the 
testing equipment.  
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3.11.2 One repetition maximum (1RM) 
Before the volunteer start he must do a one repetition maximum (1RM) assessment 
to see what weight he can lift in resistance exercise by starting from low weight and 
increase it gradually to the maximum weight.  50-60% of this weight is used for the 
moderate exercise.  Also, the target heart rate is calculated from a formula by using 
(Resting heart rate and age).  But the 1RM is from a measurement.  This target heart 
rate should always be used when volunteer is cycling in the lab. Blood glucose levels 
will be monitored before, during and after each session, using a standard finger prick 
test. In addition, HbA1c, cholesterol (TC), high density lipoprotein (HDL), low density 
lipoprotein (LDL) and triglyceride (TG) will be measured at the baseline in the first 
session, and after last exercise session of six weeks programme using a finger prick 
test. Weight, height, BMI, waist, and lung capacity should be taken at baseline in the 
first session and then after six weeks. 
3.11.3 Study design 
Each exercise session will consist of a combined exercise protocol of 30 min of 
resistance exercise followed by 20 min moderate cycling (see Figure 19). The oral 
glucose tolerance test (OGTT) will be done to assess insulin sensitivity at the beginning 
and end of the programme and blood samples will be screened for other 
immunological parameters.  For exercise sessions once the volunteer arrive, he must 
attach a polar chest for heart rate monitor; then he/she asked to sit to check his BG 
by FPP.  After that blood pressure reading is taken and he should undergo the 
complete 11 steps stretching routine, then the volunteer must cycle for five minutes 
to warm up which is necessary before performing any kind of exercise to minimize 
post exercise pain or muscle stiffness.  After warmup he will start the first set of 
resistance exercise by doing all steps for 10 times (squat, chest, back, biceps, and 
triceps) and then the second and third set similar to the first one.   
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Figure 19: Combination exercise programme.  
3.11.4 Study groups 
The intervention group are T2D and ND who are doing combination exercise. 
Study group are classified in five groups 
1- T2D volunteers with no medication.  
2- T2D volunteers on Metformin only. 
3- T2D volunteers on Metformin and Dipeptidyl Peptidase 4 inhibitor (DPP4- I).   
4- T2D volunteers on Metformin and SGT2-I. 
5-  Non diabetes (ND).         
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3.12 Analysing process  
3.12.1 Analysing venous blood sample the following 
Inflammatory markers such as IL-6, TNF, leptin, resistin, cytostatin and CRP were 
analysed by using RANDOX and sampling time in the following sessions, 1st, 2nd, 4th, 
6th, 8th, 10th, and 12th.  While insulin was analysed by using ELISA, the sampling time 
was 4 times point during the three OGTT. Finally, GLP-1 was also analysed by using 
ELISA during 1st, 2nd, 4th, 6th, 8th, 10th, and 12th sessions.  
 
3.12.2 Analysing by FPP we analyse the following 
• BG Measure frequently before exercise after 1st, 2nd and 3rd set of RE then 10 and 20 
minutes after AE.  
• HbA1c (measure at the start and after the six weeks).  
• OGGT (measure the start after S1 and after the six weeks).  
• Lipid profile (measure at the start and after the six weeks).  
• Lactate testing (measure before exercise and after AE).  
 
3.12.3 Measuring the changes during the six weeks’ exercise programme in 
the following 
• HbA1c, BG, blood pressure, heart rate, and RPE.  
• Insulin sensitivity.  
• GLP-1.  
• Inflammatory markers.  
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3.12.4 Analysing by the ADI the following 
• Aerobic to anaerobic change using gas exchange: 
Oxygen consumption (Vo2), respiratory exchange ratio (RER), carbon dioxide 
production (Vco2), heart rate (HR), and bike revolution per minutes (RPM). 
 
3.12.5 Anthropometric measurement 
Measure body composition twice at baseline before start and then finally at the end 
after 6 weeks.  This include, weight (Kg), height (cm), body mass index (BMI), lung 
capacity and waist (cm). 
3.13 Study population 
1- Healthy subjects (ND). 
2- T2D.  
 
3.13.1 Sample size 
The target of the sample size for this study is 30 Volunteers.  
3.13.2 Intervention group 
(17 T2D) doing combination exercise and (8 ND) doing combination exercise. 
 
3.13.3 Selection criteria for volunteers 
In this study our target volunteers are T2D, and ND with age group from 18-60 years 
old who met the inclusion criteria.  
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3.13.4 Exclusion criteria 
People who had any of the following were not allowed to participate 
- Heart disease. 
- Liver disease. 
- Kidney disease. 
- Uncontrolled and very high blood pressure > 160/95 mmHg. 
- Injury. 
- Bleeding. 
- Epilepsy. 
- Acute exacerbated bronchial asthma. 
- Osteoporosis. 
- Arthritis. 
- Mentally ill. 
- Had recent surgery. 
- Using medication increase blood sugar e.g. steroids. 
- Using medication mask hypoglycaemic symptom e.g. beta blockers. 
  
3.14 Statistical analysis 
Data was analysed by using Excel 2010 and SPSS (version 22), Values were expressed 
as mean with standard error of mean (SEM).  Pre and post exercise samples were 
compared using a paired-samples t-test and the level of statistical significance was act 
at (P ≤ 0.05).   
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Chapter 4 The effects of a combined exercise programme on the body blood 
glucose, HbA1c, blood pressure, heart rate, lipid and other anthropometrics 
variables in T2D and ND. 
4.1 Research question 
Are there demonstrable health differences and improvement in HbA1c, blood glucose 
(BG), blood pressure (BP), heart rate (HR), lipid and other anthropometrics variable 
after the six weeks exercise intervention in T2D and ND that can be attributed to the 
intervention? 
4.2 Aim: 
The aim of the study is to investigate the effects of a combined exercise programme 
(i.e. a combination of cardio “aerobic” and resistance) on the body in T2D and ND 
participants.  This by assessing the improvement in HbA1c, BG, BP, HR and lipid.  
Moreover, to see if there are any reduction in weight, BMI and waist.  The aim of this 
study also to see the effect of these exercise on the body fitness.  
 
4.3Definitions 
4.3.1 Physical activity 
This is the contraction of skeletal muscle that occurs due to body movement. This 
movement needs energy spending additional to resting energy expenditure (Adeva-
Andany et al., 2016).   
4.3.2 Exercise 
A type of physical activity: designed, organized body movement repeated in constant 
manner to improve or sustain physical fitness (Lucotti et al., 2011). 
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4.3.3 Resistance exercise  
Resistance exercise (RE) is mainly anaerobic exercise which means that the body is not 
using oxygen in the total support of movement.  This type of exercise uses strength of 
the muscle to move a weight or do an effort against a resistive load (Lucotti et al., 
2011). RE such as weight lifting and using weight machines (Lucotti et al., 2011). 
4.4 Aerobic exercise 
Aerobic exercise (AE) is the type of exercise where oxygen is used for energy 
production from glucose.  Typically it increases heart rate (HR) and cardiorespiratory 
fitness from movement and exercise such as cycling running, swimming, bicycling, 
jogging and walking (Lucotti et al., 2011).   AE involves regular, repeated, and constant 
movements of similar large groups of muscle for at least 10 min interval (Lucotti et al., 
2011).   For diabetes, the American Diabetes Association (ADA, 2015) recommends 
performing at least 150 minutes per week of moderate-intensity physical activity (50 
- 70% of maximum heart rate) or 90 minutes at least weekly of vigorous aerobic 
exercise (more than 70% of maximum heart rate) (Garber et al., 2017).  Performing 
regular exercise at least 3 days a week, but not more than 2 consecutive days without 
doing any kind of physical activity. ADA, (2015) also recommends three times weekly 
of resistance exercise with three sets of 8 - 10 repetitions of weight lifting.  
4.5 Effect of exercise in the body 
The cell energy is known as ATP which is energy currency.  In case of muscle 
contraction, this ATP is broken-down by the myosin ATPase into adenosine 
diphosphate (ADP) and inorganic phosphate (P1) offers the energy for muscle 
contraction (Maughan, 2013).  During rest and to cover resting energy requirements 
of the cell, each muscle cell has approximately one billion ATP molecules.   The body 
will use these molecules and after that will regenerate it in 2 minutes (Maughan, 
2013).  On the other hand, in intensive exercise, the requirements of ATP of some 
muscle cells is estimated as 100 times bigger than during rest (Maughan, 2013). This 
part will discuss different studies on the effect of exercise on the body in term of 
HbA1c, blood pressure, lipid profile and anthropometrics variables.  
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Sigal et al., (2007) found that aerobic or resistance exercise training alone improved 
glycemic control, but the effects were more evident with both combined. Their study 
established that previous works had evaluated the effects that aerobic training and 
resistance training had on the glycemic control in patients suffering from T2D. The 
effects were assessed using the values of HbA1c that were obtained from the trials. 
As such (Sigal et al., 2007) set out a randomized controlled trial with the objective of 
determining the effects that training alone had on T2D patients. The project also 
included studying the effects of resistance training, and a combination of aerobic and 
resistance training on the values of HbA1c among patients suffering from T2D.  It also 
involved 251 T2D adult whose age ranged between 39 and 70 years and control group 
(Sigal et al., 2007). The change obtained was a significant reduction in the HbA1c in 
the aerobic training compared with control group (-0.05% and P = 0.007), while in the 
resistance group compared with control was significant (-0.38% and P = 0.038).  The 
result in the combined exercise group was additional reduction in the HbA1c by -0.46% 
when compare with aerobic training group (P = 0.014) and -0.59% in comparison with 
resistance training group (P = 0.001) (Sigal et al., 2007). In conclusion, a combination 
of both aerobic and resistance training produces a significant improvement compared 
to aerobic training alone or resistance training alone. Changes in blood pressure and 
lipid profile were insignificant in all groups.  Another study has been observed that in 
T2D, only the combination, but not aerobic and resistance training alone compared 
with the non-exercise group, improved HbA1c level (Church et al., 2010). The objective 
of the Church study was to examine the ways in which T2D patients could benefit from 
aerobic training only, resistance training alone and a combination of both. The effect 
was determined using HbA1c values.  Just like the previous studies, Church used a 
randomised design in which 262 sedentary participants. T2D participants with HbA1c 
level between 6.5% and 11% (Church et al., 2010). The control group had 41 
individuals, 73 practised resistance training for three days a week, 72 did aerobic 
training and 76 did combined both aerobic and resistance training. The result of the 
reduction of HbA1c in the combination training group vs the control group was (– 
0.34% and P = 0.03).  While in aerobic training the reduction in HbA1c was (– 0.24% 
and P = 0.14%).  In the resistance training the reduction in HbA1c was (– 0.16% and P 
=0.32).  It concluded that this combination achieves HbA1c levels that cannot be 
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achieved if either aerobic or resistance training is done alone (Church et al., 2010).  
According to Yardley the order in which different type of exercise is carried out may 
be important, performing resistance exercise before aerobic exercise improved 
glycemic control during exercise; it also reduced the severity and duration of post-
exercise hypoglycemia diabetes patients. The research study carried out by (Yardley 
et al., 2013) hypothesised that resistance exercise had the capacity to reduce HbA1c.  
The researchers set out the aim of examining the acute impacts that resistance 
training had on glycaemia.  There were significant changes in the glucose levels in 
plasma attenuated to the involvement of exercise. The level of glucose in plasma was 
noted to have reduced from 8.4 ± 2.7 to 6.8 ± 2.3 mmol/L.  It has been found that 
performing RE then AE improve HbA1c and decrease post exercise hypoglycaemia 
(Yardley et al., 2013). 
Aguiar et al., (2014) conducted six months of exercise RCT among men who are at high 
risk of developing T2D in Australia.  They hypothesised that a parallel-group, assessor-
blinded, randomised controlled trial could be used. The approach used was 
characterised by the fact that it had to last six months (Aguiar et al., 2014).  The 
primary outcome of this particular exercise was that the significant change of weight 
at the end of the six months (Aguiar et al., 2014). There were also several secondary 
outcomes of the study which include; physical activity, fasting plasma glucose, body 
composition, diet quality, waist circumference, muscular fitness and HbA1C levels 
(Aguiar et al., 2014). Other changes that were included blood pressure and body 
fitness.  (Aguiar et al., 2014) concluded that such exercises and programs significantly 
improved the risk factors of T2D patients.  
This research aimed at comparing the impacts of resistance training and aerobic 
training, as well as the combination of both on the glycaemic control, body 
composition and cardiovascular risk factors among patients suffering from diabetes 
(Yavari et al., 2012). They used a sample size of 80 that consisted of 37 men and 43 
women and divided them randomly. There were four groups, each with twenty 
people. The groups were divided so that the members could undergo different 
exercises such as resistance, aerobic, control and combined training (Yavari et al., 
2012). The exercise involved training that was done three times a week for the entire 
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year. The results showed that the HbA1c levels had dropped significantly in three of 
the four groups. The control group did not have any obvious change. The most 
significant changes that the individuals experienced were improvements in blood 
pressure, postprandial glucose, VO2max and muscular percentage (Yavari et al., 2012). 
A combination of any two exercises led to a significant improvement in such 
parameters as HbA1c and alone (Yavari et al., 2012).  This study is important to this 
research because it shows that better positive changes are obtained when the two 
methods are combined. 
It has been observed that premenopausal women with T2D report greater effort 
during exercise than the control group without diabetes, as measured by the Rating 
of Perceived Exertion (RPE) scale (Huebschmann et al., 2015).   Overweight, sedentary 
women aged 50–75 years with (n=26) or without T2D (n=28) have been enrolled in the 
Huebschmann study. Participants completed submaximal cycle ergometer exercise at 
30 W and 35% of individually-measured peak oxygen consumption (35% VO2peak).  
Exercise effort was assessed by RPE and plasma lactate concentration. According to 
the Huebschmann results showed that in T2D, VO2 peak was low comparing to 
controls (p=0.003).  The RPE shows no significantly improved in T2D versus controls 
(30 W: Control, 10.4±3.2, T2D, 11.7 ±2.3, p=0.08; 35% VO2peak: Control, 11.1±0.5, 
T2DM, 12.1±0.5, p=0.21). Nevertheless, lactate level was higher in T2D than in controls 
(p=0.004 at 30 W; p<0.05 at 35% VO2peak). Higher RPE was associated with higher 
lactate, higher heart rate, and a hypertension diagnosis (p<0.05 at 30 W and 35% 
VO2peak).  The conclusion shows that in older women the exercise effort was greater 
with T2D than controls because skeletal muscle unable to use glucose as energy fuel 
(Huebschmann et al., 2015).    
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 4.6 Method: 
 4.6.1 Study design 
In each exercise session the participant should perform a combined exercise program 
consists of 30 min of resistance exercise followed by 20 min moderate cycling.  This is 
done twice a week for 6 weeks. At the beginning of each session the participants have 
to stretch-up for 11 steps of stretching, then he/she must cycle for five minutes to 
warm up.  The RE consist of 3 sets, in each set the volunteer performed (squat, chest, 
back, biceps and triceps) 10 times.  HbA1c, lipid profile, weight, BMI, waist and lung 
capacity also measured at baseline and the 12th exercise session. OGTT were done at 
the beginning, after 1st session and finally after session 12. Moreover, BG and HR 
measured before exercise, after 1st, 2ndand 3rd RE then after 10 and 20 minutes of AE.  
BP also checked before exercise after RE and then after AE. RPE were checked after 
1st, 2nd and 3rd RE as well as after 10 and 20 minutes AE.  All the blood test measured 
by using FPP as discussed before in (section 3.8.6). 
 4.6.2 Intervention group 
The intervention group are T2D (n=17) 4 female and 13 male.  ND (n=8) 5 female and 
3 male who are doing combination exercise. 
Medication Number of Volunteers 
Pravastatin 40mg OD 1 
Atorvastatin 20mg OD 3 
Metformin 500 mg BD 3 
Metformin 850 TDS 1 
Metformin 1000 mg BD 2 
Sitagliptin 50 mg OD (DPP4-I) 1 
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Sitagliptin 100mg OD (DPP4-I) 2 
Empagloflizin 10 mg OD 2 
 
 
 
 
 
 
 
4.7 Results and discussion 
4.7.1 Anthropometrics variables 
 
 Table 9: T2D anthropometric variables: 
T2D Pre 1st Se Ex 
 
Post 12th Se Ex P value 
Age (years) 
 
48.6 ± 2.6                         -                      - 
Height (cm) 
 
170.35 ± 4.8                         -                      - 
Weight (kg) 
 
92.0± 4.3 90.0± 4.5 0.001 
Waist (cm) 
 
105.2± 3.6 102.3± 3.6 0.000 
BMI (kg/m²) 
 
30.8± 1.0 30.2± 0.9 0.001 
Lung Capacity 
 
381.8 ± 39.7 423.6 ± 33.6 0.001 
 
ND anthropometric variables: 
Table 10: Anthropometric variables for ND on combination exercise. Data expressed as Means± SE, 
and P value. 
ND Pre 1st Se Ex 
 
Post 12th Se Ex P value 
Age (years) 
 
31.6 ± 4             -              - 
Height (cm) 
 
167.4 cm ± 4.4             -              - 
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Weight (kg) 
 
58.86 ± 1.2 58.22 ± 1.2 0.490 
Waist (cm) 
 
73.7 ± 1.0 71.4 ± 0.5 0.052 
BMI (kg/m²) 
 
21.2 ± 1.2 20.9 ± 0.9 0.382 
Lung Capacity 
 
380 ± 26.7 580 ± 39.8 0.008 
 
 
Figure 20: Weight changes across whole exercise sessions in both groups 
 
 
Figure 19a: T2D weight shows CI 95% higher than zero which mean this difference is significant  
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      Figure 21: Waist changes across whole exercise sessions in both groups 
 
 
Figure 20a: T2D waist shows CI 95% higher than zero which mean this difference is significant.  
Error difference (waist Pre- waist Post) > 0 
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     Figure 22: BMI changes across whole exercise sessions in both groups 
 
 
Figure 21a: T2D BMI shows CI 95% higher than zero which mean this difference is significant  
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     Figure 23: Lung capacity changes across whole exercise sessions in both groups 
 
 
Data for all study groups are presented in section (9.1.1), table (10) for T2D and section 
(9.2.1), table (25) for ND.   They show the results Pre S1 of Ex and Post S12 of 
combination exercise across the six weeks and demonstrate the chronic effect of 
exercise on those variables.  In T2D the weight reduction was significant which 
decreased from (92.0± 4.3) to (90.0±4.5) and (P< 0.001), the waist was (105.2 ± 3.6) 
and decreased to (102.3± 3.6) which is also significant (P< 0.000). Moreover, the BMI 
reduction was significant, it was (30.8± 1.0) and decreased to (30.2± 0.9) and (P< 
0.001). This sort of finding reflects previous study conducted in obese older adults that 
also demonstrated improvement in insulin sensitivity (IS) and other cardiometabolic 
risk factors such as CRP (Bouchonville et al., 2014).  It has been also been found similar 
significant reduction in weight, waist and BMI in previous studies conducted among 
T2D (Aguiar et al., 2014; Sigal et al., 2007).  There was a significant improvement in 
lung capacity for T2D as well which improved from (381.8 ± 39.7) to (423.6 ± 33.6) and 
(P< 0.001).   In ND, the result of weight reduction improved from (58.86 ± 1.2) to (58.22 
± 1.2).  It has no significant changes when comparing pre S1 and post S12; in pre S1 
(58.86 ± 1.2) and post S12 (58.22 ± 1.2), (P value=0.490).  BMI shows no significant 
reduction in pre S1 (29 ± 0.4) and decreased to (28.1 ± 0.2), (P value=0.382).  The result 
of waist reduction was close to be significant, pre S1 (21.2 ± 1.2) post S12 (20.9 ± 0.9), 
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(P value =0.052), and previous studies found it significant (Aguiar et al., 2014; Sigal et 
al., 2007).  Finally, lung capacity improved as well with significant reduction, pre S1 
(380 ± 26.7), post S12 (580 ± 39.8), and (P value =0.008).   
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4.7.2 HbA1c: 
Table 11: HbA1c changes in T2D and ND exercise group. Data expressed as Means± SE, % of 
differences, and P value.  
 Pre S1 Post S12  P. value 
HbA1c mmol/mol (T2D) 
 
55.7± 2.7 48.9  ± 2.1 0.000 which is < 0.001  
HbA1c mmol/mol (ND) 34.6 ± 0.6 31.2± 0.2 0.003 
    
 
 
Figure 24: HbA1c changes across the exercise sessions in both group 
 
In T2D and ND as in figure 23, there was significant reduction in the HbA1c level.  These 
results demonstrate improvement in both study group.  However, the improvement 
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studies (Sigal et al., 2007; Church et al., 2010). In T2D the reduction was (-6.8 
mmol/mol “0.7 %”) and in ND the reduction was (3.4 mmol/mol “0.4 %”). In the 
present study, HbA1c results in both T2D and ND has been significantly decreased 
after 12th sessions of combination exercise which would give benefit in decreasing 
their risk of having CVD or microvascular complications.  As explained before in 
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HbA1c in the group who performed combination exercise of AE and RE shows 
reduction in HbA1c more than RE group and AE group.  These finding proved that AE 
and RE alone reduce HbA1c, however a combined of AE and RE showed more 
improvement than those of either programme alone (Aguiar et al., 2014; Sigal et al., 
2007; Church et al., 2010). A combination of RE and AE cause a significant 
improvement in HbA1c compared with when either aerobic or resistance training was 
used alone (Yavari et al., 2012). 
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4.7.3 Blood Glucose level 
 T2D and ND BG changes during 12 sessions of combination exercise: 
 
 
Figure 25: BG changes across the whole exercise sessions in T2D group. 
 
 
 
 
 
Figure 26: BG changes across the whole exercise sessions in ND group. 
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4.7.4 Chronic effect of BG 
There is a reduction in the mean BG values of each group of volunteers across 12 
exercise sessions especially session 8 and session 11, while it increased in session 12 
(see figure 24, 25).  In T2D, comparisons are made between sessions 1 (S1) and 12 
(S12) before exercise, after resistance training and after aerobic training.  Before 
exercise BG was in S1 (7.7±0.6) and then decreased in S12 (7.0±0.6).  The P value were 
P=0.210.  After resistance exercise in S1 BG was (7.5±0.6) and then decreased in S12 
to (6.7±0.5), P=0.164.  Finally after AE, in S1 the BG was (6.5±0.3) and decreased in in 
S12 to (5.7±0.4), P=0.072. P values all show no significant reduction in the T2D group. 
There was an improvement after AE when comparing S1 and S12 but insignificant. 
After AE, when comparing Pre S1 and post S12, a high reduction in BG is visible but 
this is still not significant because the P value is slightly higher than 0.05.  The reason 
for the lack of significant results may be due to two reasons that we know within the 
data source. One T2D volunteer had HbA1c = 7.5 % (58 mmol/mol) and his random BG 
was usually 14 mmol/l, which needs medical intervention but there was no anti-
hyperglycaemic medication prescribed for him. The second reason, was that another 
of the T2D volunteers had ran out of medication for the last 2 weeks of the exercise 
program; which affects the BG improvement. Looking at the BG in ND when comparing 
between S1 & S12 in Pre Ex, Post RE, & Post AE.  Before exercise, BG was in S1 
(5.4±0.19) and decreased in S12 to (5.1±0.59), P=0.66.   After resistance exercise, BG 
in S1 was (5.3±0.25) then decreased in S12 to (4.8±0.32), P=0.23.  After aerobic 
exercise, BG was in S1 (5.0±0.15) then decreased in S12 to (4.4±0.27), P=0.03).    These 
P values show that the only significant reduction when comparing (S1 & S12) after 
aerobic training. In T2D and ND performing moderate intensity exercise, the 
increment in peripheral glucose uptake is matched by an equivalent increase in 
hepatic glucose production (Borghouts et al., 2002). The current study shows that BG 
level was largely reduced after AE more than RE in both T2D and ND groups, which 
shown before in previous study by Yardley et al. (2013) who compared the effect of 
performing RE then AE with AE then RE on BG (Yardley et al., 2013).  
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4.7.5 Acute effect of BG in session 1 
In T2D as in figure 24, the result of BG before exercise, after resistance exercise and 
after aerobic exercise was presented as mean± SEM.  In session one the BG pre 
exercise was (7.7±0.6), while it was decreased after RE to (7.5±0.6) and finally 
decreased more after aerobic to (6.5±0.3) which shows reduction in the very short 
term (acute as in during the very first session on untrained bodies) in BG in response 
to exercise.  P values by comparing pre exercise and post RE (P=0.596), by comparing 
pre Ex and post AE (P=0.039) which shows significant reduction of BG after AE.  In ND, 
(figure 25) was as the following, before exercise (5.4±0.19), after resistance BG 
decreased slightly to (5.3±0.25), and after aerobic it decreases more to (5.0±0.15). P 
value by comparing pre Ex and post RE was (P=0.878) while by comparing pre Ex and 
post AE was (P=0.157) which shows no significant reduction after both RE and AE 
exercise in ND group.  Previous study found that BG has been improved after 
combination exercise of AE and RE (Prior et al., 2015). In this study, the finding show 
that the significant reduction of BG was only after AE in T2D.  
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4.7.6 Blood Pressure 
 BP changes during 12 sessions of combination exercise: 
 
 
Figure 27: SBP across the whole exercise session in T2D. 
 
 
 
Figure 28: SBP across the whole exercise session in ND. 
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Figure 29: DBP across the whole exercise sessions in T2D. 
 
 
 
Figure 30: DBP across the whole exercise sessions in ND. 
 
 
 
 
 
50.0
55.0
60.0
65.0
70.0
75.0
80.0
85.0
90.0
95.0
s1 s2 s3 s4 s5 s6 s7 s8 s9 s10 s11 s12
D
P
B
 (
m
m
H
g)
Exercise sessions
DBP in T2D
 DBP  Pre EX  DBP post RE  DBP post AE
40
50
60
70
80
90
S1 S2 S3 S4 S5 S6 S7 S8 S9 S10 S11 S12
D
B
P
 (
m
m
H
g)
Exercise sessions
DBP in ND
ND DBP Pre EX (comb) ND SBP POST RE (Comb)
ND DBP POST AE (COM)
 134 
 
The SBP results for T2D are shown in figure 26.  SBP before exercise in session one was 
(133.6±4.5) and decreased in S12 to (128.2±3.4).  It shows no significant reduction 
when comparing (S6 & S12, P=0.801) and in comparing (S1 & S12, P=0.131). Finally, 
after AE exercise the result of SBP shows significant changes only after S12, in S1 was 
(129.5±2.8) which decreased in S12 to (124.2±2.2), P=0.036).  Figure 28 shows the 
results for DBP in T2D.  Before exercise, DBP changes as the following, in S1 was 
(86.6±2.1) and decreased in S12 to (79.9±2.5), P=0.010 which shows significant 
reduction when comparing S1 and S12. Moreover, after aerobic training the reading 
was in S1 (82.5±1.8),) and in S12 (79.6±1.7), P=0.963. This result presented no 
significant improvement. In this study group T2D, some of the volunteers had 
hypertension and had been stabilised on medication, although one of them had high 
blood pressure readings despite antihypertensive medication. Due to this increment 
of BP for this volunteer the results shows no significant reduction.  In the ND, SBD 
results as shown in figure 27. Before exercise, SBP in S1 was (119.4±3.5) then 
decreased in S12 to (111.8±5.9), P=0.30. Finally, after aerobic exercise the SBP in S1 
was (114.0±4.6) then decreased in S12 to (113.4±2.6), P=0.83). DBP in ND results as 
presented in figure 29.  DBP before exercise in S1 was (73.6±2.1) which decreased in 
S12 to (70.2±3.4), P=0.12.  After aerobic DBP in S1 was (70.6±1.0) and decreased in 
S12 to (68.6±3.6), P=0.60.  In ND the reduction in SBP and DBP was not significant 
that’s might be due to that these group are healthy and has no hypertension so their 
BP reading is normal before and after exercise. Hypertension plays role in the 
development of the macrovascular and microvascular complications (Frontoni et al., 
2014; North and Palmer, 2015; Takao et al., 2014).  The reduction of BP helps in 
reduced cardiovascular mortality and improved renal outcome (Lovshin and Zinman, 
2014; Takao et al., 2014). In the study, the BP has improved but not as significantly as 
found in previous studies after the combination of AE and RE (Sigal et al., 2007; 
Laoutaris et al., 2013).  The reduction in this study was only significant in SBP after AE.  
Moreover, recent studies show that the BP decreases after AE which is accompanied 
with weight reduction and accompanied by an improvement in the vascular system 
(Eskandar, Katayon and Ali, 2015).  
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4.7.7 Heart rate 
 HR changes during 12 sessions of combination exercise 
 
 
Figure 31: HR changes across the whole exercise sessions in T2D. 
 
  
 
Figure 32: HR changes across the whole exercise sessions in T2D. 
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Figure shows HR improvement in T2D. At rest, HR was in S1 (80.1±2.60) and decreased 
in in S12 (73.8±2.6), P=0.023), it shows significant reduction when comparing S1 with 
S12.  The results show a reduction in HR in T2D patients before exercise and after the 
1st set of RE but this reduction was not significant.  After the 2nd set of resistance, 
there was a reduction across the 11th exercise session, however, in the 12th session 
the HR increase slightly. In the 3rd set of RE, the HR fluctuated while the increments 
were greater but showed no improvement. Figure shows ND result, resting HR in S1 
was (69.8±6.7) which increased in S12 to (75.2±8.1), P=0.433).  The HR shows 
reduction during 12th session after 1st, 2nd and 3rd set of resistance, nevertheless this 
reduction was not significant. As shown in the result, present study showed 
improvement in the resting and that was significant in T2D. These finding are in 
agreement with a previous study which found that a combination of AE and RE 
exercise programme in T2D had a good effect across all exercise sessions on the 
resting HR (Yavari et al., 2012)
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 4.7.8 Lactate 
Lactate changes in T2D during 12 sessions of combination exercise 
 
Table 12: lactate changes across (12 sessions) for T2D group.  Data expressed as Means± SE, % of 
changes and P value: 
 S1 S2 S3 S4 S5 S6 S7 S8 S9 S10 S11 S12 
Pre Ex 
 
2.5±0.3 2.8±0.6 2.5±0.5 2.9±0.6 2.6±0.4 2.5±0.5 2.1±0.4 2.3±0.2 2.4±0.5 2.7±0.3 2.1±0.4 2.3±0.5 
Post Ex 
 
10.7±2.3 10.0±2.6 10.9±2.3 6.3±1.4 6.6±1.1 5.3±0.5 5.5±0.4 5.6±0.4 4.9±0.3 4.7±0.7 4.8±0.8 5.1±0.6 
 
 
Figure 33: Lactate changes across the whole exercise sessions in T2D
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The data for lactate have been taken from T2D only because we only received the 
lactate kits after ND finished thier programme. As in section 5.7, table (22), the level 
of lactate before exercise in S1 was (2.5±0.3), in S6 was (2.5±0.5) and decreased in S12 
to (2.3±0.5).  P values as the following, by comparing (S1 & S6, P= 1.000), (S6 & S12, 
P= 0.792), and finally by comparing (S1 & S12, P=0.516).  After exercise, in S1 lactate 
was (10.7±2.3), then decreased in S6 to (5.3±0.5) and in S12 to (5.1±0.6).  P values are 
(S1 & S6, P= 0.077), (S6 & S12, P=0.574) and (S1 & S12, P=0.111).  The lactate level was 
improved more after exercise but this reduction was not significant.   It has been found 
in a systemic review by Asano et al. that the effect of aerobic exercise on lactate 
threshold is not enough studied and until now inconclusive (Asano et al., 2014).  High 
plasma lactate found in T2D, insulin resistance and obese subjects   (Consitt et al., 
2016). Lactate plays role in inhibiting glycolysis and insulin signalling which inhibits 
insulin-stimulated glucose uptake (see section 2.9) (Consitt et al., 2016).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 139 
 
 4.7.9 Respiratory exchange ratio (RER): 
 
Table 13: RER changes across (12 sessions) for T2D and ND groups.  Data expressed as Means± SE, % 
of changes and P value: 
RER S1 S2 S3 S4 S5 S6 S7 S8 S9 S10 S11 S12 
T2D 0.91±0.04 0.86±0.03 0.86±0.05 0.91±0.04 0.97±0.02 0.94±0.04 0.93±0.04 0.91±0.03 0.86±0.05 0.91±0.04 0.91±0.03 0.93±0.03 
ND 0.92±0.04 0.90±0.04 0.93±0.03 0.94±0.04 0.92±0.04 0.94±0.03 0.91±0.04 1.00±0.05 1.00±0.04 0.96±0.04 0.92±0.04 0.96±.004 
 
 
 
Figure 34: RER in both groups during 12 sessions 
RER is the ratio of carbon dioxide (CO2) volume that released from the lung to the 
oxygen (O2) enter and used by the lungs at the same time. The volume of consumed 
oxygen per minute is termed as VO2, while the volume of produced carbon dioxide is 
VCO2 (Jeukendrup and Wallis, 2005). Thus, the ratio of VCO2/VO2 is the RER.  The 
normal range of RER is (0.7- 1.0) which demonstrates the following types of substrate 
oxidation,: 0.7 shows fat oxidation, 1.0 shows carbohydrate (CHO) oxidation, and in 
between these values it shows oxidation of both CHO and fat (Ferrannini, 1988).  In 
the human body, the main source of energy is produced by carbohydrate (CHO) and 
fat metabolism (Jeukendrup and Wallis, 2005). CHO and fat catabolises to water, CO2 
and energy.  CHO oxidation requires less O2 molecules than fat oxidation.  
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The equation of CHO molecules oxidation is: 
6 O2 + C6H12O6 = 6 CO2 + 6 H2O + 38 ATP 
In this equation there are 6 molecules of CO2 which produced for every 6 molecules 
of O2 consumed through CHO oxidation which gives ratio of 1.0. 
The equation of fat molecules oxidation is: 
23 O2 + C16H32O2 = 16 CO2 + 16 H2O + 129 ATP 
In this equation the production of 16 molecules of CO2 for every 23 molecules of 
consumed O2 through fat oxidation gives ratio of 0.7 (Jeukendrup and Wallis, 2005). 
This results of this study shows that RER readings for T2D group are started in S1 
(0.91±0.04) and become in S12 (0.93±0.03) and for ND are between (0.92±0.04) and 
(0.96±.004), which represent that during 20 min of AE exercise CHO are mainly 
oxidised.   These findings from the decline of BG after to AE exercise during the whole 
exercise sessions shows that during our study CHO are mainly oxidized. These finding 
supported by Asano et al., (2014) and explained that during exercise, metabolic stress 
increased carbohydrate oxidation, increased O2 consumption after exercise which 
keep increasing fat oxidation at rest during recovery period after exercise and 
improving glucose tolerance and insulin sensitivity (Asano et al., 2014). 
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4.7.10 1RM & RPE 
4.7.10.1 1RM 
 T2D improvement in 1RM during 12 sessions of combination exercise 
Table 14: 1RM improvement comparing Pre S1 and Post S12 for T2D.  Data expressed as Means± SE, % 
of changes and P value: 
 1RM Pre Ex S1 1RM Post Ex 
S6 
1RM Post Ex 
S12 
P value  
Squat 
 
32.5±4.1  44.5±5.6 0.002 
Chest 
 
28.1±2.0  34.0±2.9  0.001 
Back  
 
51.8±3.8  67.6±4.0 0.000 
Tricep 
 
30.2±2.6  45.3±2.9 0.000 
Bicep 
 
28.2±2.1  35.9± 2.7 0.001 
 
 
 ND 1RM improvement during 12th sessions 
The available data for 1RM only before the 1st session of exercise and after the 6th 
session of exercise for ND on combination exercise. 
Table 15: 1RM improvement comparing 1RM Pre S1 and Post S6 for ND.  Data expressed as Means± 
SE, % of changes and P value: 
 1RM Pre Ex S1 1RM Post Ex S6 P value  
Squat 
 
45.0± 8.4 52.0± 6.4 0.024 
Chest 
 
28.0± 4.6 30.0± 5.7 0.186 
Back 
  
46.0± 4.0 54.0± 2.4 0.023 
Tricep 
 
24.0± 2.4 30.0± 3.2 0.076 
Bicep 
 
24.0± 2.4 28.0± 2.0 0.185 
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Figure 35: 1RM in T2D before S1 after S6 and after S12. 
 
 
Figure 36: 1RM in ND before S1 and after S6. 
 
Figure (34) represent the result of 1RM in T2D which was as the following; when 
comparing the 1RM before S1 and after S12 squat was (32.5±4.1) and increased to 
(44.5±5.6), P= 0.002 which is significant. Chest was (28.1±2.0) and increased to 
(34.0±2.9), P=0.001.  Back was (51.8±3.8) and increased to (67.6±4.0), P=0.000.  Tricep 
was (30.2±2.6) and increased to (46.0± 3.7), P= 0.000. Bicep was (28.2±2.1) and 
increased to (35.9± 2.7), P=0.001. P values shows significant improvement in the T2D 
fitness in the whole steps of resistance exercise which illustrate the benefit of 
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combination exercise on these group. Figure 35, shows the results of ND 1RM before 
S1 and 1RM after S6.  Squat was (45.0± 8.4) and increased to (52.0± 6.4), P= 0.02.  
Chest was (28.0± 4.6) and increased slightly to (30.0± 5.7), P=0.18. Back was (46.0± 
4.0) and increased to (54.0± 2.4), P=0.02. Triceps was (24.0± 2.4) and increased to 
(30.0± 3.2), P=0.07. Bicep was (24.0± 2.4) and increased slightly to (28.0± 2.0), P=0.18.  
The significant improvement in 1RM in ND was in squat, back and bicep, while in chest 
and triceps the increment was not significant.  
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4.7.10.2 RPE  
RPE changes during 12 sessions of combination exercise 
 
 
 
 
Figure 37: RPE across the whole exercise sessions in T2D. 
 
 
 
 
 
Figure 38: RPE across the whole exercise sessions in ND. 
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Figure 36 shows mean± SEM for RPE in T2D in 5 occasions, after 1st, 2nd and 3rd set of 
resistance training, and after 10 and 20 minutes of aerobic exercise. The results show 
reduction in these 5 occasions across 12th exercise sessions. After the 1st set of resistance, 
RPE in S1 was (12.8±0.24) and decreased in S6 to (11.8±0.33) and in S12 to (11.8±0.32).  P 
value was (S1 & S6, P=0.024), (S6 & S12, P=1.00), and (S1 & S12, P=0.034). After 2nd set of 
resistance, RPE decreased significantly when comparing S1 & S12, P=0.011.  After the 3rd set 
of resistance, RPE decreased in S12, P=0.011).  After 10 minute of AE, RPE decreased in S12, 
P=0.002. After 20 minute of aerobic, RPE decreased also in S12, P=0.001. The improvement 
in T2D fitness can be presented in their RPE which shows significant reduction across the 
whole exercise session.  Their feeling of the difficulty of the exercise became more less during 
the 12th sessions which illustrates a very good improvement in their body fitness. Figure 37 
shows mean± SEM for RPE for ND in 5 occasions, after 1st, 2nd and 3rd set of resistance 
training, and after 10 and 20 minutes of aerobic exercise.  As in T2D the results show reduction 
in these 5 occasions across 12th exercise sessions.  Post 1st set of resistance, RPE decreased 
in S12, P=0.503 which not significant. Post 2nd set of resistance, RPE also decreased in S12, 
(P=0.19) not significant as well.  Post 3rd set of resistance, RPE decreased significantly in S12, 
P=0.07. While post 10 minute of aerobic, RPE decreased but not significantly, P=0.141.  Finally, 
post 20 minute of aerobic, RPE was decreased in S12, P=0.093 which also not significant. 
There was a reduction in RPE but significant in T2D, not in ND group, which demonstrates that 
the level of exercise was not as hard as compared to the position before the commencement 
of the exercise programme. In a previous study, greater RPE was associated with higher 
lactate, higher heart rate, and patients diagnosed with hypertension (Huebschmann et al., 
2015). Their conclusion shows that in older women the exercise effort was greater with T2D 
than controls (Huebschmann et al., 2015).  
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4.7.11 Lipid profile 
 Lipid profile at baseline and after 6 weeks of exercise 
Table 16: Lipid profile changes among T2D group. Data expressed as Means± SE, and P value. 
 Pre 1st Se Ex Post 12th Se Ex P value  
TC 4.44± 0.40 4.40± 0.35 0.867 
HDL 1.27± 0.21 1.25± 0.14 0.884 
TRG 1.58± 0.22 1.58± 0.31 1.000 
LDL 2.25± 0.38 2.48± 0.26 0.767 
Non-LDL 2.96± 0.31 3.16± 0.27 0.482 
LDL/HDL 2.42± 0.48 2.10± 0.20 0.403 
 
Table 17: Lipid profile changes among ND group. Data expressed as Means± SE, and P value. 
 Pre 1st Se Ex Post 12th Se Ex P value  
TC 3.94± 0.26 3.85± 0.40 0.756 
HDL 1.50± 0.19 1.55± 0.17 0.301 
TRG 1.49± 0.27 1.28± 0.36 0.246 
LDL 2.17± 0.10 2.32± 0.27 0.621 
Non-LDL 2.67± 0.22 2.63± 0.34 0.891 
LDL/HDL 1.57± 0.12 1.69± 0.32  0.780 
 
 
Figure 39: TC changes in both groups 
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Figure 40: TRG changes in both groups 
 
 
Figure 41: LDL changes in both groups 
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Figure 42: HDL changes in both groups  
As shown in (figure38, 39, 40 and 41), in T2D there was a minimal reduction in TC (P=0.867), 
however HDL (P=0.884) had been slightly decreased and LDL (P=0.767) slightly increased 
while no changes in TRG (P=1.000). Most T2D volunteers use statins which plays role in 
improving the lipid profile results.  All ND volunteer has normal level of lipid profile TC (P= 
0.756), LDL (P=0.621), and TRG (p=0.246) which shows minimum reduction. While HDL 
(P=0.301) increased slightly. Sigal et al., (2007) has found previously insignificant changes in 
lipid values which is similar to the current study.  
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4.8 Conclusion  
In conclusion, T2D combination exercise was shown to have a significant effect on HbA1c, and 
the anthropometric variables (weight, waist, BMI and lung capacity). This finding is in 
agreement with that reported by Sigal et al., (2007) and Yavari et al., (2012) where the effects 
of aerobic and resistance training, alone and in combination were shown to have effects on 
glycaemic control, specifically on HbA1c in T2D patients, although the combined exercise 
were shown to have greatest effect. In addition, the present study shows a reduction in BG 
after performing resistance exercise then aerobic exercise when compared to aerobic 
exercise then resistance exercise. Thus, the order of the exercise is seen to have an effect on 
glycaemic control, this finding correlates with that reported in the studies of Yardley et al., 
(2013). Furthermore, the present study showed that combination exercise is valuable in 
improving insulin sensitivity in T2D where OGTT shows a very significant improvement of BG 
level in both groups, which was higher in T2D.  The studies conducted by Davidson et al., 
(2009) corroborate these findings by inferring that combination exercise decreases insulin 
resistance, thus improve insulin sensitivity (Davidson et al., 2009). Other variables observed 
in T2D included SBP and DBP, and minimal reduction was observed with slight increment at 
S12. However, the effect on the mean was due to persistent hypertension of one of the 
volunteers.  More so, Resting HR improved significantly after 12th sessions of exercise which 
is also reported in studies conducted by Maiorana et al., (2002). However, HR reduction after 
resistance exercise in the present study was minimal which increase slightly at S12.  The 
improvement in 1RM after the six weeks’ exercise was significant in T2D for the five different 
RE exercises working upper and lower muscle group (Chest, Squat, Back, Biceps and Triceps) 
which illustrates the benefit of combination exercise on body fitness. In ND there was a 
significant improvement only in squat and back, not in the chest, triceps, and bicep exercise. 
Similar findings were demonstrated by previous study as both back and squat induced 
improvements in sprint performance (Seitz, Trajano and Haff, 2014).  Many factors can affect 
results observed such as diet, adherence to anti-diabetes and anti-hypertensive medication 
and other medications. The improvement in the control group in lipid and HbA1c, BMI and 
OGTT represent their adherence to medication and diet (Jorge et al., 2011). However, the 
reduction in lipid profile in this study was not significant, which could be due to the normal 
range of lipid profile recorded for the ND group prior to the main exercise. Also, the lipid 
profile in T2D was not elevated before the main study, and individuals were using statin which 
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makes the result invalid in term of the effect of exercise as an improvement, however, 
previous study by Gordon et al., (2008) and Kelley and Kelley, (2007) showed that 
combination of conventional exercise and yoga, and aerobic exercise, respectively,  have 
effects on lipid profile of adults with T2D. In addition, there was a reduction in lactate, 
however, it was not statistically significant. Although, the study of Crawford et al., (2010) 
associated plasma lactate with the prevalence of T2D and inferred that the measurement of 
this variable can be used as a biomarker in observing the decreased oxidative capacity 
associated with insulin resistance. Finally, this study recommends that the combination 
exercise programme of resistance and aerobic is valuable for T2D because it has the 
advantages skeletal muscle strength which is supported by the improvement in 1RM. Previous 
study showed similar finding that high load resistance exercise improved muscle strength 
(Schoenfeld et al., 2015). It is also shows improvements in glycaemic control as found also 
different studies before, however, this study was conducted for 6 weeks which no one else 
has done it before.  Moreover, the new finding in the current study that no other researcher 
has conduct it before are the GLP-1 comparison within T2D group who are using different 
medications (chapter 6) and the inflammatory markers which also compare between T2D and 
ND as well as within T2D who are using different medication (chapter 7).  
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Chapter 5 The effect of moderate combination exercise (cardio “aerobic” and 
resistance) on the insulin sensitivity in T2D and ND subjects 
5.1 Research question: 
Is the insulin sensitivity (IS) improved after 6 weeks of moderate combined exercise? Do the 
improvements correlate with medication type?  
5.2 Aim: 
The aim of the study is to investigate the effects of a combined exercise programme AE and 
RE on blood glucose and improve IS in T2D and ND. Moreover, to assess IS and insulin 
resistance (IR) by different indices. This study also aimed to assess the IS and IR after 6 weeks 
of combination exercise and see the effect of different medication on IS in T2D by using 
different assessment methods.  
 
5.3 Insulin resistance (IR)  
Insulin is a peptide hormone which enhances the growth cells and stimulates lipogenesis, 
glycogen and protein synthesis and prevents glycogenolysis, lipolysis and protein breakdown 
(Antuna-Puente et al., 2011; Mann and Bellin, 2016).  The definition of IR is when the insulin 
has minimum biological effect on the target tissues (Henríquez et al., 2013). It is considered 
as the main defect underlying T2D pathogenesis and associated with obesity and METs 
(Henríquez et al., 2013). It was found in T2D that the pancreas increases secretion of insulin 
where the subject becomes IR (Lee et al., 2010). In previous studies cardiovascular disease, 
diabetes, hypertension, hypertriglyceridemia, obesity and physical inactivity have a strong 
correlation with IR (Dube et al., 2012; Lorenzo et al., 2015; Verheggen et al., 2016; Lee et al., 
2010).  According to Lee et al., in 1998, a World Health Organization (WHO) consultation 
report recommended term for this condition, which is “metabolic syndrome” (Lee et al., 
2010).  Generally, IR starts many years before the diagnosis of T2D and can be considered as 
a genetic factor (Tangvarasittichai, 2015).  Insulin deficiency and IR are the main features of 
the T2D.  Abdominal obesity, modern sedentary lifestyle, cause disturbance in adipokines 
secretion and then insulin resistance (adipokines will explain more lately in chapter 7).  It has 
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been stated that the accumulation of intramuscular fat leads to insulin resistance and 
developed T2D (Asano et al., 2014).  Recently, several mechanisms have been proposed to 
explain how obesity and/or FFA can interfere with insulin signalling (Boden, 2011). As shown 
previously in section (2.7.6) additional glucose from diet enters the Krebs cycle in the 
mitochondria and produces pyruvate then Acetyl CoA then citrate which converts again to 
Acetyl CoA and via enzyme HMG CoA reductase this can produce cholesterol (see figure 3) 
(Mann and Bellin, 2016). Acetyl CoA is able to convert to FFA which then combine to glycerol 
in cytoplasm to procedure TRG and store it in adipose tissues (Morgantini et al., 2014). The 
accumulation of TRG causes IR (Boden, 2011).  Many substances stored in adipose tissue such 
as FFA, resistin, TNF and interleukin 6 (Boden, 2011).  All these substances can lead to IR when 
infused in high amount in the body.  Nevertheless, these substances should meet 3 criteria to 
consider as having physiological link between obesity and insulin resistance. The first criteria 
is that the substance elevated in the blood of obese people. The second that when the blood 
level of this substance elevated this caused elevation in IR. The third criteria is that when the 
low blood level of this substance decreased it caused reduction in the IR.  Therefore, FFA is 
only can meet these 3 criteria in human subjects (Boden, 2011).  In obesity, FFA levels found 
elevated in plasma due to the enlargement in adipose tissue mass which secretes more FFA.  
The clearance of FFA might reduce as well. Furthermore, in plasma if the FFA levels are high 
that prevent the anti-lipolytic action of insulin which will promote high production rate of FFA 
into the circulation (Boden, 2011). In the body after infusing lipid emulsion, there is an acute 
elevation of FFA into circulation which reduces insulin stimulated glucose uptake mainly in 
skeletal muscle. IR occurs within 2-4 of infusion and then disappear after 4 hours of 
elimination (Boden, 2011).  Elevated FFA have been found caused an impairment in insulin 
signalling which leads to deficiency in stimulated glucose transport and/or phosphorylation. 
The elevation of FFA intracellularly cause reduction in GLUT4 translocation to the plasma 
membrane which decreases the sensitivity of insulin receptors (IRS) to insulin and then insulin 
resistance (Ceriello and Motz, 2004; Nolan et al., 2015; Boden, 2011). It is known that plasma 
FFA are move into cells and oxidize to produce ATP or store as TRG.  As a result, high FFA 
levels in the circulation cause accumulation of TRG intracellular (Boden, 2011).  High levels of 
FFA, glucose and insulin stimulates over secretion ROS, which correlates with oxidative stress 
and causes acceleration of the onset of T2D (Tangvarasittichai, 2015).   
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The mechanism of insulin resistance occurred in the mitochondria by enhancing the 
superoxide release on mitochondrial electron transport chain (Ceriello and Motz, 2004; 
Tangvarasittichai, 2015; Boden, 2011).  That by over production of FFA and glucose in the 
circulation leads to high TG in the muscle and adipose tissue which increased the secretion of 
AcetylCoA.  AcetylCoA then enters the citric acid cycle and elevates the generation of electron 
donor (NADH) which increases membrane potential (H).  High production of NADH that is 
unable to degenerate by oxidative phosphorylation, the proton gradient in the mitochondrial 
increases and single electrons are transported to oxygen which causes the production of free 
radicals superoxide (Ceriello and Motz, 2004; Tangvarasittichai, 2015; Boden, 2011).  FFA 
consider as a pro-inflammatory mediator that activated the nuclear factor-κB (NF-κB).  NF-κB 
is a protein complex and plays an important role in regulating the immune response to 
infection, so irregulation of NF-κB has been associated with cancer, inflammatory and 
autoimmune diseases (Tangvarasittichai, 2015). NF-κB leads to overproduction of ROS and 
minimise glutathione production (Tangvarasittichai, 2015).  It has been proves that vitamin E 
supplementation prevents the activation NF-κB by FFA (Tangvarasittichai, 2015). Antioxidants 
help in protection β-cell from the oxidative stress and inhibit its toxicity, inhibit activation of 
NF-κB and minimise the production of AGEs. Examples of antioxidants are zinc, N-acetyl 
cysteine (NAC), aminoguanidine and α-phenyl-tert butylnitrone (Tangvarasittichai, 2015).   In 
the normal physiological conditions, antioxidants in the cell reduce the level of ROS 
(Tangvarasittichai, 2015). In hyperglycaemia in T2D, the increased level of glucose stimulates 
oxidative mechanisms and minimizes the antioxidant defence system (Tangvarasittichai, 
2015).  In addition to which the body fails to counteract the elevated generation of reactive 
oxygen species (ROS) (Tiwari, 2013). This leads to an imbalance between ROS and its 
protection, and this causes oxidative stress and cellular injury (Verdile et al., 2015).  Although 
ROS performs several regulatory functions in cells, uncontrolled or overproduction of ROS has 
adverse effects (Verdile et al., 2015). It should be noted that ROS levels are increased in cases 
of obesity, mainly abdominal obesity (Tangvarasittichai, 2015).  Oxidative stress mediates IR 
and impaired intolerance glucose tolerance as well as the development of diabetes, which 
consequently leads to atherosclerotic complications as well as micro- and macrovascular 
complications (Tiwari, 2013; Verdile et al., 2015). 
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Reactive nitrogen species (RNS) and ROS have negative regulation effects on the process of 
insulin regulation associated with the prevalence of resistance to insulin and T2D (Verdile et 
al., 2015).The elevation of oxidative stress acts as a risk factor in causing β-cell dysfunction, 
IR, dyslipidemia, impaired glucose tolerance and finally developing T2D (Tangvarasittichai, 
2015).   Hyperglycemia leads to increased production of hydrogen peroxide (H₂O₂), as well as 
the down-regulation of the gene that expresses catalase “antioxidant enzyme” (Patel et al., 
2013). Oxidative stress in T2D causes various adverse impacts on the physiology of cells. These 
include lipid peroxidation.  ROS target lipids, where hydroperoxides cause toxicity on cells via 
degradation.  Reactions between hydroperoxides with copper and iron form 
malondialdehyde (MDA), which damages cell membranes. Change in the structure and 
metabolism of lipids is reported in diabetes specifically in cases of vascular complications 
(Tiwari, 2013). Increased MDA levels in individuals with diabetes suggests that injury due to 
peroxidation is implicated in diabetic complications.   Increased lipid peroxidation indicates a 
drop in non-enzymatic and enzymatic antioxidants' defence mechanism (Saddala et al., 2013).  
Secondary complications of diabetes such as neural disorders and atherosclerosis are induced 
by lipid peroxidation (Ramesh et al., 2012). Consistently, an increase in lipid peroxidation 
shows a close association with high levels of glucose in patients with diabetes (Bandeira et al., 
2012).  Proteins are also potentially targeted by ROS (Tiwari, 2013). The product of protein 
oxidation is carbonyls, and these are biomarkers of the existence of oxidative stress (Tiwari, 
2013). An increase in the level of content of protein carbonyl (PC) and malondialdehyde 
(MDA) are reported in the cells and plasma of the patients with diabetes. PC is a marker of 
protein oxidative damage, while MDA is a marker of lipid oxidative damage (Deokar, Jagtap 
and Yerawar, 2016). An increase in PC and MDA among the patients with diabetes are 
important in the pathogenesis of diabetes complications (Deokar, Jagtap and Yerawar, 2016). 
Catalase is another biomarker of oxidative tension in T2D.  Shortage of catalase causes the β 
cells in the pancreas to experience oxidative stress through the production of excess ROS, 
which leads to dysfunction in β cells and eventually diabetes (Tiwari, 2013).  Furthermore, 
superoxide dismutase (SOD) is involved in protecting against histological and cellular damage 
due to ROS (Patel et al., 2013).  (Wang et al., 2011) have indicated that when SOD is over-
expressed, it prevents diabetes by overcoming oxidative stress, minimising (ROS), and 
increasing antioxidant enzymes.  Finally, oxidative stress also affects glutathione (GSH) levels 
in patients with diabetes by lowering the GSH level (Calabrese et al., 2012). Indeed, the 
 155 
 
complications associated with lowered GSH in the plasma include inflammation and 
hyperlipidemia in patients suffering from diabetes (Das, Vasan and Sil, 2012). The 
accumulation of FFA leads to the inhibition of glucose oxidation, glycogen synthesis, and 
elevate the production of advanced glycation end product (AGE) (Nolan et al., 2015). 
Elevation of FFA and glucose levels has been found to stimulate inflammatory markers as a 
result of elevation of oxidative stress, ROS and reduced antioxidants (Tangvarasittichai, 2015).  
Pro-inflammatory markers are detected in different diseases such as T2D, atherosclerosis, 
cancer and aging (Tangvarasittichai, 2015). Numerous clinical trials have found that some 
antioxidants medication could improve insulin sensitivity in insulin-resistant subjects, such as 
glutathione vitamin C, or vitamin E (Ceriello and Motz, 2004; Tangvarasittichai, 2015).    If 
there is mild postprandial hyperglycaemia, hyperinsulinaemia and insulin resistance, this can 
be considered as an impaired glucose-tolerant state (Codario, 2011).  This conclude that high 
fat diet and obesity are linked to insulin resistance, inflammation and T2D.  
 
5.4 Factors stimulated by insulin resistance 
Many factors are stimulated by IR such as enhanced lipolysis i.e. adipose cells produce free 
fatty acids, inhibition of glucose transport and phosphorylation (Antuna-Puente et al., 2011; 
Codario, 2011). Moreover, reduction of glucose oxidation rate and glycogen synthesis, 
increased apolipoprotein B secretion and hepatic lipase activity (Antuna-Puente et al., 2011; 
Codario, 2011).  As a result, high levels of free fatty acids prevent insulin secretion from the 
beta cells, which leads to decreased IS in the muscles and liver.  IR and T2D are characterized 
by dyslipidaemia which is a main risk factor for CVD (Tangvarasittichai, 2015). Eating high fat 
diet, creates a chylomicron rich in TG which triggers elevation of hepatic FFAs and VLDL TG-
rich particles secretion. That influence metabolism of HDL-C by exchange with TG- rich 
lipoproteins via cholesteryl ester transfer protein to release particles of HDL consists of high 
concentrations of TG (Tangvarasittichai, 2015). Moreover, hepatic lipase hydrolysed the 
particles of HDL-TG to HDL and TG.  The HDL molecule is very small which facilitates its 
excretion from the kidney. This elevation of TG and reduction of HDL leads to dyslipidaemia 
(Tangvarasittichai, 2015).  
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5.5 Assessment of methods and indexes of insulin sensitivity  
 
IR linked to obesity, dyslipidemia, hypertension, atherosclerotic vascular disease, stroke and 
coronary heart disease and plays crucial role in the pathophysiology of diabetes (Patarrão, 
Lautt and Macedo, 2014; Gutch et al., 2015).  The β-cell secretes Insulin and C- peptide at 
equivalent amount in the plasma. Therefore, the level of insulin secretion can be estimated 
from plasma C-peptide level which is a marker of insulin secretion (Dickson et al., 2016). 
Nevertheless, peripheral insulin has shorter half-life than C-peptide which affect accuracy of 
assessing insulin secretion by measuring C-peptide (Ajmera et al., 2013).  Thus, it is very 
essential to measure IS and IR in human (Patarrão et al., 2014; Gutch et al., 2015).  Berson 
and Yalow won the Nobel Prize by discovering a technique to measure blood insulin 
concentration in the late 1950s (Lee et al., 2010).   Recently, there are several methods and 
indexes to assess IS and IR (Patarrão et al., 2014; Gutch et al., 2015).  These methods assist in 
investigating the pathophysiology and epidemiology and the effect of therapeutic agents and 
indeed the best way of assessing the progression in human from normal glucose tolerance 
(NGT) to T2D is by measuring the IS (Davidson, Docherty and Chase, 2014) (Patarrão et al., 
2014).  There are diverse glucose tolerance tests have been used to diagnose prediabetes and 
diabetes subjects.  Examples of these diagnostic tests, intravenous glucose tolerance test 
(IGTT), oral glucose tolerance test (OGTT) and meal glucose tolerance test (MTT).  It is used 
to assess IS, glucose effectiveness (SG), β-cell function and insulin secretion (Ajmera et al., 
2013). Furthermore, different physiology-based indexes are used as well for diagnosis e.g. 
Matsuda, HOMA, QUICKI and CIGMA (Ajmera et al., 2013).  Currently, the best consistent 
methods to quantify IR are hyperinsulinemic euglycemic clamp (HIEC) and intravenous 
glucose tolerance test (IGTT) (Gutch et al., 2015). Different indices have been used in different 
situation and so for clinical uses the best indices that are applicable be use are HOMA, QUIKI 
and Matsuda, while in the epidemiological studies the suitable indices are McAuley, Belfiore, 
Avignon, Cederholm, HES and Stumvoll (Gutch et al., 2015).  
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5.6 Methods of insulin sensitivity/resistance assessment 
5.6.1 Hyperinsulinemic Euglycemic Clamp (HIEC) 
The HIEC test is established by DeFronzo, it is known as the “gold standard” test (Muniyappa, 
Madan and Quon, 2015; Patarrão et al., 2014; Davidson et al., 2014).  This test needs 2.5- 4 
hours to be done as well as it needs to draw up to 20 blood samples (Davidson et al., 2014).  
In this test, insulin should infused to fasting individuals at infusion rate from 5 – 120 
mU/m²/min (dose per body surface area per minute, through 180 minutes. The advantage of 
HIEC is that it quantifies the disposal of the whole body glucose at a certain level of 
insulinemia in steady-state condition, so direct measure insulin at steady state condition 
(Gutch et al., 2015). HEIC has some limitations as it is expensive, needs intravenous infusion, 
requires many workers who had very good experience, frequent blood samples and time 
consuming.  
Equation: IS Clamp = MG×ΔI 
 M is normalized for G (steady-state blood glucose concentration)  
 ΔI is (the difference between fasting and steady-state plasma insulin concentrations) 
5.6.2 Insulin tolerance test (ITT) 
ITT is a good method to measure insulin resistance and has a good correlation with the 
frequently sampled intravenous glucose tolerance test (Sin et al., 1996).  It is a valid and useful 
test for evaluating IS in diabetes individual, even after insulin treatment (Okita et al., 2014). 
It can be conducted by infusion intravenous insulin at rate 0.1 IU/kg for fasting individuals. 
Blood samples collected at 9 times points (2 samples before infusion and 7 after). After half 
an hour, intravenous glucose should be injected to avoid any hypoglycaemia. IS can be 
measured in the individuals as the faster the decrease in blood glucose, the better the IS. The 
equation is to measure the linear decline in plasma glucose (KITT) by dividing 0.693 by the 
plasma glucose half-life (the reduction by 50% from baseline):  
Equation:  KITT=0.693/t1/2×100 
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5.6.3 Insulin suppression test (IST) 
IST methods developed by Shen et al. in 1970 and later amended by Harano et al. which is 
quantifies directly IS and IR (Patarrão et al., 2014; Muniyappa et al., 2015; Bonadonna et al., 
2018; Kim et al., 2016).  This test is used to suppress insulin and glucagon endogenous 
secretion. The IST conducted by the infusion of somatostatin (250 µg/h) or octreotide 
“somatostatin analog” (25 µg bolus then intravenous infusion 0.5 µg/min) (Patarrão et al., 
2014; Muniyappa et al., 2015).  Intravenous glucose (240mg/m²/min) and intravenous insulin 
(25 mU/m²/min) infused at the same time over 3 hours. Every 30 min the blood samples 
should be taken over 2.5 hours.  The steady state of plasma insulin (SSPI) and glucose (SSPG) 
started from 150 minutes to 180 minutes of IST, thus the blood samples should be then taken 
every 10 minutes at that time (Patarrão et al., 2014; Muniyappa et al., 2015).  The advantage 
of (SSPI) and (SSPG) that it needs few numbers of workers, less technically demanding than 
HIEC and measures directly the metabolic action of insulin.  IST has some limitations such as 
it needs intravenous infusion, expensive and time consuming (Patarrão et al., 2014; 
Muniyappa et al., 2015).   
 
5.6.4 Continuous infusion of glucose with model assessment (CIGMA) 
CIGMA methods needs intravenous infusion of glucose, then IS should be measured near 
steady state of insulin and glucose concentrations (Patarrão et al., 2014). CIGMA acts as 
postprandial insulin and glucose concentration (Patarrão et al., 2014).  This test quantify IS, 
glucose tolerance and β-cell function, thus it is used as diagnostic test in clinical setting 
(Ajmera et al., 2013; Patarrão et al., 2014). 
5.6.5 Minimal model analysis of frequently sampled intravenous glucose 
tolerance test (FSIVGTT) 
Bergman, Cobelli and colleagues have been developed the FSIVGTT model in 1979 (Patarrão 
et al., 2014).  Intravenous bolus glucose should infused to fasting individual at (0.3g/kg bw) 
over 2 min, then after 20 min an insulin (4 mU/kg/min) should infused over 5 min. In the 
modified FSIVGTT mode, infuse calcium channel blocker like tolbutamide after 20 min of 
glucose administration to stimulate the secretion of endogenous insulin (Patarrão et al., 2014; 
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Muniyappa et al., 2015).    Blood samples collected at 2 time points (0 and 180 min after the 
administration of glucose) (Patarrão et al., 2014; Muniyappa et al., 2015).  This model has two 
equations, one to quantify plasma insulin dynamics and the other one to assess plasma 
glucose dynamics (Patarrão et al., 2014) (Patarrão et al., 2014; Muniyappa et al., 2015). It has 
some advantages over HIEC, because it is easier, the IV bolus doesn’t need adjustment of 
infusion and does not required steady state condition.  Moreover, the assessment of (SI), (IG) 
and β-cell function can be easily achieved from a single dynamic test (Patarrão et al., 2014; 
Muniyappa et al., 2015). However, FSIVGTT model requires multiple sampling, IV injection, 
time consuming (3 hours), and requires extensive labor workers similar to IST and HIEC 
(Patarrão et al., 2014; Muniyappa et al., 2015).   
5.6.6 Oral Glucose Tolerance Test (OGTT) 
The OGTT is very simple test and probably the most common test that has been used as 
diagnostic test in the clinical practice (Ajmera et al., 2013; Patarrão et al., 2014; Muniyappa 
et al., 2015).  Fasted subjects have to drink oral glucose load (75g), then blood samples at (0, 
30, 60, and 120 minutes). Comparing OGTT with HIEC, IST and FSIVGTT it demonstrates that 
the OGTT mimics the physiological conditions of glucose and insulin dynamics more than 
other tests (Patarrão et al., 2014; Muniyappa et al., 2015).   The advantages of OGTT over 
HIEC and FSIVGTT that it is simple, and cheap so in clinical setting it is considered the test of 
choice (Patarrão et al., 2014; Muniyappa et al., 2015).  OGTT has some limitations, such as the 
data obtained not showing enough evidence of glucose and insulin dynamics action.  
However, using OGTT data in some indices gives best prediction of IS and β-cell function 
(Patarrão et al., 2014; Muniyappa et al., 2015).  It can be adapted to give more data points. 
5.6.7 Meal Tolerance Test (MTT) 
MTT has been developed by some authors to assess IS, glucose effectiveness and insulin 
secretion (Patarrão et al., 2014).  A meal (liquid or solid) consists of CHD, protein and fat is 
ingested by fasting subjects and then glucose and insulin measurement should be taken 
during 2 hours (Patarrão et al., 2014). MTT does not have an artificial post-load hypoglycaemia 
which presented an advantage to the test. Using different models to quantify (SI), (IG), insulin 
secretion, β-cell function and incretins is achievable (Patarrão et al., 2014).  
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5.6.8 Rapid Insulin Sensitivity Test (RIST) 
RIST is new test which have been developed and used in human, mice, cats, and rats. Insulin 
is infused to the subjects by (50mIU/kg) over 5 minutes and then check glucose samples after 
1, and 2 minutes, as well as take arterial venous blood samples at 5 minutes time (Patarrão 
et al., 2014).  After that start intravenous infusion of glucose to avoid hypoglycaemia (Patarrão 
et al., 2014).    
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5.7 Simple surrogate indexes for insulin sensitivity/resistance 
5.7.1 Homeostasis Model Assessment (HOMA) 
HOMA is used to assess insulin resistance and β-cell function from basal (fasting) glucose and 
insulin concentration; and it was established in 1985 by Matthews et al. (Gutch et al., 2015; 
Patarrão, Lautt and Macedo, 2014; Muniyappa, Madan and Quon, 2015; Abbasi et al., 2018). 
The glucose level are controlled by insulin-dependent hepatic glucose production, whereas 
the level of insulin depend on the response of pancreatic β-cell to glucose concentrations. 
Therefore, any defect in β-cell function leads to a lower response to glucose-stimulated 
insulin secretion. Similarly, the reduced suppressive effect of insulin on hepatic glucose 
production shows insulin resistance (Patarrão et al., 2014).   HOMA has some advantages such 
as it is a simple index, shows fasting steady state of glucose and insulin levels, requires only 
one fasting blood sample, less cost, minimum needs of technical expertise and minimally 
invasive (Gutch et al., 2015; Patarrão et al., 2014; Muniyappa et al., 2015).  HOMA is a durable 
tool and widely used in clinical setting, research and epidemiological studies (Gutch et al., 
2015; Patarrão et al., 2014; Muniyappa et al., 2015).  
Equation by Matthews et al.: IRHOMA = (I0 × G0)/ 22.5 
5.7.2 Quantitative insulin sensitivity check index (QUICKI) 
QUICKI quantifies the fasting blood glucose and insulin concentrations mainly in obese and 
diabetes in a linear association of insulin sensitivity and glucose clamp (Gutch et al., 2015).  
QUICKI advantages is that it is accurate index of IS, reliable, requires only one fasting blood 
samples, less cost, minimum needs of technical expertise and minimally invasive.  The 
limitation here are that because of inter laboratory differences in insulin assay, QUICKI 
requires varying normal levels to be developed for each laboratory (Gutch et al., 2015; 
Patarrão et al., 2014; Muniyappa et al., 2015). 
 
Equation: QUICKI = 1/(logI0 + logG0) 
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5.7.3 McAuley index 
The McAuley index requires different data such as fasting blood insulin concentration and 
TRG (Gutch et al., 2015; Abbasi et al., 2018).  This index is used to quantify IR in normoglycemic 
subjects. This index showed an advantage of given best result of IR by using both fasting 
insulin and TRG.  The limitation is that it is a laborious method and only applicable for 
epidemiological studies (Gutch et al., 2015). 
Equation: McAuley = e (2,63–0,28 ln (I0) – 0,31 ln (TAG0) 
5.7.4 Matsuda index 
Matsuda index was developed by Matsuda and Defronzo (Gutch et al., 2015).  It is considered 
as a novel index which quantifies the whole body IS index (WBISI) from OGTT in a simple way 
(Gutch et al., 2015).  The data consist of the collected blood samples while fasting and then 
during the 2 hours of the test which shows peripheral tissues and hepatic IS.  It measures 
insulin (mIU/l) and glucose (mg/dl) concentrations at 4 times points (0, 30, 60 and 120 
minutes) (Gutch et al., 2015).  This index had some advantage of predicting T2D onset, by 
using data of blood insulin and glucose concentration at 30 minutes of OGTT to measure IS 
with  (ΔI0–30/ΔG0–30 or ΔI0–120/ΔG0–120) and ISI (Matsuda) or modified ISI (Matsuda) (Patarrão et al., 
2014; Gutch et al., 2015). Moreover, it is represent hepatic and peripheral tissue sensitivity 
to insulin (Gutch et al., 2015).   
Equation: Matsuda = 10000/sqr (fasting I*Fasting G)*(Mean I*Mean G) 
5.7.5 Belfiore index 
Primarily, Belfiore index is used to measure IS.  It requires blood samples of basal insulin and 
glucose concentration (fasting state) as well as the mean value of the insulin and glucose level 
during the OGTT test (Gutch et al., 2015).  This index compares the defined normal reference 
value with specific time points for insulin and glucose values at (0-1-2 h or 0-2 h) (Gutch et al., 
2015).  This formula can be possible quantify IS which located between 0 and 2, so in 
individuals who have normal IS it will be around 1 (Patarrão et al., 2014). Any index higher 
than 1.27 represents a pathological IR (Gutch et al., 2015).  The advantage of Belfiore that it 
represented the values of insulin and glucose concentration at basal state (fasting) as well as 
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the mean concentration during OGTT. The requirement of multiple blood samples give 
limitation to this index (Gutch et al., 2015).   
Equation: Belfiore= 2/ (AUC (I(mIU/ml) * AUC(G(mg/dl)))+1 
5.7.6 Cederholm index 
Cederholm index developed by Cederholm and Wibell. Mostly, it shows the peripheral IS and 
glucose uptake in skeletal muscle during OGTT because of the main role of peripheral tissue 
in the disposal of glucose (Patarrão et al., 2014; Gutch et al., 2015). This index requires blood 
samples in two time points (0 - 2 h) during OGTT.  In normal non-obese subjects, the value of 
IS around 79±14mgI1²/mmol/mIU/min.  While in obese, pre-diabetes and T2D the value is 
less (Patarrão et al., 2014).  
Equation: Cederholm= 75000 +(G0-G120)*1.15*180*0.19*m/120*Gmean*log(Imean) 
5.7.7 Avignon index 
Avignon index has been developed by Avignon et al. in 1999, which required collecting blood 
samples at basal "fasting state" (Sib), after 2 hours of OGTT (Si2h) and then measure the IS at 
these two time points Sib and Si2h as well as measuring the average of Sib and Si2h which is 
(SiM) (Patarrão et al., 2014; Gutch et al., 2015). Avignon is a simple test which achieve glucose 
tolerance and insulin sensitivity in single test (Gutch et al., 2015). 
Equation: Avignon=10 /(I0(mU/L)*G0(mmol/L)*VD) 
 
5.7.8 Stumvoll index 
Stumvoll et al developed this index which quantify IS during the OGTT by measuring plasma 
insulin and glucose concentration, BMI and age (Patarrão et al., 2014; Gutch et al., 2015).  This 
laborious techniques requires multiple sampling at (0, 1 and 2h) of the OGTT (Patarrão et al., 
2014; Gutch et al., 2015). It has some advantage that it gives accurate result by using 
demographic data (age, BMI and sex) as well as the plasma glucose and insulin concentration 
(Gutch et al., 2015). 
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Equations with or without demographic data:  
Stumvoll = 0.222 − 0.00333 × BMI − 0.0000779 × I120 − 0.000422 × age 
Stumvoll = 0.156 − 0.0000459 × I120 − 0.000321 × I0 − 0.00541 × G120 
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5.8 Effects of exercise on the insulin sensitivity 
 
Regular exercise shows benefit in reducing and reversing T2D (Dube et al., 2012).  Therefore, 
regular exercise consider as the best choice for the prevention of diabetes (Dube et al., 2012). 
IR defined if the individual has these values; Matsuda <4.3 McA ≤5.8, HOMA ≥2.6 and QUICKI 
≤0.33. While IS defined when the subject has Matsuda ≥4.3 McA >5.8, HOMA <2.6 and QUICKI 
>0.33 (Menik and Palangasinghe, 2006; Gutch et al., 2015).  It has been found that IS improved 
by exercise because it has insulin sensitizing properties (Ortega et al., 2014; Jorge et al., 2011).  
When muscle contracted during exercise it helps GLUT-4 to transfer to cell membrane 
(Kjobsted et al., 2017; Jorge et al., 2011).  Insulin-stimulated glucose uptake has been 
improved in skeletal muscle after a single bout of exercise in both IR and ND muscle (Kjobsted 
et al., 2017).  It has been found that there is a link between improving IS and improving 
inflammatory markers which explain the association of IR and the presence of low grade 
inflammation (Verheggen et al., 2016).   
A study by Whyte et al. 2013 was aimed to see the effect of single session of sprint interval 
training (SIT) and a single extended sprint (ES) on metabolic biomarkers and IS (Whyte et al., 
2013). The participants were men, overweight/obese (n=10).  All of them go through three 2 
days randomized trial. The first OGTT was performed before the 1st day of exercise and before 
that the metabolic measurement has been taken to assess resting metabolic rate and rate of 
fat and carbohydrate oxidation. On the first day, the volunteers divided in three groups (CON= 
control), (SIT= four maximal 30-s sprints, with recovery period of 4.5 min in between each 
set), and (SE= single maximal extended sprint.  On the second day, all individual should go 
through OGTT test to measure FBG, 2hrs post glucose load and blood pressure (Whyte et al., 
2013). The plasma samples used to analyse lipid profile and glucose and insulin concentration 
by using enzyme-linked immunosorbent assay (ELISA).  Moreover, IS index was measured by 
using Matsuda method and assess insulin resistant by Homeostasis Model Assessment 
(HOMA-IR) method (Whyte et al., 2013). The results shows improvement in ISI when 
comparing to CON, it was significantly higher in ES group by (44.6%, p= 0.022) as well as 
HOMA-IR was significantly lower by (31.8%, p=0.043).   In the other hand, the differences 
between CON and SIT in ISI (1.5% higher, p=0.208) and HOMA-IR (18% lower, p=0.556) was 
not significant. The BP results show no significant changes in both systolic and diastolic BP 
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between groups (Whyte et al., 2013). In conclusion, the main outcome was the significant 
improvement in ISI and fat oxidation in the SE group (Whyte et al., 2013). 
Older men and women (50-80 years) were participating in a study by Prior et al., in Baltimore, 
Maryland (Prior et al., 2015).  All participants had diabetes or CVD and planned to do 6 months 
AE.  OGTT have been taken at baseline and then after 2 weeks of stopping last AE session. AE 
individuals were used motorized treadmills 3 times weekly, each session take 45 min (Prior et 
al., 2015). IS was measured by using HIEC after fasting for 12 hours.  Muscle biopsies have 
been taken from the right vastus lateralis immediately before HEIC and 2 hrs after infuse 
insulin to quantify GS activation, glycogen content and CS activity.  Immunohistochemistry 
were used to assess capillaries in the muscle. Furthermore, GLUT4 was identified to compare 
basal sample and 2 hrs post insulin infusion.  Subjects used indirect calorimetry while 
exercising on treadmill to calculate Vo2max. The changes in IS after 6 months increased by 
25% and contributes in the enhancement of GLUT4 and skeletal muscle CD (Prior et al., 2015).  
It shows a correlation between the reduction of inflammatory cytokine, improve glucose 
phosphorylation and the sustained improvement of IS (Prior et al., 2015).  This conclude that 
after AE the elevation of skeletal muscle CD is higher and that correlate to improvement in 
the metabolism of glucose and glucose transporter (Prior et al., 2015). Many factors 
contribute to improve IS after aerobic exercise such as elevated GLUT-4 appearance in 
skeletal muscle, AMPK expression and insulin activation of glycogen synthesis (Prior et al., 
2015). 
Another study was conducted by Fenicchia et al. (2004) to assess the influence of acute and 
chronic resistance training on glucose and insulin responses to an oral glucose tolerance test 
in women with T2D (Fenicchia et al., 2004a). Participants performed RE session for 50 minutes 
for 3 non-consecutive days per week for 6 weeks.  Baseline measurement for body 
compositions has been taken before first exercise session and then at the end of 6 weeks. The 
OGTT was completed in 3 occasions, first one before starting the exercise programme, the 
second one after the acute exercise and finally the third one after the last session in week 6.  
(Fenicchia et al., 2004b) shows the results after 6 weeks in the body composition, in diabetic 
group the fat mass decreased significantly (P < 0.01), but, this reduction was not significantly 
matched by an improvement in glucose AUC (r = 0.3, P > 0.05).  The result of OGTT shows that 
the first test before starting the RE was significantly higher in diabetic group (9.1 ± 1.3 
 167 
 
mmol/L) than the control group (5.3 ± 0.7 mmol/L, P < 0.05).  In the control group, the results 
showed no differences after exercise. This study suggested that there was no chronic effect 
on the insulin sensitivity after 6 weeks of RE (Fenicchia et al., 2004b).  
This study aimed to assess the insulin sensitivity (IS) after 6 weeks of combination exercise 
and see the effect of different medication on IS in T2D by using different assessment methods.  
5.9 Assessment of insulin sensitivity from OGTT: 
Methods that directly assess insulin sensitivity and resistance are expensive, complex and 
invasive (Lorenzo et al., 2015).  Accordingly, researchers developed number of surrogates 
indices to quantify IS and IR from OGTT alone or with other metabolic variables (Lorenzo et 
al., 2015). The aim of this study also is to assess insulin sensitivity by different methods. Three 
indices has been used in this study to assess IS values, HOMA-IR, QUICKI and Matsuda index.  
As discussed previously (section 5.5) these three indices are the most useful in clinical 
practice. It has also strong correlation with HIEC the gold standard method in assessing IS, 
while in this study OGTT method has been used instead. Ortega, 2014 found that Matsuda IS 
index represent both peripheral and hepatic insulin sensitivity (Ortega et al., 2014).  In this 
study  T2D and ND participants have been conducted in doing moderate combination exercise 
twice a week for 6 weeks to assess the insulin sensitivity from OGTT in three occasions, before 
the volunteer starts 1st exercise session, after 1st exercise session and then finally after 
finishing 12th exercise session.  
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5.10 Method  
5.10.1 Study design 
In each exercise session the participant performed a combined exercise program consists of 
30 min of resistance exercise followed by 20 min moderate cycling.  This is done twice a week 
for 6 weeks. At the beginning of each session the participants have to stretch-up for 11 steps 
of stretching, then he/she must cycle for five minutes to warm up.  The RE consist of 3 sets, 
in each set the volunteer performed (squat, chest, back, biceps and triceps) 10 times.  Blood 
samples collected at base line after these sessions (S1, S2, S4, S6, S8, S10 and S12), centrifuge 
and refrigerate the plasma to be analysed later by a commercially-available enzyme-linked 
immunosorbent assay (ELISA) with <0.01 cross reactivity with pro-insulin to measure insulin 
level as explained before in (section 3.9.1).  
5.10.2 Intervention group 
The intervention group are T2D (n=11) of five sub-groups and ND (n=8) who are doing 
combination exercise. 
Intervention group are classified in five groups 
1- T2D volunteers with no medication. 
2- T2D volunteers on Metformin only. 
3- T2D volunteers on Metformin and Dipeptidyl Peptidase 4 inhibitor (DPP4-I).  
4- T2D volunteers on Metformin and SGT2-I.  
5- Non-diabetes (ND).   
 
Medication Number of Volunteers 
Pravastatin 40mg OD 1 
Atorvastatin 20mg OD 3 
Metformin 500 mg BD 3 
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Metformin 850 TDS 1 
Metformin 1000 mg BD 2 
Sitagliptin 50 mg OD (DPP4-I) 1 
Sitagliptin 100mg OD (DPP4-I) 2 
Empagloflizin 10 mg OD 2 
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5.11 Results and discussion: 
The data of T2D and ND participants have been used to analyse insulin level by ELISA and BG 
by using FPP during OGTT. Data are analysed by using Excel 2010 and SPSS (version 22), Values 
were expressed as mean with standard error of mean. Pre and post exercise samples were 
compared using a paired-samples t-test. The level of statistical significance (P < 0.05).  
5.11.1 OGTT and ISI in T2D and ND 
5.11.1.1 Results of BG and insulin in T2D and ND  
Table 18: BG level from OGTT comparisons between pre-exercise, post 1st session of exercise and post 12th 
session of exercise for T2D on combination exercise. Data expressed as Means± SEM and P value. 
Time point 
(Minutes)  
Pre Ex (1st OGTT) Post S1 (2nd OGTT) Post S12 (3rdOGTT) 
0 8.7± 0.6 8.1± 0.9 6.9± 0.2 
30 14.4± 1.2 13.4± 1.9 12.1± 0.7 
60 17.3± 1.4 15.6± 2.1 14.2± 0.9 
120 15.1± 1.4  12.1± 1.9 10.2± 1.0 
AUCs 30.55±2.5 27.6±3.6 24.4±1.9 
P value by comparing (Pre Ex & Post S1) = 0.000 which is < 0.05 
P value by comparing (Pre Ex & Post S12) = 0.000 which is < 0.05 
 
Figure 43: BG level during the 3 OGTT in T2D 
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Table 19: Insulin concentration (mU/L) from OGTT comparisons between pre-exercise, post 1st session of 
exercise and post 12th session of exercise for T2D on combination exercise. Data expressed as Means± SEM and 
P value. 
Time point (Minutes) Pre Ex (1st OGTT) Post S1 (2nd OGTT) Post S12 (3rdOGTT) 
0  55.75± 12.31  45.50± 12.19 26.89± 9.21 
30 221.34± 71.65  229.34± 69.83  68.24± 24.76  
60  226.17± 82.88  168.44± 36.78 66.84± 24.16 
120  183.20± 57.28 180.87± 62.73 63.98 ± 21.68 
AUCs 94.5± 31.6  85.2± 24.0 30.1± 10.7 
P value by comparing (Pre Ex & Post S1) = 0.363 
P value by comparing (Pre Ex & Post S12) = 0.031 
 
Figure 44: Insulin level during the 3 OGTT in T2D  
 
Table 20: BG level from OGTT comparisons between pre-exercise, post 1st session of exercise and post 12th 
session of exercise for ND on combination exercise. Data expressed as Means± SEM and P value: 
0.00
100.00
200.00
300.00
400.00
-20 0 20 40 60 80 100 120 140
In
su
lin
 m
U
/L
Minutes
Insulin level across the 3 OGTT in T2D
1st OGTT 2nd OGTT 3rd OGTT
   
   Time point 
(Minutes)  
Pre Ex (1st OGTT) Post S1 (2nd OGTT) Post S12 (3rdOGTT) 
0 5.3± 0.2 4.7±0.5 4.8± 0.3 
30 9.4±1.9 7.4±1.8 9.5± 2.6  
60 8.2±2.3 8.2±2.1  9.0± 2.7  
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P value by comparing (Pre Ex & Post S1) = 0.055 
P value by comparing (Pre Ex & Post S12) = 0.175 
 
Figure 45: BG level during the 3 OGTT in ND 
 
Table 21: Insulin concentration from OGTT comparisons between pre-exercise, post 1st session of exercise and 
post 12th session of exercise for ND on combination exercise. Data expressed as Means± SE and P value 
Time point 
(Minutes) 
Pre Ex (1st OGTT) Post S1 (2nd OGTT) Post S12 (3rdOGTT) 
0  6.21± 1.72  5.52± 1.13  3.78± 0.95 
30 49.22± 9.55  49.03± 11.24  45.95± 18.10  
60  60.50± 21.82  48.95± 27.47  55.64± 26.74 
120  32.38± 8.82  18.88± 4.25  14.15± 2.11 
AUCs 21.5± 6.0 18.4± 6.9 18.4± 7.7 
P value by comparing (Pre Ex & Post S1) = 0.162 
P value by comparing (Pre Ex & Post S12) = 0.148 
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Figure 46: Insulin level during the 3 OGTT in ND 
 
The FBG was different in each test throughout the 3 OGTT. Most of T2D and ND participants 
came to the next OGTT with lower FBG that’s why it was unable to control their FBG and keep 
it within same level. The shape of the BG curve represent the information of number of 
metabolic factors such as IS, insulin secretion and hepatic glucose sensitivity (Chung et al., 
2017; Cree-Green et al., 2018; Tschritter et al., 2003). In T2D, usually BG reached a maximum 
level between 30 and 90 minutes followed by a decrease until 120 minutes.  On the other 
hand, BG in ND usually peaked at 30 or 60 minutes (Chung et al., 2017).  In the current study, 
figure 42 shows BG curve which means that these individuals have T2D and less IS and the 
peak started between 60 and 90 minutes and then began to decrease till 120 minutes. P 
values shows significant reduction in BG after S1 and after S12 as well. It has been stated 
previously that delay in BG peak time indicated increase in BG and decrease in insulin 
sensitivity and secretion (Wang et al., 2018).  In clinical setting, BG peak at 60 minutes might 
needs also screening for another metabolic abnormalities such as hepatic steatosis in obese 
subjects (Cree-Green et al., 2018). The AUC of BG for the 1st OGTT was (30.55±2.5 mmol/L/h) 
then decreased in the 2nd OGTT finally decreased more in the 3rd OGTT to (24.4±1.9 
mmol/L/h), this reduction demonstrates improvement in the IS in T2D.  Figure 44 represents 
the data of BG for ND, curve starts the 1st peak before 30 minutes in the 2nd OGTT.  While in 
1st and 3rd OGTT the peak was at 30 minutes.  Finally, the 3rd OGTT shows the highest reduction 
in BG which illustrates the significant effect of chronic exercise on BG (P <0.05). The AUC for 
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the 1st OGTT was (14.9±3.2 mmol/L/h) and became (13.9±3.0 mmol/L/h) in the 2nd OGTT 
which slightly increased in the last OGTT to (14.4±3.2 mmol/L/h) but still less than baseline.  
Insulin level in T2D as represented in figure 43, the 1st OGTT showed first peak of insulin at 60 
minutes. While in the 2nd and 3rd OGTT showed maximum elevation at 30 minutes then 
decreased slightly at 60 min.  The highest reduction has been found at 120 min in the 1st and 
3rd OGTT while increased in the 2nd OGTT and that improved more by the 3rd OGTT (P=0.031).  
The AUC for insulin in the 1st OGTT was (94.5±31.6 mU/L/h) while this decreased slightly in 
the 2nd OGTT to (85.2±24.0 mU/L/h) and decreased more in the last OGTT to (30.1±10.7 
mU/L/h).  In ND (figure 45), the insulin elevated at 30 minutes while the maximum peak was 
at 60 min ad it was higher in the 1st and 3rd OGTT and then decreased by 120 min and shows 
the highest reduction in the 3rd OGTT but not significant.  Furthermore, AUC was (21.4± 6.0 
mU/L/h) at baseline which decreased slightly in the 2nd OGTT and similar in the 3rd OGTT 
(18.4± 7.7 mU/L/h). This result in contrast to the result that found previously by Fenicchia et 
al., which shows no effect on BG after 6 weeks of RE exercise nevertheless, the effect was 
after the acute bout of exercise only (Fenicchia et al., 2004). It has been found in his study 
that there was no effect on insulin after both acute and chronic exercise. The study duration 
of Fenicchia et al., is similar to the current study however, the current study consists of 
combination exercise which could be the reason behind the significant results in BG reduction 
after chronic exercise. 
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5.11.1.2 IS in the both T2D and ND 
Table 22: Insulin sensitivity in T2D by using 3 different indices (Values expressed as mean ± SEM) and P value 
 OGTT 
(Matsuda index) 
 
OGTT 
(HOMA-IR) 
OGTT 
(QUICKI) 
T2D ND T2D ND T2D ND 
Pre Exercise 
(baseline)  
16.27±3.45 
 
100.82±17.10 
16.66±2.85 1.47±0.27 0.27±0.01 0.36±0.01 
 
Post 1st Exercise 
session (acute)             
20.71±4.03 133.04±12.47 11.25±2.81 1.15±0.21 0.22±0.03 0.38±0.01 
P value 
 
0.285 0.284 0.134 0.140 0.251 0.130 
Post 12th Exercise 
session (Chronic) 
 
32.65±6.64 155.01±18.12 
 
8.83±2.19 0.80±0.11 
 
0.29±0.01 0.40±0.01 
 
P value 
 
0.017 0.156  0.016 0.054 0.057 0.032 
  
This study calculated ISI in T2D and ND subjects by three different indices (as described in 
section 5.9). If the values of Matsuda <4.3 McA ≤5.8, HOMA ≥2.6 and QUICKI ≤0.33 so it 
considered that subjects had IR (Menik and Palangasinghe, 2006; Gutch et al., 2015).  Table 
37 displays all the three indices and demonstrates that there is an improvement in IS in both 
groups. Firstly, the Matsuda index show minor improvement in IS in T2D after the first 
exercise session. In T2D it was (16.27±3.45) then increased after S1 to (20.71±4.03), and 
(P=0.285). While the chronic effect of six weeks of exercise represents more increments in IS 
after (32.65±6.64) and (P= 0.017) which considered as a significant improvement (see Table 
22).  In the ND group, the Matsuda also illustrates some improvement in IS as it was 
(100.82±17.10) and increased after session one to (133.04±12.47), (P= 0.284).  It is also 
elevated more to (155.01±18.12), (P= 0.156) though no significant result was found.  Previous 
studies have found a significant improvement in IS using Matsuda index (Whyte, Gill and 
Cathcart, 2010). 
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Secondly, HOMA-IR also displays slight reduction in IR in T2D after the 1st session from 
(16.66±2.85) to (11.25±2.81) and (P= 0.134).  This reduction was higher after six weeks of 
chronic exercise (8.83±2.19) and (P= 0.016) which also considered as a significant 
improvement.  In ND, the improvement in IR was higher than T2D. HOMA-IR was (1.47±0.27) 
before performing any exercise and decreased to (1.15±0.21) and (P= 0.140).  The reduction 
was higher after 6 weeks and decreased to (0.80±0.11), (P= 0.054) which is nearly significant. 
Similar studies of combination exercise on T2D was conducted and HOMA-IR displays a 
significant reduction after combination exercise compared to AE or RE alone (Jorge et al., 
2011). Moreover, a significant improvement in HMOA-IR after diet and RE in obese women 
(Antuna-Puente et al., 2009). Another study states that a sing maximal extended sprint 
improved IS significantly by using HOMA-IR (Whyte et al., 2013). In contrast, Ortega et al., 
(2014) demonstrates insignificant improvement in HOMA-IR post exercise (Ortega et al., 
2014). The reason behind the insignificant of Ortega study might be that the exercise only one 
bout and the current study is 6 weeks of exercise.  
Finally, QUICKI as well demonstrates an improvement in IS in T2D after session 12 only while 
no improvement found after the 1st exercise session. This value was (0.27±0.01) as base line 
and then decreased to (0.22±0.03) and (P=0.251). Moreover, this increased again after S12 
higher than baseline to (0.29±0.01) and (P= 0.057) which states a very good improvement and 
it is nearly significant.  While in ND participants, QUICKI shows improvement after 1st and 12th 
sessions, it was (0.36±0.01) and then increased after S1 to (0.38±0.01) and (P=0.130). 
Furthermore it is increased more after S12 to (0.40±0.01) and (P=0.032) which is significant. 
This result is in agreement with previous study which assess the IS after diet and RE, QUICKI 
improved significantly after intervention in obese women (Antuna-Puente et al., 2009).  
 
.  
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5.11.2 Results of OGTT and ISI in T2D subgroups according to the medication types 
5.11.2.1 BG and insulin in T2D subgroups 
1- T2D with no medication 
 
Figure 47: BG in T2D with no medication  
 
Figure 48: Insulin in T2D with no mediaction 
In the subgroup of T2D who are not using any medication, AUC of BG was (21.0±2.6 mmol/L/h) 
at baseline which decreased to (20.9±2.9 mmol/L/h) in the 2nd OGTT and finally in the last 
OGTT decreased more to (19.1±1.9 mmol/L/h).  Moreover, insulin AUC shows also reduction 
from (57.4±19.9 mU/L/h) to (52.4±20.0 mU/L/h) and then further reduction in the last OGTT 
to (46.2±15.6 mU/L/h).  
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2- T2D on metformin only 
 
Figure 49: BG in T2D on metformin only  
 
Figure 50: Insulin in T2D on metformin only 
This group of T2D on metformin demonstrated reduction in AUC of BG which was (31.5±3.6 
mmol/L/h) at baseline and then decreased in the 2nd OGTT to (27.0±3.7 mmol/L/h) and 
decreased more in the last OGTT to (24.1±2.8 mmo/L/h).  However, AUC of insulin shows no 
reduction during the 12th exercise sessions which increased from (33.2±13.1 mU/L/h) to 
(66.3±19.3 mU/L/h) after 1st exercise and decreased to (40.8±16.0 mU/L/h) after the 3rd OGTT 
but still higher than baseline.   
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3- T2D on metformin and DPP4-I 
 
 
Figure 51: BG in T2D on metformin & DPP4-I 
 
Figure 52: Insulin in T2D on metformin & DPP4-I 
The AUC of this group illustrates reduction in BG and insulin nevertheless, the reduction in 
insulin AUC was higher in the 2nd OGTT than the 3rd. AUC of BG was (29.9±5.2 mmol/L/h) and 
decreased to (27.6±7.2 mmol/L/h) in the 2nd OGTT and to (23.7±3.6 mmol/L/h) in the 3rd 
OGTT.  Insulin was (95.4±19.9 mU/L/h) before exercise then decreased to (91.2±33.3 mU/L/h) 
and increased slightly to (92.7±8.9 mU/L/h) but still higher than baseline.  
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4- T2D on metformin and SGT2-I 
 
Figure 53: BG in T2D on metformin and SGT2-I 
 
 
Figure 54: Insulin in T2D on metformin & SGT2-I 
AUC in BG in this subgroup was (35.0±5.6 mmol/L/h) and decreased in the 2nd OGTT to 
(25.8±6.2 mmol/L/h) then increased slightly to (26.8±4.0 mmol/L/h) but still less than 
baseline. Insulin shows reduction in AUC from (36.9±8.4 mU/L/h) to (28.3±6.7 mU/L/h) in the 
2nd OGTT then to (25.5 mU/L/h) in the 3rd OGTT.  
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5.11.2.2 IS in T2D subgroups 
Table 23: Insulin sensitivity in T2D by Matsuda index according to medication type (Values expressed as mean ± 
SEM) 
 
No medication Metformin only Metformin 
&DPP4-I 
Metformin & 
SGT2-I  
Pre Exercise 
(baseline)  
7.43±1.75 
 
24.42±9.73 10.92±1.49 18.34±5.21 
Post 1st Exercise 
session (acute)             
24.96±12.94 24.84±3.05 15.04±8.99 25.92±0.58 
P value 0.285 0.814 0.640 0.350 
Post 12th Exercise 
session (Chronic) 
22.37±7.26 
  
51.02±12.19 
 
11.71±2.75 
 
54.80±9.88 
P value 0.151 0.151 0.621 0.081 
 
By comparing medication types, Matsuda index in T2D group that have no medication was 
(7.43±1.75) at baseline and then increased to (24.96±12.94), (P=0.285) after 1st OGTT which 
then decreased slightly after 6 weeks to (22.37±7.26), (P=0.151).  In T2D with metformin, 
Matsuda before exercise was (24.42±9.73) and became (24.84±3.05), (P=0.814) which 
increased more after six weeks of exercise to (51.02±12.19), (P=0.151).  The result of Matsuda 
in T2D using metformin and DPP4-I was (10.92±1.49) and increased to (15.04±8.99), (P=0.640) 
after 1st exercise session and finally become (11.71±2.75), (P=0.621) after six weeks.  The best 
improvement was in T2D participants who were using metformin and SGT2-I which shows 
that Matsuda level was (18.34±5.21) and then increased after 1st exercise session to 
(25.92±0.58), (P=0.350), this elevated more after 12th exercise session to (54.80±9.88), 
(P=0.081) which shows that it is close to be significant.  
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Table 24: Insulin sensitivity in T2D by HOMA-IR index according to medication type (Values expressed as mean 
± SEM) 
 
No medication Metformin only Metformin & 
DPP4-I 
Metformin & 
SGT2-I  
Pre Exercise 
(baseline)  
26.12±4.49 10.93±7.65 16.42±5.73 12.92±1.68 
Post 1st Exercise 
session (acute)             
10.88±4.24 2.91±1.52 22.39±7.37 8.89±0.44 
P value 0.008 0.389 0.559 0.190 
Post 12th Exercise 
session (Chronic) 
 
11.01±3.90 
  
2.33±0.32 
 
17.52±4.44 
 
4.54±1.10 
P value 0.003 0.374 0.878 0.204 
 
The results of HOMA-IR index in T2D who were on no medications was (26.12±4.49) at 
baseline and decreased after 1st exercise session to (10.88±4.24), (P=0.008) which shows a 
significant improvement in IS while after six weeks of exercise HOMA-IR level decreased to 
(11.01±3.90), (P=0.003) which is very significant. This significant improvement could be 
because this group has just diagnosed as T2D and had the lowest HbA1c therefore the 
exercise intervention plays a role in improving IR in this group.  In T2D group who were used 
metformin only, HOMA-IR was (10.93±7.65) and decreased to (2.91±1.52), (P= 0.389), while 
after six weeks it became (2.33±0.32), (P= 0.374).  Moreover, HOMA-IR in T2D who used 
metformin and DPP4-I was (16.42±5.73) and increased to (22.39±7.37), (P= 0.559) and then 
become (17.52±4.44), (P= 0.878).  The result in T2D who used metformin and SGT2-I was 
(12.92±1.68) and decreased to (8.89±0.44), (P= 0.190) which decreased more to (4.54±1.10), 
(P= 0.204). 
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Table 25: Insulin sensitivity in T2D by QUICKI index according to medication type (Values expressed as mean ± 
SEM) 
 
No medication Metformin only Metformin 
&DPP4-I 
Metformin & 
SGT2-I  
Pre Exercise 
(baseline)  
0.246±0.003 0.297±0.023 0.267±0.009 0.265±0.005 
Post 1st Exercise 
session (acute)             
0.283±0.014 0.305±0.005 0.257±0.012 0.295±0.005 
P value 0.093 0.705 0.580 0.205 
Post 12th Exercise 
session (Chronic) 
 
0.280±0.010 
  
0.337±0.007 
 
0.260±0.010 
 
0.330±0.10 
P value 0.038 0.195 0.635 0.144 
 
Finally QUICKI as well illustrates a significant improvement after six weeks in T2D who used 
no medication.  QUICKI was (0.246±0.003) and increased to (0.283±0.014), (P= 0.093) and 
decreased more to (0.280±0.010), (P= 0.038) which is a significant improvement in IS. The 
improvement in this had similarity to HOMA-IR and the reason behind the significant result 
might be because this group had the lowest HbA1c as explained before and still had good β-
cell function which benefits in the improvement of IS.  In the metformin group, QUICKI was 
(0.297±0.023) and increased after 1st exercise session to (0.305±0.005), (P=0.705) which 
increased more after six weeks to (0.337±0.007), (P=0.195).  Furthermore, in metformin and 
DPP4-I group the level was (0.267±0.009) and decreased after 1st session to (0.257±0.012), 
(P= 0.580) and after 12th session (0.260±0.010), (P= 0.635).  In metformin and SGT2-I group, 
QUICKI was (0.265±0.005) and increased after 1st session to (0.295±0.005), (P= 0.205) and 
then increased more after the 12th exercise session to (0.330±0.10), (P=0.144).  
Recent study states that assessing insulin resistance by using Matsuda “4 or 5 time point “is 
valuable and better than other indices that only use fasting time point (Lorenzo et al., 2015).  
It is applicable to use during pharmacological intervention, exercise and weight loss and may 
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be attractive in these because it is cheaper than the HIEC method (Lorenzo et al., 2015). It has 
been proves that indices of ISI quantified from IVGTT and OGTT are valid surrogates of HIEC 
(Ortega et al., 2014).  Matsuda indices calculated from OGTT, however illustrates good 
correspondence with the HIEC (Ortega et al., 2014). Other researchers have found that results 
from HOMA could be affected more by reason of variation in fasting insulin more than QUICKI 
(Antuna-Puente et al., 2008). Ortega compared OGTT and IVGTT and concluded that the 
values of ISI quantified from IVGTT were more appropriate than OGTT for identifying the 
acute effect of aerobic exercise and IVGTT was also more reproducible (Ortega et al., 2014).  
The oral glucose has an extra effect compared with IV glucose by stimulating GI hormones 
and influence metabolism in the liver.  OGTT results in release of incretins that enhance insulin 
secretion therefore OGTT might afford more physiological conditions for estimation of β-cell 
function than IVGTT (Hayashi et al., 2013). These hormones interact with the oral glucose and 
affect its absorption as well as affect insulin secretion which cause variability within 
individuals BG and insulin concentration (Ortega et al., 2014).  
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5.12 Conclusion:  
The results show correlation between Matsuda, HOMA-IR and QUICKI in the improvement of 
IS.  T2D participants show some IR at baseline when assessing IS and IR by using these three 
indices.  This resistance improved across the whole exercise sessions which illustrates 
improvement by the end of six weeks but this was only significant after six weeks when using 
Matsuda and HOMA-IR indices.  On the other hand, ND volunteers have no IR before 
performing any exercise therefore the improvement in IR was only significant in QUICKI after 
6 weeks of exercise comparing to T2D group.  In the group that had no medication for diabetes 
the results states that the combination exercise was very useful in improving IS and IR in these 
subjects as found by HOMA-IR and QUICKI indices. HOMA-IR might be more sensitive to the 
variation in fasting insulin than QUICKI so QUICK might provide more accurate results.  
Moreover, previous research state that Matsuda is more valued during intervention such as 
exercise and weight loss.  In conclusion, Matsuda could be more applicable in this study while 
it is using 4 time point not only fasting values. OGTT also is cost effective comparing with HIEC.  
However, OGTT has some limitation that the absorption of BG and BI affected by gastric 
hormone and cause intra-subject variation in their concentration. Diet and adherence to 
antidiabetic medication also could affect the IS results (Jorge et al., 2011).  
 
5.12.1 Limitations: 
1- Use of OGTT rather than the gold standard of glucose clamp technique (HIEC).  
2-  Only few volunteers have been recruited. 
3- No control group. 
4- No specific diet has been followed.  
5.12.2 Future work: 
1- Arrange to use HIEC method which available in hospitals to give valid results. 
2- Recruit more participants as intervention and control group.  
3- Assess GLP-1 during OGTT. 
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Chapter 6 The effect of moderate combination exercise aerobic and resistance on 
the incretin hormone (GLP-1) in T2D subjects 
 
6.1 Research questions: 
Is the incretin hormone improved after 6 weeks of moderate combined exercise? Do the 
improvements correlate with medication type?  
6.2 Aim:  
Few studies have been conducted to investigate the effect of exercise on incretin hormones 
especially GLP-1.  Thus, the aim of this study is to investigate the effect of combination 
exercise programme (cardio “aerobic” and resistance) on GLP-1 levels in T2D participants. In 
the last few years, incretin has become an important hormone in the treatment of T2D, 
therefore, it is very important to assess GLP-1 level in T2D subjects.   
6.3 Incretin hormones and DDP-IV:  
Incretins are peptide hormones that are secreted by the entero-endocrine cells in the 
gastrointestinal tract such as L and K cells (Fava, Dong and Wu, 2016; Rhee et al., 2014).  The 
common incretin hormones that have been identified include glucose-dependent 
insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) (Nauck and Meier, 2016). 
GIP is secreted by the K-cells in duodenal part of the small intestine whereas GLP-1 is secreted 
by the L-cella of the large and small intestine (Nauck et al., 2011). Recent research reported 
that GLP-1 is also produced by the pancreatic α-cells (Fava, Dong and Wu, 2016).   The 
hypothesis of stimulating pancreatic secretion by the gut endocrine was reported as a 
breakthrough in medical sciences (Friedman, 1954). This is also true for understanding the 
role of incretins in regulating the secretion of insulin and glucagon, thus regulating the blood 
glucose (Kim and Egan, 2008; Ahrén, Carr and Deacon, 2010; Mudaliar and Henry, 2012; 
Lastya, Saraswati and Suastika, 2014; Rehfeld, 2018). There are numerous incretin hormones, 
however, the present study will focus on GLP-1 because it plays a vital role in T2D (Spellman, 
2011; Lastya, Saraswati and Suastika, 2014). It is noteworthy to mention that GLP-1 is a 
metabolic hormone which stimulates a decrease in BG and is reported that intra-islet GLP-1 
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may exert insulinotropic and glucagonostatic effects by paracrine and/or autocrine actions 
(Fava, Dong and Wu, 2016).  GLP-1 is said to exert its action by increasing insulin levels which 
is released from pancreatic β-cells after food consumption before the BG begins to rise, thus 
decreasing β-cell apoptosis, enhance β-cell proliferation and neogenesis (Fava, Dong and Wu, 
2016; Kayaniyil et al., 2016; Campbell and Drucker, 2013). This hormone reduces the rate of 
absorption of nutrients into the bloodstream by reducing gastric emptying which can reduce 
appetite and food intake in both normal and obese individuals through the nervous system 
(Kim and Egan, 2008; Fava, Dong and Wu, 2016).  It also reduces glucagon release from α 
pancreatic cells which play an important role in blood glucose regulation (Fava, Dong and Wu, 
2016).  On the other hand, in hyperglycaemia the high level of glucagon suppresses the 
release of GLP-1 but the mechanism underlying this suppression is not fully understood 
(Nauck et al., 2011). 
  
 188 
 
  
Figure 55: Physiological effects of GLP-1 after food ingestion 
 
In the basal state, the level of GLP-1 is (5-15 pmol/l) while, in postprandial or after oral glucose 
the level becomes (20-60 pmol/l) (Nauck et al., 2011). After a meal, GLP-1 starts to elevate 
after 10 to 15 minutes and reaches a peak in two hours then decreases slowly for hours until 
it reaches a baseline (Nauck et al., 2011). When GLP-1 binds to a single GLP-1 receptor it 
shows various physiological functions which play a role in regulating glucose homeostasis (see 
figure 54) (Holst, 2013).  Therefore, any deficiency in GLP-1 can play a major role in 
pathophysiology of type 2 diabetes (Spellman, 2011). In the case of obesity the secretion of 
GLP-1 decreases with increasing appetite (Hussein et al., 2014).  The levels of GLP-1 are 
decreased in the T2D individual (Szablewski, 2011). However, in such a case the body retains 
the capability to respond to this hormone.  So, administration of exogenous GLP-1 can control 
 189 
 
hyperglycaemia (White, 2008).  At high glucose levels, GLP-1 and GIP lead to a glucose 
dependent increase in insulin secretion. In case of obesity, GLP-1 level was indirectly 
associated to the status of insulin resistance (Hussein et al., 2014). 
 It has been found that some neurotransmitters such as gastrin-releasing peptide and 
acetylcholine trigger the release of GLP-1 which proves that intramural enteric nervous 
system contributes in mediating the upper gut signal (Nauck et al., 2011). The GLP-1 level is 
not decreased in case of gut resections which demonstrate that GLP-1 secretion is started 
immediately when L-cell exposed to the food in the upper part of small intestines, not in the 
lower part of large intestine and ileum (Nauck et al., 2011).  Interestingly, the level of GLP-1 
after ingestion of food was found higher than GIP level possible because the required velocity 
for the movement of gastric secretion to stimulate K-cells  in the duodenum is less than the 
one required to stimulate L-cells at many distal locations (Nauck et al., 2011).  The incretin 
system has been a common intervention for treating T2D for many years (Kayaniyil et al., 
2016).  Several studies have indicated the beneficial aspects of GLP-1 approaches in managing 
T2D as sufficient via controlling cardiovascular conditions like blood pressure, patient body 
weight, protein metabolism that is individually created by GLP-1 consequences from glycemic 
control and atherosclerosis markers (Satoh-Asahara et al., 2013; Petrie, 2013).  After food 
ingestion, the level of GLP-1 is elevated in the circulation and enter capillaries of endothelial 
cell, then degraded by DPP-4 which is located there.  Approximately third to fourth level of 
the original GLP-1 level reaches the portal vein, then transported to the liver (Holst, 2013).  
The role of GLP-1 in decreasing appetite and regulating glucose metabolism occurs after food 
intake in the intestinal L cells which release GLP-1.  First, GLP-1 binds to receptors inside the 
gut which in turn activate and send a signal to CNS to suppress appetite. Secondly, GLP-1 
absorption occurs through the blood circulation system, then enters the pancreatic β cells 
and regulates pancreatic secretion (Holst, 2013). Medication such as metformin is shown to 
affect the secretion of GLP-1 by increasing its level in human and rodent L cells but not the 
GIP (Campbell and Drucker, 2013).  The underlying mechanism for the increase of GLP-1 by 
metformin is not fully understood (Campbell and Drucker, 2013).  In normal physiological 
conditions, the enzyme Dipeptidyl Peptidase 4 (DPP-4) degrades GLP-1 and GIP (Holst, 2013).   
For that reason, GLP-1 is not useful as pharmacological agent, however, injectable GLP-1 
receptor agonists are resistant to degradation by DPP-4 enzymes thus preserving the effects 
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of GLP-1 analogue, e.g. exenatide (Byetta,Bydureon®) and liraglutide (Victoza®). Other 
inhibitors of DPP-4 are those that increase serum levels of GLP-1 and enhance insulin 
secretion e.g. sitagliptin (Januvia®) and vildagliptin (Galvus®) (ADA, 2018).  Furthermore, 
evidence from clinical trials showed that exenatide and liraglutide have significant effect in 
reducing the body weight of participant with and without diabetes (Holst, 2013). In addition, 
Exenatide was reported to have anti-inflammatory effect on the CNS, pancreas and 
cardiovascular system by suppression pro-inflammatory cytokines (Campbell and Drucker, 
2013). Cross-sectional studies have indicated that serum postprandial concentrations of GLP-
1 are considerably lower among obese individuals and this increased when weight was lost 
(Holst, 2013).  These reduction might be due either to the elevation of free fatty acid which 
lowers responsiveness of L-cells to carbohydrate or to the insulin resistance in these obese 
subjects (Holst, 2013). In summary, literature have presented the vital role of GLP-1 in 
diabetes, thus it levels was studied in the present study.  
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6.4 Effect of exercise on GLP-1 level:  
 
Few research studies have studied the effect of exercise on GLP-1 level and most reported 
that exercise generally elevates GLP-1 plasma levels in T2D and at different intensity (Ueda, 
Nakahara and Miyamoto, 2013). The mechanism of this increase is not fully clear, however, it 
is important to understand it so to design an exercise program which could be used as 
preventive therapy for obesity and its complications (Ueda et al., 2013).  A study of assessing 
appetite after exercise has proven that the GLP-1 increment after exercise was due to the 
physiological suppression of appetite (Beaulieu et al., 2014). A review by Hazell et al., (2016) 
compared the effect of exercise intensity from different studies on GLP-1 and hypothesized 
that the potential mechanisms on how the level of GLP-1 changes after exercise could be the 
variation of BG and blood insulin level, the cytokine release or muscle metabolism (Hazell, 
2016).  
Recently a Canadian study was piloted to see the effect of exercise intensity on GLP-1 in 
healthy active female (Hallworth et al., 2017), where participants were divided into three 
groups based on training type namely sprint interval training (SIT), moderate intensity 
continues training (MICT), and no exercise control (CTRL). The exercise study was scheduled 
to last for 10 days and blood samples were collected before and immediately after each 
exercise session. Samples were transferred into EDTA tubes 90 mins after exercise, then 
protease inhibitor cocktail was added to prevent GLP-1 degradation. A visual analogue scale 
was used to assess hunger at each sampling time points (Hallworth et al., 2017).  The literature 
concluded that GLP-1 showed significant elevation after postprandial exercise in participants 
of SIT and MICT grouped when compared to the control, however, there was no differences 
in the increased GLP-1 level between SIT and MICT group (Hallworth et al., 2017).   
 Another recent study was conducted on endurance-trained males (Holliday and Blannin, 
2017). Result illustrated a significant elevation of GLP-1 level immediately after exercise in 
30min and also in 45 min cycling exercise (P=0.001) (Holliday and Blannin, 2017). In addition, 
Howe et al., (2016) studied the effect of acute intense exercise on appetite and guts 
hormones one of which was GLP-1. To achieve this, 15 eligible trained endurance female 
athletes (18-40 years) participants were recruited. The exercise programme consisted of two 
randomised trials which were 7 days apart, namely moderate intensity exercise (MIE) and 
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high intensity exercise (HIE) at 60% and 85% VO2MAX, respectively. The effect of intense 
exercise on GLP-1 was shown to significantly increase after 60 min(s) (Howe et al., 2016).   
It is important to mention that some researchers reported that neither intense nor moderate 
exercise has effect on GLP-1.  An example of such study is that conducted by Kawano et al., 
(2013) which was a randomised control trial focusing on the effect of weight-bearing on GLP-
1 and hunger rate, and participants were healthy non-obese sedentary young men. The 
bicycle ergometer was considered as non-weight bearing exercise while rope skipping as 
weight-bearing exercise. GLP-1 and hunger rating were monitored before, during and after 
exercise (Kawano et al., 2013).  Although data presented by Kawano et al., (2013) showed 
that hunger was suppressed during and after exercise for short period of time, there was no 
increase in GLP-1 level. 
In regards to T2D, Eshghi, Bell and Boulé, (2013) conducted a crucial study that aimed at 
studying the effects of aerobic exercise on the plasma incretins among T2D individuals. The 
study was motivated by the fact that there are very few studies on the effect of exercise on 
incretins on the secretion of insulin. Eshghi and colleagues aimed at examining the effects of 
aerobic exercise and/or metformin on the levels of incretin hormones, their reason on 
including metformin was due to the fact that is largely used among diabetic. The randomised 
crossover study concluded that exercise has an effect on incretin hormone level including 
GLP-1, however, the level of GLP-1 was seen to be higher among participants on metformin 
in both pre-lunch and post-lunch sessions when compared to participants in the placebo 
group (Eshghi et al., 2013). Another study with similar results as Eshghi et al., (2013) is that 
reported by O'Connor et al., (2006) , where their findings showed prolonged aerobic exercised 
showed a significant increment of incretin hormones level (GLP-1 and GIP) in non-diabetic 
individuals, while no significant effect was observed in T2D participants.  
 Shaabani, Abolfathi, and Alizadeh (2016) also looked into the effect of exercise on GLP-1 via 
a randomised control study. In their study, participants recruited were female T2D (n=20, age 
33-53 years) which were divided into exercise and control group.  The exercise conducted was 
running on a treadmill (VO2max 55-80%) for 5 days a week for the duration of 4 weeks, and 
each session was 30 min long which was increased slightly to 60 min in week 4.  Blood samples 
were collected at baseline and after the 4thweek of exercise. ELISA kit was used in analysing 
GLP-1 and insulin.  The result showed that aerobic exercise has no significant effect on GLP-
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1, BG, insulin and BMI  (P> 0.05) compared to control (Shaabani et al., 2016).  This study, the 
studies by Eshghi et al., (2013) and that of O'Connor et al., (2006) are important because they 
focus on T2D while other studies were on athletes, heathy and obese subjects.    
Although literature on the effect of exercise on GLP-1 and T2D was reviewed, it is important 
to also look at the literature on the effects of exercise and GLP-1R agonist on GLP-1 level. The 
study by Mensberg et al., (2017) has been considered as the first clinical trial that combined 
exercise and a GLP-1R agonist to assess GLP-1 hormone level in the body. The following 
parameters namely HbA1c, FBG, body weight, insulin, C-peptide, glucagon, and incretins 
hormones were all assessed at baseline and after the programme.    Participants were T2D (> 
18 years) who are treated with diet and/or metformin and are randomly grouped into 2 
groups namely exercise-placebo and exercise-liraglutide (Victoza®) group. Each exercise 
session was designed for a duration of one hour and conducted three times weekly for 16 
weeks. Two trained exercise physiologists assigned as supervisors during the exercise 
programmes. Participants received daily injectable dose (0.1ml) of liraglutide or placebo for 
the first week then 0.2ml for the second week and 0.3ml for the third week and continue 
using this dose until the end of the programme. The results published showed that GLP-1 level 
in the placebo group decreased from (20.1±8.2) to (18.1±5.7), while liraglutide group showed 
an elevated level of GLP-1 level (18.7±3.9) to 19.3±5.6).  Moreover, HbA1c was shown to have 
greatly reduced in liraglutide group from (66.0±16.0) to (44.0±8.0) and slightly decreased 
from (64.0±13.0) to (61.0±17.0) in the placebo group.  The study concluded that the 
combination of exercise and GLP-1R agonist has better effect on both HbA1c and GLP-1 level, 
suggesting that this could be a suitable therapeutic option for obese individuals with T2D who 
are on diet and/or metformin (Mensberg et al., 2017).   
Recent study by Tura et al., (2017) stated that there is some incretin resistance in individuals 
with T2D who are overweight. The study was conducted with two groups including 8 T2D and 
8 normal glucose tolerant participants and both groups received 25, 75, 125 g oral glucose 
tolerance test with corresponding isoglycemic glucose infusion and a mathematical model 
was used obtain β-cell sensitivity to incretins. Although GLP-1 response was seen to be higher 
in the insulin sensitive participants, BMI was lower. Despite the secretion of GLP-1, it was seen 
to have improper action in T2D pointing to the possibility of GLP-1 resistance. (Tura et al., 
2017).   
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T2D, obesity and exercise are linked to elevated IL-6 level while contracting skeletal muscle is 
also associated with the release of interleukin-6 (IL-6).  The latter is said to stimulate the 
secretion of GLP-1 from the intestine and the pancreas (Ellingsgaard et al., 2011).  
From the above reviewed literature, it is recommended that combine exercise can be used to 
control diabetes and increase insulin sensitivity in T2D patients, however, further research 
should be conducted to provide more options and evidence, since some literature present 
contradictory evidence.    Despite the wide range of studies on incretin, only few studies have 
been conducted on T2D participants and still there is a need to compare the effect of exercise 
and different types of pharmacological therapy on GLP1. In this study, the researcher are 
going to analyse new thing which no researcher before have demonstrate it.  The finding of 
T2D have been used to compare between those who are using different types of medication 
and doing exercise with those who are not using any medication just doing exercise; and 
analyse the effect of that on GLP-1 level in each group.  
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6.5 Method: 
6.5.1 Study design 
In each exercise session, volunteers performed a combined exercise program consisting of 30 
mins of resistance exercise followed by 20 mins moderate cycling twice a week for 6 weeks. 
At the beginning of each session, the volunteers started with 11 steps of stretching, then 
cycled for five minutes to warm up.  Blood samples were collected at baseline after (S1, S2, 
S4, S6, S8, S10, and S12), then centrifuged and refrigerated to be analysed later by a 
commercially available enzyme-linked immunosorbent assay (ELISA) with <0.01 cross 
reactivity with GLP-1 kit as explained in section 3.9.2.    
6.5.2 Intervention group 
The intervention groups were T2D participants (n= 11) and categorised into three groups 
based on medication namely T2D volunteers on metformin only, T2D volunteers on 
metformin and Dipeptidyl Peptidase 4 inhibitor (DPP4 I) and T2D volunteers on metformin 
and SGT2-I.  
 
Medication Number of Volunteers 
Pravastatin 40mg OD 1 
Atorvastatin 20mg OD 3 
Metformin 500 mg BD 3 
Metformin 850 TDS 1 
Metformin 1000 mg BD 2 
Sitagliptin 50 mg OD (DPP4-I) 1 
Sitagliptin 100mg OD (DPP4-I) 2 
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Empagloflizin 10 mg OD 2 
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6.6 Results and discussion: 
The GLP-1 data were processed using Excel 2010 and SPSS (version 22), values were expressed 
as mean with standard error of mean. Pre and post exercise samples were compared using a 
paired-samples t-test with statistical significance of P < 0.05.  
Table 26: Age, weight and HbA1c in T2D participants. 
 Pre Ex Post S12 
Age (years) 49 ± 3.11  
Weight (KG) 96.00 ± 9.4 93.04 ± 8.7 
HbA1c  7.45 ± 0.7 % 
(58± 8.1 mmol/mol) 
6.4 ± 0.4 % 
(46.5±4.5 mmol/mol) 
 
6.6.1 The incretin result among the whole T2D: 
 
Table 27: GLP-1 level during the 1st session of exercise where results shows acute effect, Data expresses as 
mean ± SEM and P value: 
GLP-1 
(pmol/L) 
S1 
 
P value 
Pre Ex Post RE Post AE 
T2D 
 
9.7±2.1 10.4±2.0 8.7±0.9 0.594 
 
  
Table 28: GLP-1 level during the 12 sessions of exercise where results shows chronic effect, Data expresses as 
mean ± SEM and P value:  
GLP-1 
(pmol/L) 
Pre Ex S1 
 
S2 S4 S6 S8 S10 S12 P value  
T2D 
 
9.7±2.1 8.7±0.9 7.7±1.5 8.6±1.3 9.6±1.0 7.7±1.1 9.6±1.7 7.0±1.0 0.333 
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Figure 56: GLP-1 level during the 12 sessions of Exercise in the whole 3 groups of T2D, showing a downward 
trend as opposed to what was reported in literature. 
 
 
 
Figure 54a: This is a regression with normalised intervals, showing a slight downward trend but poor 
relationship over the 6 weeks (where not all sessions were measured) 
 
The result obtained from the combination of three groups as in (figure 54), shows a slight 
reduction in the trend of the means between session one and session 12.  GLP-1 was (9.7±2.1) 
at baseline and decreased to (8.7±0.9), (P= 0.594) after the 1st session.  This decreased slightly 
more after the 12th session to (7.0±1.0), (P= 0.333), illustrating that exercise has statistically 
insignificant effect on GLP-1 hormone as measured in this group, although there is a 
downward trend. 
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6.6.2 Results according to medication type: 
Table 29: GLP-1 level during the 1st session of Exercise (Metformin group), where results shows acute effect. 
Data expresses as mean ± SEM and P value: 
GLP-1 
(pmol/L) 
S1 
 
P value 
Pre Ex Post RE Post AE 
T2D 
 
11.6±3.3 11.4±2.8 9.6±1.7 0.444 
 
 Table 30: GLP-1 level during the 12 sessions of Exercise (Metformin group) where results shows chronic effect. 
Data expresses as mean ± SEM and P value: 
GLP-1 
(pmol/L) 
Pre Ex S1 
 
S2 S4 S6 S8 S10 S12 P value  
T2D 
 
11.6±3.3 9.6±1.7 7.1±2.2 9.9±2.2 8.1±1.3 6.1±0.7 7.7±2.1 5.2±0.9 0.092 
 
 
Figure 57: GLP-1 level in Metformin group during the whole exercise sessions 
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Figure 55a: This is a regression with normalised intervals, showing a strong downward trend and stronger 
relationship over the 6 weeks (where not all sessions were measured) 
 
Interrogating this result for the effect of individual adjunct drugs in regards to metformin, a 
reduction in GLP-1 level was more evident in the metformin group among the three groups.  
Before the 1st session, GLP-1 was (11.6±3.3) and decreased to (9.6±1.7) (P=0.444) after S1.  
This decreased further after S12 to (5.2±0.9), (P=0.092) but no significant reduction was found 
in the chronic and acute effect of exercise when assessing the trend of means over the 12 
sessions. 
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Table 31: GLP-1 level during the 1st session of Exercise (Metformin and DPP4-I group) where results shows acute 
effect, Data expresses as mean ± SEM and P value: 
GLP-1 
(pmol/L) 
S1 
 
P value 
Pre Ex Post RE Post AE 
T2D 
 
11.8±4.1 12.2±6.0 7.2±1.3 0.347 
 
Table 32: GLP-1 level during the 12 sessions of Exercise (Metformin and DPP4-I group) where results shows 
chronic effect, Data expresses as mean ± SEM and P value: 
GLP-1 
(pmol/L) 
Pre Ex S1 
 
S2 S4 S6 S8 S10 S12 P value  
T2D 11.8±4.1 7.2±1.3 5.8±2.1 6.8±0.4 8.9±1.3 6.2±0.7 9.6±5.3 6.8±0.2 0.423 
 
 
Figure 58: GLP-1 level in Metformin and DPP4-I group during the whole exercise sessions 
 
0
2
4
6
8
10
12
14
16
18
20
Pre Ex Post RE S1 S2 S4 S6 S8 S10 S12
G
LP
-1
 (
p
m
o
l/
L)
Exercise sessions
GLP-1 in Metformin and DDP4-I group
 202 
 
 
Figure 56a: This is a regression with normalised intervals, showing a very slight downward trend and very poor 
relationship over the 6 weeks (where not all sessions were measured)  
   
In the 2nd group (Metformin and DPP4-I group), a reduction also occurred thus GLP-1 
decreased from (11.8±4.1) to (7.2±1.3), (P= 0.347) after S1.  This reduction was slightly more 
after the 12th session (6.8±0.2), (P= 0.423).   
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Table 33: GLP-1 level during the 1st session of Exercise (Metformin and SGT2-I group) where results shows acute 
effect, Data expresses as mean ± SEM and P value: 
GLP-1 
(pmol/L) 
S1 
 
P value 
Pre Ex Post RE Post AE 
T2D 
 
3.9±1.5 6.4±2.4 8.4±1.2 0.345 
 
Table 34: GLP-1 level during the 12 sessions of Exercise (Metformin and SGT2-I group) where results shows 
chronic effect, Data expresses as mean ± SEM and P value:  
GLP-1 
(pmol/L) 
Pre Ex S1 
 
S2 S4 S6 S8 S10 S12 P value  
T2D 3.9±1.5 8.4±1.2 10.7±4.6 7.9±3.6 13.3±0.3 12.6±0.9 13.4±0.8 11.0±0.8 0.196 
 
 
Figure 59: GLP-1 level in Metformin and SGT2-I group during the whole exercise sessions 
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Figure 57a: This is a regression with normalised intervals, an upward trend but not a very convincing 
relationship over the 12 sessions, although the R2 value is much better than the one above over the 6 weeks 
(where not all sessions were measured) 
 
In the third group, the trend was reversed. In this set (Metformin and SGT2-I group), the result 
shows elevation in GLP-1 after both acute and chronic effect, however, the elevation after 
12th sessions was higher.  GLP-1 in this group was (3.9±1.5) and increased to (8.4±1.2), (P= 
0.345) after S1 and then increased more to (11.0±0.8), (P=0.196) after 6 weeks of exercise.  
The result demonstrates that the combination of metformin and SGT2-I is associated with the 
elevation of GLP-1 hormone.  The improvement in GLP-1 in the last group could be a result of 
an improvement in HbA1c as mentioned in previous literature published by Mensberg et al., 
(2017) where a correlation between GLP-1 and HbA1c was reported.   In the present study, 
the highest reduction of HbA1c among all T2D groups was observed in the metformin and 
SGT2-I group and it reduced from (77 mmol/mol) to (58 mmol/mol).    
The combination of metformin with SGT2 inhibitors plus exercise is an improvement in 
diabetes control, despite the statistically ambivalent result. It is clear that in this group, there 
may be a trend that is worth further investigation and should be examined with other relevant 
factors. 
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6.7 Conclusion: 
SGLT2-I and metformin are shown to affect individuals` weight and the reduction in weight 
could be due to improved level of GLP-1. Since research showed that there is a correlation 
between increased level of GLP-1 and weight reduction. As seen in the study of Hussein et al., 
(2014) which showed lower GLP-1 levels in obese individuals and negatively correlated GLP-1 
with BMI and waist circumference, however, no significant correlation was noticed between 
GLP-1 levels and age or sex. Some studies state that no significant correlation was noticed 
between GLP-1 levels and age or sex (Hussein et al., 2014).  Thus, the present study didn’t 
correlate GLP-1 level with age or sex.  Another factor that might also affect the level of GLP-1 
during six weeks is eating prior to the sessions, because Nauck et al., (2011) showed that age, 
body weight and fasting state could affect GLP-1 level. In addition, insulin resistance can also 
impair the secretion of GLP-1 (Nauck et al., 2011). Thus, suggesting that there are several 
factors that could affect the response of GLP-1 in both T2D and ND. However, the study 
exercise training programme used in the present study showed no significant differences in 
serum GLP-1 levels which could be due to the small sample size or other unknown factors.  
In summary, according to outcomes of other studies, it looks that assessment of variations in 
serum GLP-1 levels need more studies with longer duration and higher number of participants 
to show valid results.   
6.7.1 Limitations: 
 
1- Only few volunteers were recruited after we received the specific tube for collecting 
blood samples. 
2- No data of GLP-1 was collected from ND group due to high price of special tubes that 
was used to collect blood sample (BD P800). 
3- No specific diet has been followed.  
 
6.7.2 Future work: 
Conduct another study with larger sample size and analyse GLP-1 in ND group as well with 
longer time follow up to obtain conclusive results. 
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Chapter 7 The effect of moderate combination exercise cardio “aerobic” and 
resistance on the inflammatory markers in T2D and ND subjects 
7.1 Research questions: 
Do inflammatory markers improve after 6 weeks of exercise? Do the improvements 
correlate with medication type?  
7.2 Aim: 
The aim of the study is to investigate the effects of a combined exercise programme (cardio 
“aerobic” and resistance) on the inflammatory markers in T2D and ND.   
 
7.3 Inflammatory markers: 
Cytokines are protein molecules that play main roles in operating the body immune system 
(Vijayaraghava and Doreswamy, 2017). They are secreted by different kind of cells into the 
circulation, the reticulo-endothelial, the adipose tissue and the musculoskeletal systems. 
Their release into circulation in response to different stimuli e.g. infections, antigens, mental 
stress and exercise (Vijayaraghava and Doreswamy, 2017). Adipose tissue is the main site for 
storage of extra energy in the form of TG. It consists of multiple cell types such as pre-
adipocytes, adipocytes, immune cells and endothelial cells (Jung and Choi, 2014).  Obesity 
causes adipose tissue dysfunction which leads to metabolic complication (Abate, 2013). There 
are two kind of adipose tissue which have two opposite function; white adipose tissue (WAT) 
and brown adipose tissue (BAT).  The role of WAT is to store extra energy in form of TG while 
BAT is responsible for dissipation of energy by heat production (Saely, Geiger and Drexel, 
2012). WAT can be considered as a disseminated endocrine organ that consists of various 
cells such as adipocyte, macrophage, T lymphocyte and endothelial cells (Feijóo-Bandín et al., 
2016).    WAT plays a role in the metabolism and regulation of lipid and energy homeostasis.  
The distribution of WAT in the body consists of subcutaneous adipose tissue (SAT) which 
accumulates under the skin of abdominal, femoral and gluteus area and also in visceral 
adipose tissue (VAT) which located in the visceral of abdominal cavity specifically in the 
mesentery (Feijóo-Bandín et al., 2016). Various studies found that SAT is associated with a 
cardioprotective phenotype and VAT was contributed to the development of insulin 
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resistance, T2D, dyslipidaemia and cardiovascular disease (CVD) (Feijóo-Bandín et al., 2016). 
The large mass of VAT augments the synthesis of triacylglycerol-rich lipoproteins (Kishida, 
Funahashi and Shimomura, 2014).   These occur because VAT venous blood drains through 
the portal vein into liver and secrets large quantities of FFA that may then locate in the 
skeletal muscle and pancreas.  This enhances glucose production and decreased the dispose 
of glucose in the liver (Kishida, Funahashi and Shimomura, 2014; Feijóo-Bandín et al., 2016).  
SAT plays a role in energy long-term storage and preservation of IS in infants and in 
adolescence (Kishida, Funahashi and Shimomura, 2014).   Although, consuming large amounts 
of food in these ages leads to obesity. Furthermore, BAT is a special tissue which converts 
energy to heat when activated by the sympathetic nervous system following signals from the 
hypothalamus.   It has been believed that BAT only found in infants but recently research 
proved that BAT also found in adults (Betz and Enerback, 2015; Saely, Geiger and Drexel, 
2012). BAT plays a central role in IS in humans and rodents (Betz and Enerback, 2015). BAT is 
a thermogenic connective tissue that preserves body central temperature at a constant 37 ֯C 
even in moderately cold weather.  The differences between WAT and BAT is that WAT 
generally contains only a huge lipid droplet and have only a few mitochondria while BAT 
consist of numerous lipid droplets in each cell and are full with mitochondria (Betz and 
Enerback, 2015).   High amount of BAT in the body is associated with lower body weight (Saely, 
Geiger and Drexel, 2012). In humans BAT is found in fat tissues in the neck, thorax, and 
abdomen, intestines, heart, lungs, kidneys, and adrenals (Lee, Swarbrick and Ho, 2013). 
Production of an interplay of metabolic active proteins such as pro-inflammatory cytokines 
(TNF and IL-6) and adipokines or adipocytokines (leptin, resistin and adiponectin) (Abate, 
2013).  
7.3.1 C - reactive protein (CRP)  
William Tillet and Thomas Francis discovered CRP in 1930, at the Rockefeller Institute for 
Medical Research, New York (Shrivastava et al., 2015). CRP is a 206- amino acid member of 
the short pentraxin family and mostly synthesized in the hepatic cells. Its production is 
controlled by cytokines, mainly interleukin 6 (IL-6) (Salazar et al., 2014; Tanaka and Kishimoto, 
2014).  The normal median level of CRP is 0.8 mg/L, while during acute infection the level of 
CRP elevated to about 10,000-fold and then after that it became very low level (Shrivastava 
et al., 2015). CRP is a non-specific marker for inflammation such as infection (Salazar et al., 
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2014; Liu et al., 2016; Dasgupta and Wahed, 2013a). It plays a role in body defence against 
infective diseases (Shrivastava et al., 2015). An increase in CRP level has been associated with 
IR, higher BMI, elevated WC, T2D and MetS, as well as different chronic inflammatory disease 
such as CVD, certain rheumatoid condition and cancer (Kaur, 2014; Salazar et al., 2014). The 
level of CRP in obese individuals is reported to be elevated when compared to insulin sensitive 
individuals.  CRP is good independent indicator of cardiovascular disease (CVD) which is 
associated with MetS (Kaur, 2014; Aggarwal et al., 2015; Hayashino et al., 2014). Lukic et al. 
states that the level of CRP increased in obese T2D individuals with hypertension when 
compared to obese subjects with T2D (Lukic et al., 2014).  Research shows an association 
between CRP and atherosclerosis and CRP are said to bind lipoproteins especially low-density 
(LDL) and very low-density lipoproteins (VLDL) which are found in in atherosclerotic plaque 
(Shrivastava et al., 2015). It contributes to atherosclerosis by enhancing the activation of 
endothelial cell generation of foam cell inside the wall of artery (Hayashino et al., 2014).   
Furthermore, increased CRP is associated with coronary heart disease (CHD), peripheral 
artery disease (PAD) and Ischemia, myocardial infarction (MI), stroke and sudden cardiac 
death (Shrivastava et al., 2015).  It was reported that neuropathy is associated with high level 
of CRP (Grossmann et al., 2015).  Interestingly, T2D subjects who are using GLP-1 receptor 
agonist showed reduction in CRP level which reduced complications such as atherosclerosis 
and nephropathy (Grossmann et al., 2015).   
 
7.3.2 Interleukin (IL-6) 
In humans, IL-6 is a protein synthesized by T cells and macrophages at the sites of 
inflammation to stimulate immune response in case of infection, burn, trauma or tissue injury 
(Tanaka, Narazaki and Kishimoto, 2014). Then it transfers in the blood to liver and stimulates 
hepatic secretion of CRP (Tanaka, Narazaki and Kishimoto, 2014).  IL-6 is also induced by TNF 
and is produced widely including in striated (skeletal) muscle and visceral tissue (Liu et al., 
2016; Kaur, 2014).  IL-6 receptors are found in the hypothalamus and is important in appetite 
regulation. IL-6 normal value is 0.5-15 pg/ml (Alecu et al., 1998).  In healthy subjects, IL-6 has 
vital roles such as regulating glucose metabolism, increasing the release of leptin, increasing 
lipolysis and suppressing the activity of lipoprotein lipase in adipocyte (Kaur, 2014; Lukic et 
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al., 2014).  On the other hand, IL-6 affects the function of pancreatic β-cells as well as 
interfering with insulin signalling and also, its reduction linked to increase high-density 
lipoprotein (HDL) (Liu et al., 2016; Kaur, 2014). High level of IL-6 associated with Mets, but the 
mechanisms by which IL-6 decrease HDL levels are unclear (Feingold and Grunfeld, 2015).  The 
anti-inflammatory effect of IL-6 inhibits TNF from affecting insulin signalling which could 
prevent MetS and hyperglycaemia (Brown et al., 2015). The action of IL-6 is altered according 
to the secreting tissue and its action is controversial because it acts as anti-inflammatory and 
pro-inflammatory cytokine (Jung and Choi, 2014; Brown et al., 2015).   Dual action might be 
due to either individual variation of training status or methodological differences in exercise 
intensity or duration (Brown et al., 2015). Therefore IL-6 secreted acutely after muscle 
contracted during exercise and this is useful in the metabolism because it acts in this case as 
anti-inflammatory cytokine by an inhibition of TNF‐α and by stimulating IL‐1ra (IL‐1 receptor 
antagonist) (Karstoft and Pedersen, 2016).    IL-6 is increased with obesity and T2D, as it linked 
to IR and high level of IL-6 activates the secretion of CRP in the liver (Liu et al., 2016; Kaur, 
2014).  High mass of adipose tissue linked to highly secreted pro-inflammatory cytokine and 
cause insulin resistance (Jung and Choi, 2014; Pedersen and Fischer, 2007).  The studies by 
Lukic et al. showed that the level of IL-6 is higher in T2D obese and HTN individuals compared 
to T2D obese subjects (Lukic et al., 2014).  While the increase of muscle mass that strongly 
associated with the secretion of anti-inflammatory cytokine and has beneficial effect on 
metabolism (Pedersen and Fischer, 2007).  Also, it has been found that the administration of 
IL-6 to human body increases insulin-stimulated glucose disposal as well as FA oxidation, and 
therefore it has been suggested that IL-6 and its receptors might be useful as a targets for the 
treatment of some metabolic diseases (Pedersen and Fischer, 2007).   
7.3.3 Tumor Necrosis Factor (TNF) 
TNF is a pro-inflammatory cytokine and a produced mostly by macrophages and monocytes 
(Liu et al., 2016; Feijóo-Bandín et al., 2016).  TNF enhances the production of CRP and is 
positively correlated with IR and T2D (Liu et al., 2016; Kaur, 2014).  An increase in TNF is 
associated with elevated level of TG, LDL, body weight and WC as well as decrease HDL. 
However, a decreased level of TNF is associated with high levels of HDL (Feijóo-Bandín et al., 
2016). A positive correlation between TNF and T2D is reported, where plasma level of TNF 
can be used to obtain the status of IR (see figure 49) (Liu et al., 2016). Primarily, the production 
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of TNF is enhanced by IL-18 (IL-1 family member), and in turn, TNF enhances the release of IL-
6 and CRP (Liu et al., 2016).  The normal level of TNF 0-16 pg/ml (Alecu et al., 1998). 
7.3.4 Leptin   
Leptin was the first adipokine, discovered by Friedman in 1994. It is a 167 aminoacid 
polypeptide, with production on chromosome 7 (Feijóo-Bandín et al., 2016; Li and Li, 2016).  
Friedman called the newly discovered hormone ‘‘leptin’’ (Greek = thin) (Li and Li, 2016).  
Leptin is mainly secreted in WAT and can be secreted by skeletal muscle, liver, kidneys, ovary, 
placenta, bone marrow and heart. It mainly acts in the central nervous system and plays 
essential role in decreasing appetite and enhancing the consumption of energy by acting on 
hypothalamus (Mechanick, Zhao and Garvey, 2018; Li and Li, 2016; Feijóo-Bandín et al., 2016).  
In women, leptin levels are higher than in men which might be due to the greater ratio of 
body fat in female (Mechanick et al., 2018). Elevated leptin levels are associated with 
decreased energy intake and increased energy utility, thus decreased storage as adiposity 
(Mechanick et al., 2018).  Paradoxically, the level of leptin was shown to increase in obese 
subjects and decrease when the weight is lost, suggesting that these subjects have leptin 
resistance (Kaur, 2014; Feijóo-Bandín et al., 2016). Leptin resistance is linked to obesity 
because the plasma level of leptin was shown to associate with the mass of WAT.  The 
receptors of leptin found in WAT, kidneys, liver, skeletal muscle, pancreas, ovaries, heart and 
brain (Kaur, 2014; Feijóo-Bandín et al., 2016). Leptin activates macrophages and monocyte 
which regulate inflammation by releasing pro-inflammatory cytokines such as TNF and IL-6.   
Elevation of leptin (leptin resistance) is also associated with insulin resistance, rheumatoid 
arthritis, Alzheimer’s and cancer as well as increased risk of stroke and MI (Feijóo-Bandín et 
al., 2016).  Various studies showed that leptin stimulates macrophage and leukocyte into 
endothelial wall. This cascade increase the risk of atherosclerotic plaque by enhancing platelet 
activation and formation of plaques in the arteries, also by enhancing the secretion of pro-
inflammatory markers such as IL-6, TNF or reactive oxygen species (ROS) which cause 
oxidative stress (OS) then endothelial dysfunction and finally atherosclerosis (Feijóo-Bandín 
et al., 2016).  Although leptin is a vasodilator, its elevation is associated with hypertension 
because it stimulates peripheral vascular resistance (Kaur, 2014; Feijóo-Bandín et al., 2016).  
The effects relate to hyperglycaemic states in MetS and T2D are interesting.  A study 
conducted by Meek, describes the role of leptin in controlling hyperglycaemia in uncontrolled 
 211 
 
insulin-deficient diabetes (uDM) (Meek and Morton, 2016).  In an insulin resistant diabetes 
rodent model, the administration of leptin reduces severe insulin resistance and improve 
diabetes associated with leptin deficiency. The mechanism of glucose lowering effect of leptin 
acts by decrease consumption of food and elevate the glucose urinary excretion or increase 
β-cell recovery.  Furthermore, it normalizes the secretion of glucose from the liver and the 
peripheral tissue uptake of glucose (Meek and Morton, 2016). It has been found that leptin 
would be a useful anti-obesity medication (Mechanick et al., 2018). Therapeutic treatment of 
leptin has been approved in case of lipodystrophy. The action of leptin on lowering glucose in 
T1D and T2D rodents gives possibility in using it in future as adjunct therapy to insulin in 
diabetes subjects (Meek and Morton, 2016). 
7.3.5 Resistin 
Resistin is an adipokine with a similar molecular structure to adiponectin, it is a protein 12.5 
kDa of molecular weight and is produced in human by macrophages and pre-adipocytes 
(Feijóo-Bandín et al., 2016). In obese individuals, the resistin level is increased but the 
mechanism is unknown (Feijóo-Bandín et al., 2016). The mechanism of the association 
between resistin and obesity, T2D, MetS and CVD is also still unknown (Abate et al., 2014). 
Some studies were illustrated that the association between obesity component in MetS and 
resistin is controversial, but others show a correlation between resistin and BMI or WC (Abate 
et al., 2014). Resistin thus has a crucial role in MetS pathogenesis (Abate et al., 2014).  The 
expression of resistin in the pancreatic β-cell is greater in T2D than in healthy people and 
resistin correlates positively with CRP and IL-6 in T2D subjects (Abate et al., 2014).  Its 
elevation is also associated with the complication of T2D such as neuropathy, nephropathy, 
atherosclerosis and gout (Abate et al., 2014).   The level of resistin is reported to increase with 
the increment of OS and myocardial injury (Feijóo-Bandín et al., 2016).   
7.3.6 Cystatin C (CysC) 
Cystatin C is a 13 kDa protein consisting of 122-amino acid, belonging to the family of cysteine 
protease inhibitors and produced by different nucleated cells (Javanmardi et al., 2015; Shetty 
et al., 2017).  It is also called microprotein (Javanmardi et al., 2015). Cystatin C (CysC) 
considered as alternative markers for glomerular filtration rate (GFR) which can be detected 
in urine and blood samples (Di Somma and Marino, 2019).  The plasma level of CysC increased 
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in case of kidney function declined and it is a precise test for kidney function (Di Somma and 
Marino, 2019). In early stage chronic kidney disease (CKD), CysC is superior to serum 
creatinine as a marker of kidney function (Čabarkapa, 2015).  Elevated level of CysC linked to 
increased cardiovascular risk in general population or preeclampsia in pregnant women.  
Some factors could affect the level of CysC such as the use of glucocorticoids, smoking, 
malignancy, inflammation, adiposity or thyroid dysfunction (Inker and Levey, 2014; 
Čabarkapa, 2015). When compared with serum creatinine, CysC is not influenced by gender, 
race, age, diet and muscle mass (Javanmardi et al., 2015; Král et al., 2016). While creatinine 
is strongly dependent upon the body composition, age, gender, ethnicity and GFR (Grubb, 
2011). As a result, CysC has been recommended as the best reliable predictor for both CKD, 
atherosclerosis and high risk of CVD (Kobayashi et al., 2017). CVD and CKD represent similar 
pathophysiologic bases such as metabolic abnormalities, endothelial dysfunction, chronic 
inflammation and OS (Satoh-Asahara et al., 2011).  The mechanism of the elevation of CysC 
in CVD is unclear, the justification is only that CVD is linked to renal impairment (Magnusson 
et al., 2016). The mechanism of this correlation is also unknown (Magnusson et al., 2016). 
CysC elevation correlate with abdominal obesity and IR developing in T2D (Schmid et al., 
2014).  The normal level reported is between 0.52 and 0.98 mg/L (Král et al., 2016).  An 
increase in the level of plasma CysC is associated with the decline in GFR in diabetes compared 
to healthy subjects (Javanmardi et al., 2015).  In T2D, CysC is a useful marker compared to 
serum creatinine or microalbuminuria in predicting diabetes nephropathy (Javanmardi et al., 
2015; Shetty et al., 2017).   
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Figure 60: Cytokines disturbance in adipose tissue and diabetes 
 
7.4 Inflammatory markers of diabetes 
Markers and other factors demonstrate inflammation play a vital role in T2D development 
(Wang et al., 2013a).  The high level of these biomarkers stimulate IR and are associated with 
high risk in T2D (see figure 59) (Liu et al., 2016).  In previous studies, chemokines, cytokines 
and white blood cell count have been identified as inflammatory factors that can anticipate 
the development of T2D (Esser et al., 2014).  A meta-analysis and systematic review confirmed 
this by demonstrating that increased levels of CRP and IL-6 considerably relate to a higher risk 
of developing T2D (Wang et al., 2013b; Esser et al., 2014). In T2D and obesity, the pancreas, 
the adipose tissue, and the skeletal muscle cells responsible for producing pro-inflammatory 
cytokines, e.g. include IL-1β, tumor necrosis factor (TNF-α), and IL-6 (Wada and Makino, 2013; 
Esser et al., 2014).  These cytokines facilitate insulin resistance by interfering with the insulin 
signalling in the tissues (Esser et al., 2014). In non-obese, adipocyte secrete anti-inflammatory 
adipokine such as adiponectin., while in case of obesity the genes responsible for encoding 
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inflammatory factors are up-regulated and that cytokines and chemokines are overproduced 
in distended adipose tissues (Ouchi et al., 2011). Thus by  the macrophage content of adipose 
tissue increased in correlation with adipocyte size and body mass, and expression of pro-
inflammatory cytokinesis generally come from macrophages. As the quantity of macrophages 
increased in adipose tissue, obesity convert these cells from an anti-inflammatory to a pro-
inflammatory state (Jung and Choi, 2014).  Therefore, improving insulin sensitivity via weight 
loss leads to a decline in the expression of pro-inflammatory genes (Esser et al., 2014). These 
pro-inflammatory cytokines correlate with the extent of obesity and they are related to the 
resistance of insulin and systemic inflammation (Esser et al., 2014).   Inflammation exists in 
the pancreatic islets of individuals suffering from T2D as demonstrated by the existence of 
higher levels of pro-inflammatory chemokine and cytokine levels, and increased death of β 
cells (Donath and Shoelson, 2011).  Furthermore, there is an increase in the manifestation 
and localised release of IL-1β, which is a pro-inflammatory cytokine in the pancreatic islet of 
diabetic individuals (Verdile et al., 2015; Esser et al., 2014). Obesity, resistance towards 
insulin, and T2D are linked to chronic inflammation (Sell, Habich and Eckel, 2012).  
Several studies illustrate, that there is a link between greater risk of increasing CVDs and 
adipose tissue pathological function.  That risk increases by producing different chemical 
mediators to act in paracrine, endocrine and autocrine (Feijóo-Bandín et al., 2016).  As stated 
above, biomarkers such as adiponectin, IL-6, CRP and TNF linked to pathogenesis of T2D which 
could help in the development of new treatment for T2D (Liu et al., 2016). 
7.5 Effect of exercise on the inflammatory markers 
The value of exercise is closely linked to the anti-inflammatory effect. Physical exercise is 
linked to a decline in TNF-, IL-6, and CRP (Teixeira de Lemos et al., 2012; Orsatti et al., 2014; 
Phillips et al., 2012). However, evidence suggests that the intensity and duration of exercise 
and muscle damage after acute exercise could influence IL-6 response to acute exercise 
(Reihmane and Dela, 2014).  Physical exercise has a known impact in cytokines released by 
cells in the muscle. The production of TNF was directly inhibited by physical exercise via the 
production of IL-6 from the exercising muscles (Fisman and Tenenbaum, 2010).  In this case, 
IL-6 is an anti-inflammatory factor whose concentration increases in the plasma after physical 
exercise which illustrates its dual action (Fisman and Tenenbaum, 2010). Several studies have 
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focused on determining the anti-inflammatory effects of inflammatory markers by chronic 
exercises. Different inflammatory markers have been found to demonstrate different 
response to training activities. Basically, various studies on the effect of exercise on 
inflammatory markers demonstrate that exercise and training have a potential of reducing 
the level of circulation of the inflammatory markers in T2D as it is an inflammatory disease 
(Hamer et al., 2014).  The majority of studies have shown that cardiac rehabilitation and 
chronic physical exercises have indicated a possible anti-inflammatory effect (Orsatti et al., 
2014). The anti-inflammatory impact of exercise in T2D is concerned with reducing levels of 
inflammatory cytokines and increasing the anti-inflammatory cytokines (Teixeira de Lemos et 
al., 2012; Hamer et al., 2014). 
 In a 12-month follow-up study, it was revealed that an increase from moderate to vigorous 
exercise was linked to a decline in IL-6 and CRP, independently of changes in BMI among the 
T2D individuals (Herder et al., 2009). Consistently, aerobic exercise training resulted in a 
declined CRP and that a decrease in central adiposity partly mediated this effect (Vieira et al., 
2009).  Campbell et al., (2009) reported similar results in a 12-month trial where it was shown 
that moderate exercise training led to a decrease in CRP only in women with obesity at 
baseline and in those whose body fat loss was over 2%.  Other studies however found that 
there is no changes in CRP level after exercise (Nygaard et al., 2017; Mendham et al., 2011).  
A systemic review concluded that exercise is a good therapeutic option to improve 
adiponectin and leptin level in over weight and obese individual (Yu et al., 2017). As such, this 
acts as an independent factor affecting the inflammatory markers and inhibiting physical 
activity. On the other hand, cross-sectional studies demonstrated that physical activity is 
related to reductions in the circulating levels of TNF and IL-6 (Bongers et al., 2017).  Patients 
with heart failure complications were found to have a reduced skeletal muscle TNF after 6-
month exercise training.  Although, serum levels were not affected in this same group (Brown 
et al., 2015).  Exercise training promotes bioavailability and minimises circulating markers that 
are found in the endothelial dysfunction (Verheggen et al., 2016). Some previous studies 
demonstrate that exercise improve CysC (Eskandar, Katayon and Ali, 2015). Positive effects of 
aerobic exercise have been noticed in improving cardiac and kidney function by improving 
CysC.  While Serin et al. (2009) found that 6 weeks submaximal exercise has no effect on renal 
function (Eskandar, Katayon and Ali, 2015). A study by Eskandar et al. (2015) has stated that 
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aerobic exercise improve FBG, SBP and lipid profile significantly, however the effect on CysC, 
WC and DBP was not significant, before exercise CysC was (0.62± 0.29 ng/mL) and after 
exercise become (0.61± 0.25 ng/mL)  (Eskandar, Katayon and Ali, 2015).  Resistance training 
was found to induce an improvement in CRP, lipid profile and alterations of muscle strength 
in postmenopausal obese women (Orsatti et al., 2014). As such, the findings of the study 
concluded that 8-week resistance training is useful in improving inflammation levels, glycemic 
profiles, strength and muscle mass for individuals with obesity. The main weakness of the 
Orsatti study is that it used a relatively small sample size in the study. Recruiting women was 
a significant strength for this study because they are not usually involved in resistance training 
(Orsatti et al., 2014). Resistin is an adipocyte that is linked to obesity and inflammation which 
is linked to obesity disorders like IR and diabetes mellitus. In order to identify the effect of 
serum resistin and physical exercise for men, Yahya et al. (2014) used 14 men who were 
exposed to a 40 minutes running that was exercised in moderate intensity (Yahya et al., 2014). 
The study concluded that exercise test for a particular single session with moderate intensity 
does not have significant effect on resistin in sedentary obese men. This insignificant result 
might be due to small sample size for the study (Yahya et al., 2014).  CRP is linked to a high 
severity of atherosclerosis. The evidence is insufficient to demonstrate the effect of resistance 
training on CRP (Hayashino et al., 2014). A meta-analysis of randomized control trials by 
Hayashino et al., (2014) found that exercise is beneficial in improving CRP and IL-6 in subjects 
with T2D as well as in subjects with diabetes it might be a good therapeutic option to reduce 
inflammatory markers (Hayashino et al., 2014). The study by Ramel et al. (2015) was 
established to found out the response of CRP to resistance exercise in adult individuals. The 
intervention was set as a 12-week resistance training (Ramel et al., 2015). The study concludes 
that the level of CRP decreased significantly after enduring 12 weeks exercise activity for all 
subjects exhibiting abnormal high CRP, which is important in reducing the possibility of future 
diseases. The result of this study was not significant to the hypothesis created in this particular 
study (Ramel et al., 2015). In addition, additional RCT of 8 weeks of walking exercise was 
conducted on 30 men aged (51.56± 11.28) years and divided into two groups; control group 
and intervention group (Nuri et al., 2016).  The results illustrate improvement of VO2peak and 
reduction in body fat percentage (P < 0.05). However, the level of leptin and IR has no 
significant improvement (Nuri et al., 2016).  It has been concluded that that 8 weeks of aerobic 
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exercise improved body fat percentage and VO2peak, nevertheless it has no effect on serum 
leptin or IR (Nuri et al., 2016).    
The anti-inflammatory impact of exercise in T2D individuals has been demonstrated in the 
literature. Eckardt et al. (2014), suggested that regular exercise reduces inflammatory marker 
levels and protects against diseases caused by inflammation (Eckardt et al., 2014; Esser et al., 
2014).  In conclusion, this part shows the connection that exists between T2D and 
inflammation by highlighting the inflammatory markers linked to this disease. Therefore, 
regular exercise should be a critical part of the various strategies used in managing T2D.  The 
plan in this study is to start 6 weeks combination exercise to measure the effect of exercise 
on the inflammatory markers in T2D and ND, and to see the effect of pharmacological 
treatment on these markers which no one else has conduct it before.  
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7.6 Method: 
7.6.1 Study design 
Each exercise session will consist of a combined exercise protocol of 30 min of resistance 
exercise followed by 20 min moderate cycling twice a week for 6 weeks. Volunteer should 
stretch-up for 11 steps of stretching, then the volunteer must cycle for five minutes to warm 
up.  Blood samples collected at base line after S1, S2, S4, S6, S8, S10 and S12.  Blood samples 
centrifuge and refrigerate to be analysed by The Evidence Investigator™ Biochip Array 
technology (Randox, UK) is a Multiplexing ELISA technology which described previously in 
section 3.10.   
7.6.2 Intervention group 
The intervention group are T2D (n= 13) and ND (n=8) who are doing combination exercise. 
Intervention group are classified in four groups 
1- T2D volunteers with no medication. 
2- T2D volunteers on Metformin only. 
3- T2D volunteers on Metformin and Dipeptidyl Peptidase 4 inhibitor (DPP4 I).  
4- Non-diabetes (ND).   
Medication Number of Volunteers 
Pravastatin 40mg OD 1 
Atorvastatin 20mg OD 3 
Metformin 500 mg BD 3 
Metformin 850 TDS 1 
Metformin 1000 mg BD 2 
Sitagliptin 50 mg OD (DPP4-I) 1 
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Sitagliptin 100mg OD (DPP4-I) 2 
Empagloflizin 10 mg OD 2 
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7.7 Results and discussion: 
The plasma obtained from T2D and ND volunteers was used to analyse for inflammatory 
markers with the aid of Randox machine in this study.  Data was analysed by using Excel 2010 
and SPSS (version 22), Values were expressed as mean with standard error of mean.  Pre and 
post exercise samples were compared using a paired-samples t-test and the level of statistical 
significance was act at (P < 0.05).   
7.7.1 Results among the two groups (ND and T2D) 
7.7.1.1 CRP 
 
Table 35: Changes in CRP level was observed during the 1st exercise session (acute effect) in T2D and ND. Data 
is express as mean± SEM and P value for the effect Pre Ex (S1) and after S1 was obtained. 
CRP (ng/ml) 
 
S1 
 
P value 
Pre Ex Post RE Post AE 
T2D 
 
21.2±5.5 26.3±8.4 23.1±6.0 0.268 
ND 
 
7.4±2.5 6.2±1.7 6.9±1.9 0.784 
 
 
Figure 61: CRP level in T2D and ND in the 1st exercise session  
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 Table 36: Changes in CRP level was observed during the 12 exercise sessions (chronic effect) in T2D and ND. 
Data is express as mean± SEM and P value for the effect Pre Ex (S1) and after S12 was obtained. 
CRP 
(ng/ml) 
 
Pre Ex S1 
 
S2 S4 S6 S8 S10 S12 P value  
T2D 
 
21.2±5.5 23.1±6.0 16.3±4.9 11.1±4.5 15.1±3.5 19.0±5.5 15.3±5.3 14.7±5.5 0.014 
ND 
 
7.4±2.5 6.9±1.9 7.2±1.4 5.3±0.95 4.7±0.5 5.9±1.4 4.4±0.4 5.1±1.1  0.396 
 
 
 Figure 62: CRP level in T2D and ND across the whole exercise sessions  
 
 
Figure 60a: This is a regression with normalised intervals, representing a downward trend and a poor relationship 
over the 6 weeks (where not all sessions were measured) 
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Figure 60b: This is a regression with normalised values, showing a slight downward trend with a strong 
relationship over the 12th sessions (where not all sessions were measured)  
 
 
 
Figure (60c): T2D CRP shows CI 95% higher than zero which mean this difference is significant even if there are 
overlap in SEM 
 
In T2D individuals, an elevation in the level of CRP (figure 60) was observed after the 1st 
exercise session from 21.2±5.5 to 23.1±6.0 ng/ml (P=0.268) and this level decreased 
significantly after 12th exercise session to14.7±5.5 ng/ml (P=0.014) (figure 61). Moreover, 
combination of exercise and the use of Metformin improve CVD risk factors such as CRP 
(Malin and Braun, 2016). In our study, 14 volunteers out of 17 were using Metformin in 
combination with exercise which explain this significant improvement.  In ND, the results of 
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CRP after the acute effect of exercise was observed to have decreased from 7.4±2.5 to 6.9±1.9 
ng/ml (P=0.784).   However, this decreased more after the 6th week exercise session to 5.1±1.1 
ng/ml (P=0.396) which was not significant.  In T2D, the results showed that CRP increased 
after acute effects of exercise and finally decrease after 6 weeks of exercise while in ND CRP 
decreased after acute and chronic effect of exercise. CRP is reported to have increased after 
acute effect of exercise due to muscle injury in untrained adults (Brown et al., 2015). The 
reduction in CRP by exercise is reported to minimise T2D risk (Malin and Braun, 2016). A cross 
sectional comparison and longitudinal exercise studies were conducted and showed acute 
elevation of CRP and reduction after long term exercise which is similar to this study (Kasapis 
and Thompson, 2005;Fernandes et al., 2011).  Furthermore, different intervention study 
illustrates that there is a reduction in CRP level after 12 weeks of resistance exercise program 
(Ramel et al., 2015). 
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7.7.1.2 IL-6 
 
Table 37: Changes in level of IL-6 was observed during the 1st exercise session (acute effect) in T2D 
and ND. Data is express as mean± SEM and P value for the effect Pre Ex (S1) and after S1 was 
obtained.  
IL6 (pg/ml) 
 
S1  
 
 
P value  
Pre Ex Post RE Post AE  
T2D 
 
1.79±0.4 2.34±0.4 2.61±0.5 0.007 
ND 0.64±0.1 0.71±0.1 1.51±0.4 0.074 
 
 
 Figure 63: IL-6 level in T2D and ND across the 1st exercise session 
 
Table 38: Changes in IL-6 level was observed during the 12 exercise sessions (chronic effect) in T2D and ND. 
Data is express as mean± SEM and P value for the effect Pre Ex (S1) and after S12 was obtained. 
IL6 
(pg/ml) 
Pre Ex Post S1 S2 S4 S6 S8 S10 S12 P value 
T2D 1.79±0.4 2.61±0.5 2.20±0.5 2.20±0.4 3.10±0.7 2.39±0.4 2.21±0.5 3.88±1.9 0.282 
ND 0.64±0.1 1.51±0.4 1.14±0.3 1.16±0.3 1.18±0.3 0.79±0.1 0.94±0.2 1.10±0.5 
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Figure 64: IL-6 level in T2D and ND across the whole exercise sessions  
  
 
Figure 63a: This is a regression with normalised intervals, an upward trend over the 6 weeks (where not all 
sessions were measured) 
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Figure 63b: This is a regressions with normalised intervals, showing a slight upward trend but not a very strong 
relationship (where not all sessions were measured) 
 
The data obtained (in figure 62) for IL-6 shows an increment from 1.79±0.4 to 2.61±0.5 pg/ml 
(P=0.007) after the first exercise session which shows that the acute effect of combination of 
exercise is significant.  Similar affect was recently reported by Eshghi et al. and a significant 
elevation of IL-6 was reported (P=0.03) (Eshghi et al., 2017; Bongers et al., 2017).   Moreover, 
IL-6 level was observed to increase with continuous performing regular exercise (figure 63), 
an increase from 1.79±0.4 to 3.88±1.9 pg/ml (P=0.002), this significant change suggests that 
chronic exercise increases the level of IL-6 higher than acute exercise. It was mentioned 
previously that IL-6 is linked to T2D and obesity but it is higher in T2D subject with HTN (Lukic 
et al., 2014).  Our finding shows that most of our volunteer had HTN and higher BMI than ND 
which suggest that is the main reason for increasing IL-6 with exercise. Previous study 
reported similar finding that there is significant improvement in insulin sensitivity however, 
no improvement in the IL-6 level after exercise (Verheggen et al., 2016). In ND, the results for 
IL-6 show elevation after the 1st exercise session from 0.64±0.1 to 1.51±0.4 pg/ml, (P=0.074). 
Moreover, this level is found to remain high after 12th exercise session and a value of 1.10±0.5 
pg/ml is obtained (P=0.126).  It was clarified that T2D, obesity and Exercise are linked to 
elevate IL-6 level (Ellingsgaard et al., 2015). A recent study also states that chronic moderate 
aerobic exercise lead to elevation in IL-6 (Eshghi et al., 2017).  
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7.7.1.3 TNF  
 
Table 39: Changes in TNF-α level was observed during the 1st exercise session (acute effect) in T2D and ND. 
Data is express as mean± SEM and P value for the effect Pre Ex (S1) and after S1 was obtained. 
TNFA (pg/ml) 
 
S1 
 
P value 
Pre Ex Post RE Post AE 
T2D 
 
8.76±3.2 8.20±2.6 8.06±2.7 0.489 
ND 
 
4.07±0.8 4.44±0.8 4.36±0.8 0.059 
 
 
Figure 65: TNF-α level in T2D and ND in the 1st exercise session 
 
Table 40: Changes in TNF-α level was observed during the 12 exercise sessions (chronic effect) in T2D and ND. 
Data is express as mean± SEM and P value for the effect Pre Ex (S1) and after S12 was obtained. 
TNFA 
(pg/ml) 
 
Pre Ex S1 
 
S2 S4 S6 S8 S10 S12 P value 
T2D 
 
8.76±3.2 8.06±2.7 5.97±0.7 8.37±2.7 8.55±2.7 7.05±2.1 5.82±0.79 7.85±2.4 0.423 
ND 
 
4.07±0.8 4.36±0.8 4.15±0.5 4.18±0.6 4.12±0.7 4.11±0.6 4.07±0.5 4.11±0.5 0.890 
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Figure 66: TNF-α level in T2D and ND across the whole exercise sessions  
 
Figure 65a: This is a regression with normalised intervals, representing a very slight downward trend and not 
strong relationship (where not all sessions were measured) 
 
Figure 65b: This is a regressions with normalised intervals, a very slight upward trend with a poor relationship 
(where not all sessions were measured) 
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The value of TNF-α before exercise was recorded as 8.76±3.2 pg/ml and then decreased 
slightly to 8.06±2.7 pg/ml (P=0.489) after the acute effect of 1st exercise session (figure 64).  
Moreover, this level more slightly decreased after 6 weeks of exercise to 7.85±2.4 pg/ml 
(P=0.423) (figure 65).  In ND, there was a closely significant effects on TNF-α after 1st exercise 
session, data obtained was from 4.07±0.8 to 4.36±0.8 pg/ml (P=0.059).  However, after 6 
weeks of exercise a slight elevation of 4.11±0.5 pg/ml was observed (P=0.890). A study by 
Matthew Bouchonville shows similar finding to our finding which improve TNF-α after acute 
effect but the result is not significant as well (Bouchonville et al., 2014).  
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7.7.1.4 Leptin  
 
Table 41: Changes in leptin level was observed during the 1st exercise session (acute effect) in T2D and ND. 
Data is express as mean± SEM and P value for the effect Pre Ex (S1) and after S1 was obtained. 
 
 
Figure 67: Leptin level in T2D and ND in the 1st exercise session  
 
Table 42: Changes in leptin level was observed during the 12 exercise sessions (chronic effect) in T2D and ND. 
Data is express as mean± SEM and P value for the effect Pre Ex (S1) and after S12 was obtained. 
LEPT 
(ng/ml) 
 
Pre Ex S1 
 
S2 S4 S6 S8 S10 S12 P value 
T2D 
 
7.95±1.8 9.15±2.4 10.48±2.5  10.42±3.6 11.68±3.6 10.52±3.6 11.85±3.3 7.25±1.8 0.522 
ND 
 
8.24±3.3 7.01±2.4 8.91±4.1 8.49±5.9 7.39±3.0 7.30±3.7 6.33±2.6 7.21±3.2 0.536 
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S1 
 
P value  
Pre Ex Post RE Post AE 
T2D 
 
7.95±1.8 8.77±2.6 9.15±2.4 0.707 
ND 8.24±3.3 7.55±2.8 7.01±2.4 0.384 
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Figure 68: Leptin level in T2D and ND across the whole exercise sessions  
 
 
Figure 67a: This is a regression with normalised intervals, a downward trend over the 6 weeks (where not all 
sessions were measured) 
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Figure 67b: This is a regression with normalised intervals, showing a strong relationship (where not all sessions 
were measured) 
 
As represents in (figure 66) leptin levels increased after 1st exercise session from 7.95±1.8 to 
9.15±2.4 ng/ml (P=0.707), the observed increase could be a result of the acute effect of 
combination of exercise. This increases during the whole exercise sessions and then 
decreased after S12 to 7.25±1.81 ng/ml (P=0.522) (figure 67). Leptin resistance is also linked 
to insulin resistance and rheumatoid arthritis, from 1st exercise session to 10th exercise session 
its level stays slightly high which might be due to leptin resistance (Feijóo-Bandín et al., 2016).  
Our finding shows improvement in insulin sensitivity (see section 6.1.7) as well as slight 
reduction in IL-6 which illustrate that the chronic effect of exercise shows improvement in 
insulin and leptin resistance. This finding was illustrated in a systemic review (8 studies and 
231 T2D participants) which reported that reduction in leptin after combination exercise was 
not significant (Hayashino et al., 2014). Another systemic review showed that exercise 
stimulates catecholamines release which affects serum leptin level (Yu et al., 2017).    On the 
other hand, the present study showed that the level of leptin slightly decreased in session 
one from 8.24±3.3 to 7.01±2.4 ng/ml (P=0.536), then increased after 12th sessions to 7.21±3.2 
ng/ml (P=0.693) in ND but still lower than the baseline. Recent randomised control study by 
Nuri et al, found that there was no significant effect of exercise on leptin level (Nuri et al., 
2016).  
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7.7.1.5 Resistin  
Table 43: Changes in Resistin level was observed during the 1st exercise session (acute effect) in T2D and ND. 
Data is express as mean± SEM and P value for the effect Pre Ex (S1) and after S1 was obtained.  
RETN (ng/ml) 
 
S1 
 
 
 
Pre Ex Post RE Post AE P value 
T2D 3.23±0.9 3.71±1.1 2.52±0.3 0.832 
ND 
 
2.60±0.47 2.79±0.54 2.64±0.46 0.710 
 
 
 
Figure 69: Resistin level in T2D and ND across the 1st exercise session  
 
Table 44: Changes in Resistin level was observed during the 12 exercise sessions (chronic effect) in T2D and ND. 
Data is express as mean± SEM and P value for the effect Pre Ex (S1) and after S12 was obtained. 
RETN 
(ng/ml) 
 
Pre S1 S1 S2 S4 S6 S8 S10 S12 P 
value 
T2D 3.23±0.9 2.52±0.3 4.40±1.3 4.33±1.2 4.67±1.5 3.83±1.5 4.45±1.4 3.79±1.5 0.320 
ND 2.60±0.5 2.64±0.5 2.34±0.3 2.59±0.6 2.53±0.4 2.26±0.2 2.19±0.2 2.92±0.6 0.197 
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Figure 70: Resistin level in T2D and ND across the whole exercise sessions  
 
 
 
Figure 69a: This is a regression with normalised intervals, showing a very slight upward trend and a poor 
relationship over the 12th sessions (where not all sessions were measured) 
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Figure 69b: This is a regression with normalised intervals, a very slight upward trend with no relationship over 6 
weeks (where not all sessions were measured) 
 
Resistin level in T2D before exercise was recorded as 3.23±0.9 ng/ml which decreased after 
1st session of exercise to 2.52±0.3 ng/ml (P=0.832) (figure 68).  While figure 69 represents  the 
chronic effect of 6 weeks combination of exercise shows an insignificant increase in its level 
to 3.79±1.5 ng/ml (P=0.320).  On the other hand, the systemic review from 7 studies showed 
that there was no significant reduction in resistin among 250 T2D participants (Hayashino et 
al., 2014).  In ND, the result of resistin shows no notable changes after the acute effect of 
combination exercise from 2.60±0.47 to 2.64±0.46 ng/ml (P=0.710).  And there was very slight 
elevation after the chronic effect up to2.92±0.6 ng/ml (P=0.197); nevertheless, it is not 
significant effect. Other studies found no effect of exercise on the resistin level (Yahya et al., 
2014). 
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7.7.1.6 Cystatin C 
 
Table 45: Changes in cytstatin C level was observed during the 1st exercise session (acute effect) in T2D and ND. 
Data is express as mean± SEM and P value for the effect Pre Ex (S1) and after S1 was obtained.  
CYSC (ng/ml) 
 
S1 
 
P value 
Pre Ex Post RE Post AE 
T2D 
 
5.9±1.5 6.4±1.5 7.3±1.8 0.404 
ND  
 
3.1±1.6 3.5±1.6 2.8±1.3 0.513 
 
 
 
Figure 71: Cystatin C level in T2D and ND in the 1st exercise session  
 
Table 46:  Changes in cytstatin C level was observed during the 12 exercise sessions (chronic effect) in T2D and 
ND. Data is express as mean± SEM and P value for the effect Pre Ex (S1) and after S12 was obtained.  
CYSC 
(ng/ml) 
 
Pre Ex S1 
 
S2 S4 S6 S8 S10 S12 P value 
T2D 
 
5.9±1.5 7.3±1.8 6.8±1.9 7.9±1.8 6.3±1.7 8.3±1.9 6.3±1.6 6.6±1.9 0.400 
ND 
 
3.1±1.6 2.8±1.3 3.7±2.4 3.4±2.0 4.1±2.1 3.2±1.6 3.1±1.7 4.1±2.8 0.446 
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Figure 72: Cystatin C level in T2D and ND across the whole exercise sessions  
 
 
Figure 71a: This is a regression with normalised intervals, showing a very slight downward trend with a strong 
relationship over the 12th sessions (where not all sessions were measured) 
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Figure 71b: This is a regression with normalised intervals, representing an upward trend with poor relationship 
over 6 weeks (where not all sessions were measured) 
 
CysC levels in T2D was observed to have increased after the 1st session from 5.9±1.5 ng/ml to 
7.3±1.8 (P=0.404) (figure 70) and decreased after 12 exercise session to 6.6±1.9 ng/ml 
(P=0.732) but still higher than baseline (figure 71). Similar findings were reported by a recent 
study which states that the acute effect of exercise (treadmill walk) could result in minor 
kidney injury (elevate CysC) (Bongers et al., 2017).  However, another study illustrates that 
prolong walk decreases this level of Cystatin C (Bongers et al., 2017). On the other hand, in 
ND, the results of CysC obtained showed reduction after 1st day of exercise from 3.1±1.6 to 
2.8±1.3 ng/ml (P=0.513), however, after 12th exercise sessions the level increased to 4.1±2.8 
ng/ml (P=0.446).  These data obtained suggest that the exercise has no effect on CysC values 
in both T2D and ND. Recent study illustrate similar finding, that eight weeks of aerobic 
exercise alone has no significant effect on CysC on females with KT (Eskandar, Katayon and 
Ali, 2015).  
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7.7.2 Results between the three T2D groups: 
7.7.2.1 CRP 
1-T2D with no medication for diabetes: 
Table 47:  Changes in CRP level was observed during the 1st exercise session (acute effect) in T2D subjects with 
no pharmacological intervention. Data is express as mean± SEM and P value for the effect Pre Ex (S1) and after 
S1 was obtained. 
CRP (ng/ml) 
 
S1 
 
P value 
Pre Ex Post RE Post AE 
T2D 
 
36.28±14.46 38.15±13.36 27.99±19.58 0.403 
 
Table 48: Changes in CRP level was observed during the 12 exercise sessions (chronic effect) in T2D subjects 
with no pharmacological intervention. P value for the effect Pre Ex (S1) and after S12 was obtained. 
 
2-T2D on metformin only. 
Table 49: Changes in CRP level was observed during the 1st exercise session (acute effect) in T2D subjects with 
pharmacological intervention (Metformin only). P value for the effect Pre Ex (S1) and after S1 was obtained. 
CRP (ng/ml) 
 
S1 
 
P value 
Pre Ex Post RE Post AE 
T2D 
 
18.7±8.2 29.6±20.9 22.5±11.4 0.327 
 
Table 50: Changes in CRP level was observed during the 12 exercise sessions (chronic effect) in T2D subjects 
with pharmacological intervention (Metformin only). P value for the effect Pre Ex (S1) and after S12 was 
obtained.   
CRP 
(ng/ml) 
Pre Ex S1 
 
S2 S4 S6 S8 S10 S12 P value  
T2D 
 
18.7±8.2 22.5±11.4 17.6±10.9 15.4±8.1 15.5±8.2 
 
18.2±9.1 
 
16.8±6.9 13.6±5.8 0.122 
CRP (ng/ml) 
  
Pre Ex S1 
 
S2 S4 S6 S8 S10 S12 P 
value  
T2D 
 
36.28±14.5 27.99±19.6 18.44±13.5 23.93±15.6 14.09±7.9 24.50±16.3 22.36±18.6 45.46±20.1 0.644 
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3-T2D on metformin and DPP4-I  
Table 51: Changes in CRP level was observed during the 1st exercise session (acute effect) in T2D subjects with 
pharmacological intervention (Metformin and DPP4-I). P value for the effect Pre Ex (S1) and after S1 was 
obtained. 
CRP (ng/ml) 
 
S1 
 
P value 
Pre Ex Post RE Post AE 
T2D 
 
14.27±5.52 17.30±6.60 24.51±0.50 0.517 
 
Table 52: Changes in CRP level was observed during the 12 exercise sessions (chronic effect) in T2D subjects 
with no pharmacological intervention (Metformin and DPP4-I). P value for the effect Pre Ex (S1) and after S12 
was obtained. 
CRP 
(ng/ml) 
 
Pre Ex S1 
 
S2 S4 S6 S8 S10 S12 P value  
T2D 
 
14.27±5.52 24.50±.050 13.91±4.98 6.59±3.58 18.14±4.46 18.32±9.86 8.44±4.34 7.97±0.84 0.638 
 
 
 
 
 
Figure 73: T2D CRP in metformin and DDP4-I group shows CI 95% lower than zero which means this difference 
is not significant even if the chart shows the highest elevation after S1 and highest reduction after S12 
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In T2D the type of medication might have different effect on the inflammatory markers. The 
first group haven’t receive any medication for diabetes, in the first exercise session CRP shows 
reduction from 36.3±14.5 to 28.0±19.6, and (P= 0.403). While after session 12 CRP has been 
increased to 45.5±20.1 and (P=0.644). In metformin group, CRP increased after acute effect 
of exercise from 18.7±8.2 to 22.5±11.4 and (P= 0.327).  However, this decreased after 12 
sessions to 13.6±5.8 and (P= 0.122).  The last group was metformin and DPP4-I group, the 
acute effect in the first exercise session showed elevation from 14.27±5.52 to 24.51±0.50 and 
(P= 0.517).  While this decreased after 6 weeks of exercise to 7.97±0.84 and (P= 0.638).  
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7.7.2.2 IL-6 
1- T2D volunteers with no medication. 
 
Table 53:  Changes in IL-6 level was observed during the 1st exercise session (acute effect) in T2D subjects with no 
pharmacological intervention. P value for the effect Pre Ex (S1) and after S1 was obtained. 
IL-6 (pg/ml) 
 
S1 
 
P value 
Pre Ex Post RE Post AE 
T2D 
 
3.04±1.21 2.98±1.19 3.47±1.39 0.336 
 
Table 54: Changes in IL-6 level was observed during the 12 exercise sessions (chronic effect) in T2D subjects with no 
pharmacological intervention. P value for the effect Pre Ex (S1) and after S12 was obtained.  
IL-6 
(pg/ml) 
 
Pre Ex S1 
 
S2 S4 S6 S8 S10 S12 P value  
T2D 
 
3.04±1.21 3.47±1.39 3.20±1.75 2.91±1.18 4.17±1.22 2.88±0.86 3.16±1.72 9.41±5.63 0.459 
 
2- T2D volunteers on Metformin only. 
Table 55: Changes in IL-6 level was observed during the 1st exercise session (acute effect) in T2D subjects with 
pharmacological intervention (Metformin only). P value for the effect Pre Ex (S1) and after S1 was obtained. 
IL-6 (pg/ml) 
 
S1 
 
P value 
Pre Ex Post RE Post AE 
T2D 
 
1.37±0.50 1.93±0.36 1.53±0.61 0.361 
 
Table 56: Changes in IL-6 level was observed during the 12 exercise sessions (chronic effect) in T2D subjects with 
pharmacological intervention (Metformin only). P value for the effect Pre Ex (S1) and after S12 was obtained. 
IL-6 
(pg/ml) 
 
Pre Ex S1 
 
S2 S4 S6 S8 S10 S12 P value  
T2D 
 
1.37±0.50 1.53±0.605 1.61±0.35 2.41±0.24 2.02±0.54 0.10±0.10 1.66±0.29 1.68±0.04 0.666 
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3-  T2D volunteers on Metformin and Dipeptidyl Peptidase 4 inhibitor (DPP4- I).  
Table 57: Changes in IL-6 level was observed during the 1st exercise session (acute effect) in T2D subjects with 
pharmacological intervention (Metformin and DPP4-I). P value for the effect Pre Ex (S1) and after S1 was 
obtained. 
IL-6 (pg/ml) 
 
S1 
 
P value 
Pre Ex Post RE Post AE 
T2D 
 
0.99±0.18 1.63±0.36 2.08±0.84 0.277 
 
Table 58: Changes in IL-6 level was observed during the 12 exercise sessions (chronic effect) in T2D subjects with 
pharmacological intervention (Metformin and DPP4-I). P value for the effect Pre Ex (S1) and after S12 was 
obtained. 
IL-6 
(pg/ml) 
 
Pre Ex S1 
 
S2 S4 S6 S8 S10 S12 P value  
T2D 
 
0.99±0.18 2.08±1.50 1.50±0.13 2.10±0.53 1.44±2.16 0.98±0.58 2.68±0.30 1.50±0.40 0.161 
 
 
IL-6 showed very slight elevation in the group who haven’t receive any pharmacological 
treatment from 3.04±1.21 to 3.47±1.39 and (P= 0.336). On the other hand, this increased 
after 12 exercise sessions to 9.41±5.63 and (P= 0.459) but not significant.  This IL-6 slightly 
increased in metformin group after 1st session from 1.37±0.50 to 1.53±0.61, (P= 0.361) and to 
1.68±0.04, (P= 0.666) after 6 weeks of exercise.  In the last group (metformin and DPP4-I), IL-
6 increased after acute effect of exercise from 0.99±0.18 to 2.08±0.84, (P= 0.277) and then to 
1.50±0.40, (P= 0.161) after 12th sessions.  
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7.7.2.3 TNF  
1- T2D volunteers with no medication. 
Table 59: Changes in TNF level was observed during the 1st exercise session (acute effect) in T2D subjects with 
no pharmacological intervention.  P value for the effect Pre Ex (S1) and after S1 was obtained. 
TNF (pg/ml) 
 
S1 
 
P value 
Pre Ex Post RE Post AE 
T2D 
 
6.30±0.32 5.97±0.13 5.74±0.12 0.662 
 
Table 60: Changes in TNF level was observed during the 12 exercise sessions (chronic effect) in T2D subjects 
with no pharmacological intervention.  P value for the effect Pre Ex (S1) and after S12 was obtained. 
TNF 
(pg/ml) 
 
Pre Ex S1 
 
S2 S4 S6 S8 S10 S12 P value 
T2D 
 
6.30±0.32 5.74±0.12 5.51±0.38 5.62±0.15 6.35±0.78 5.58±0.32 5.74±0.53 5.76±0.50 0.349 
 
2- T2D volunteers on Metformin only. 
Table 61: Changes in TNF level was observed during the 1st exercise session (acute effect) in T2D subjects with 
pharmacological intervention (Metformin only). P value for the effect Pre Ex (S1) and after S1 was obtained. 
TNF (pg/ml) 
 
S1 
 
P value 
Pre Ex Post RE Post AE 
T2D 
 
5.28±1.50 4.83±1.14 4.72±1.06 0.424 
 
Table 62: Changes in TNF level was observed during the 12 exercise sessions (chronic effect) in T2D subjects 
with pharmacological intervention (Metformin only).  P value for the effect Pre Ex (S1) and after S12 was 
obtained. 
TNF 
(pg/ml) 
 
Pre Ex  S1 
 
S2 S4 S6 S8 S10 S12 P value 
T2D 
 
5.28±1.50 4.72±1.06 4.64±0.80 4.56±0.81 4.58±0.72 4.27±0.61 4.34±0.61 4.52±0.10 0.368 
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3-  T2D volunteers on Metformin and Dipeptidyl Peptidase 4 inhibitor (DPP4 I).  
 
Table 63: Changes in TNF level was observed during the 1st exercise session (acute effect) in T2D subjects with 
pharmacological intervention (Metformin DPP4-I).  P value for the effect Pre Ex (S1) and after S1 was obtained. 
TNF (pg/ml) 
 
S1 
 
P value 
Pre Ex Post RE Post AE 
T2D 
 
18.43±9.68 19.27±8.55 21.26±9.69 0.570 
 
Table 64: Changes in TNF level was observed during the 12 exercise sessions (chronic effect) in T2D subjects 
with pharmacological intervention (Metformin DPP4-I). P value for the effect Pre Ex (S1) and after S12 was 
obtained. 
TNF 
(pg/ml) 
 
Pre Ex S1 
 
S2 S4 S6 S8 S10 S12 P 
value 
T2D 
 
18.43±9.68 21.26±9.69 8.43±0.98 17.23±7.71 15.37±7.42 16.54±6.05 9.92±0.34 19.56±6.45 0.646 
 
 
TNF represent slight reduction in the first group without any pharmacological treatment from 
6.30±0.32 to 5.74±0.12, (P= 0.662).  In the last exercise session TNF was 5.76±0.50, (P= 0.349) 
and showed no significant changes. Similarly, in the metformin group the reduction not 
significant after 1st and 12th exercise sessions, it was 5.28±1.50 and slightly decreased to 
4.72±1.06, (P= 0.424) after the 1st session then to 4.52±0.10, (P= 0.368) after the 12th session.  
Nevertheless, the last group (metformin and DPP4-I) demonstrated slight elevation after 1st 
session from 18.43±9.68 to 19.56±6.45 and P= 0.646.  
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7.7.2.4 Leptin 
1- T2D volunteers with no medication. 
Table 65: Changes in leptin level was observed during the 1st exercise session (acute effect) in T2D subjects with 
no pharmacological intervention. P value for the effect Pre Ex (S1) and after S1 was obtained. 
 
Table 66: Changes in leptin level was observed during the 12 exercise sessions (chronic effect) in T2D subjects 
with no pharmacological intervention. P value for the effect Pre Ex (S1) and after S12 was obtained. 
LEPT 
(ng/ml) 
 
Pre Ex S1 
 
S2 S4 S6 S8 S10 S12 P value 
T2D 
 
6.46±3.52 6.04±3.34 6.04±3.01 4.84±2.68 6.00±3.10 6.84±4.13 6.12±2.77 6.45±3.25 0.980 
 
2- T2D volunteers on Metformin only 
Table 67: Changes in leptin level was observed during the 1st exercise session (acute effect) in T2D subjects with 
pharmacological intervention (Metformin only). P value for the effect Pre Ex (S1) and after S1 was obtained. 
 
Table 68: Changes in leptin level was observed during the 12 exercise sessions (chronic effect) in T2D subjects 
with pharmacological intervention (Metformin only). P value for the effect Pre Ex (S1) and after S12 was 
obtained. 
 
 
LEPT (ng/ml) 
 
S1 
 
P value  
Pre Ex Post RE Post AE 
T2D 
 
6.46±3.52 5.59±3.12 6.04±3.01 0.21 
LEPT (ng/ml) 
 
S1 
 
P value  
Pre Ex Post RE Post AE 
T2D 
 
12.32±4.59 10.88±3.56 11.86±3.38 0.769 
LEPT 
(ng/ml) 
 
Pre Ex S1 
 
S2 S4 S6 S8 S10 S12 P value 
T2D 
 
12.32±4.59 11.86±3.38 11.36±4.26 13.22±3.77 14.69±3.17 14.83±8.61 12.73±6.84 12.91±6.12 0.764 
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3-  T2D volunteers on Metformin and Dipeptidyl Peptidase 4 inhibitor (DPP4 I).  
Table 69: Changes in leptin level was observed during the 1st exercise session (acute effect) in T2D subjects with 
pharmacological intervention (Metformin and DPP4-I). P value for the effect Pre Ex (S1) and after S1 was 
obtained. 
 
Table 70: Changes in leptin level was observed during the 12 exercise sessions (chronic effect) in T2D subjects 
with pharmacological intervention (Metformin and DPP4-I). P value for the effect Pre Ex (S1) and after S12 was 
obtained. 
LEPT 
(ng/ml) 
 
Pre Ex S1 
 
S2 S4 S6 S8 S10 S12 P value 
T2D 
 
13.29±3.31 7.64±1.71 9.47±2.41 9.87±1.44 16.21±4.22 10.95±2.87 16.46±2.06 9.89±2.48 0.403 
 
 
Leptin in the group without any medication shows very slight reduction after S1 which was 
(6.46±3.52) and became (6.04±3.01), and P= 0.210.  While after S12 became (6.45±3.25), 
P=0.980 which shows no changes. Moreover, metformin group represent similar changes to 
the previous group, which reduce very slightly after S1 fro (12.32±4.59) to (11.86±3.38), and 
P= 0.769.  After S12 became (12.91±6.12), and P=0.764 which considered not significant.  The 
last group (metformin and DPP4-I) also displays reduction after S1 from (13.29±3.31) to 
(9.47±2.35), and P=0.880 which illustrate no significant results as well. After S12 this become 
(9.89±2.48), and P=0.403 which is represent no significant effect.  
 
 
 
 
LEPT (ng/ml) 
 
S1 
 
P value  
Pre Ex Post RE Post AE 
T2D 
 
13.29±3.31 7.64±1.71 9.47±2.35 0.880 
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7.7.2.5 Resistin 
1- T2D volunteers with no medication. 
Table 71: Changes in Resistin level was observed during the 1st exercise session (acute effect) in T2D subjects 
with no pharmacological intervention. P value for the effect Pre Ex (S1) and after S1 was obtained. 
RETN (ng/ml) 
 
S1 
 
 
 
Pre Ex Post RE Post AE P value 
T2D 3.96±0.37 2.87±0.13 3.58±0.10 0.744 
 
Table 72: Changes in Resistin level was observed during the 12 exercise sessions (chronic effect) in T2D subjects 
with no pharmacological intervention.  P value for the effect Pre Ex (S1) and after S12 was obtained. 
RETN 
(ng/ml) 
 
Pre S1 S1 S2 S4 S6 S8 S10 S12 P 
value 
T2D  3.96±0.37 3.58±0.10 3.44±0.27 4.34±0.21 5.83±1.21 3.96±0.73 6.00±0.91 4.64±0.20 0.129 
 
2- T2D volunteers on Metformin only. 
Table 73: Changes in Resistin level was observed during the 1st exercise session (acute effect) in T2D subjects 
with pharmacological intervention (Metformin only). P value for the effect Pre Ex (S1) and after S1 was 
obtained. 
RETN (ng/ml) 
 
S1 
 
 
 
Pre Ex Post RE Post AE P value 
T2D 2.50±0.63 2.44±0.51 2.42±0.41 0.795 
 
Table 74: Changes in Resistin level was observed during the 12 exercise sessions (chronic effect) in T2D subjects 
with no pharmacological intervention (Metformin only).  P value for the effect Pre Ex (S1) and after S12 was 
obtained. 
RETN 
(ng/ml) 
 
Pre S1 S1 S2 S4 S6 S8 S10 S12 P 
value 
T2D  2.50±0.63 2.42±0.41 2.05±0.17 2.94±0.39 2.39±0.27 2.38±0.51 2.46±0.46 2.54±0.68 0.535 
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3-  T2D volunteers on Metformin and Dipeptidyl Peptidase 4 inhibitor (DPP4 I).  
 
Table 75: Changes in Resistin level was observed during the 1st exercise session (acute effect) in T2D subjects 
with pharmacological intervention (Metformin and DPP4-I). P value for the effect Pre Ex (S1) and after S1 was 
obtained. 
RETN (ng/ml) 
 
S1 
 
 
 
Pre Ex Post RE Post AE P value 
T2D 6.67±2.45 8.69±2.42 3.32±0.66 0.686 
 
Table 76: Changes in Resistin level was observed during the 12 exercise sessions (chronic effect) in T2D subjects 
with no pharmacological intervention (Metformin and DPP4-I).  P value for the effect Pre Ex (S1) and after S12 
was obtained. 
RETN 
(ng/ml) 
 
Pre S1 S1 S2 S4 S6 S8 S10 S12 P 
value 
T2D  6.67±2.45 3.32±0.66 8.69±2.13 7.44±2.56 9.23±3.29 13.96±4.37 8.51±3.74 14.13±4.45 0.543 
 
 
Resistin result in the first group with no medication after S1 demonstrates no significant 
reduction which reduced from (3.96±0.37) to (3.58±0.10), P=0.744.  In contrast, after S12 this 
level increased to (4.64±0.20), and P=0.129. Furthermore, metformin group shows no 
significant changes.  After S1 resistin decreased very slightly from (2.50±0.63) to (2.42±0.41), 
and P=0.795. After S12 this become very slightly higher than the base line (2.54±0.68), 
P=0.535 which still not significant.  Resistin level in the metformin and DPP4-I decreased after 
S1 from (6.67±2.45) to (3.32±0.66), and P=0.686 however P value still not significant. While 
after S12 this became (14.13±4.45), P=0.543 which is not significant as well.   
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7.7.2.6 Cystatin C 
1-T2D with no medication for diabetes:  
Table 77: Changes in cytstatin C level was observed during the 1st exercise session (acute effect) in T2D subjects 
with no pharmacological intervention. P value for the effect Pre Ex (S1) and after S1 was obtained.  
CYSC (ng/ml) 
 
S1 
 
P value 
Pre Ex Post RE Post AE 
T2D 
 
11.19±3.10 10.55±3.83 11.64±4.15 0.735 
 
Table 78: Changes in cytstatin C level was observed during the 12 exercise sessions (chronic effect) in T2D 
subjects with no pharmacological intervention. P value for the effect Pre Ex (S1) and after S12 was obtained. 
 
2-T2D on metformin only: 
Table 79: Changes in cytstatin C level was observed during the 1st exercise session (acute effect) in T2D subjects 
with pharmacological intervention (Metformin only). P value for the effect Pre Ex (S1) and after S1 was 
obtained.  
CYSC (ng/ml) 
 
S1 
 
P value 
Pre Ex Post RE Post AE 
T2D 
 
5.2±1.9 5.3±2.6 5.7±1.7 0.743 
 
Table 80: Changes in cytstatin C level was observed during the 12 exercise sessions (chronic effect) in T2D 
subjects with pharmacological intervention (Metformin only). P value for the effect Pre Ex (S1) and after S12 
was obtained. 
CYSC 
(ng/ml) 
 
Pre Ex S1 
 
S2 S4 S6 S8 S10 S12 P value 
T2D 
 
5.2±1.9 5.7±1.7 4.6±2.8 7.4±2.0 4.7±2.7 8.8±3.2 7.9±3.2 7.7±3.4 0.217 
 
 
CYSC 
(ng/ml) 
 
Pre Ex S1 
 
S2 S4 S6 S8 S10 S12 P value 
T2D 
 
11.19±3.10 11.64±4.15 12.25±4.90 13.06±4.20 12.02±4.12 13.17±4.07 7.64±2.67 11.30±3.97 0.920 
 251 
 
4-T2D on metformin and DPP4-I: 
Table 81: Changes in cytstatin C level was observed during the 1st exercise session (acute effect) in T2D subjects 
with pharmacological intervention (Metformin and DPP4-I). P value for the effect Pre Ex (S1) and after S1 was 
obtained.  
CYSC (ng/ml) 
 
S1 
 
P value 
Pre Ex Post RE Post AE 
T2D 
 
2.94±0.61 5.38±1.55 1.37±1.37 0.182 
 
Table 82: Changes in cytstatin C level was observed during the 12 exercise sessions (chronic effect) in T2D 
subjects with pharmacological intervention (Metformin and DPP4-I).  P value for the effect Pre Ex (S1) and after 
S12 was obtained. 
CYSC 
(ng/ml) 
 
Pre Ex S1 
 
S2 S4 S6 S8 S10 S12 P value 
T2D 
 
2.94±0.61 1.37±1.37 5.10±1.97 3.27±0.91 3.60±0.84 3.88±2.14 3.12±0.14 1.81±0.69 0.030 
 
 
 
 
Figure 74: T2D CysC shows CI 95% higher than zero which mean this difference is significant even if the 
reduction seems not significant  
 
CysC results in the first group who haven’t receive any treatment showed very slight elevation 
after 1st session from 11.19±3.10 to 11.64±4.15, (P= 0.735) and this changed to 11.30±3.97, 
(P= 0.920) after last exercise session.  Similar elevation in the metformin group after 1st 
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exercise session from 5.2±1.9 to 5.7±1.7, (P= 0.743).  While this increased more after the 12th 
exercise session to 7.7±3.4, (P= 0.217).  On the other hand, CysC decreased in the metformin 
and DPP4-I group after 1st exercise session from 2.94±0.61 to 1.37±1.37, (P= 0.182) and then 
changed after the last session to 1.81±0.69, (P= 0.030) which showed very significant 
improvement.   
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7.8 Conclusion:   
Literature correlates elevated CRP level with increased risk of diabetes mellitus among adults  
(Prestes et al., 2009) and its level is increased in individuals with T2D (Thomsen et al., 2010), 
hence associated with IR and the dysfunction of endothelial cells  and is used as a predictor 
biomarker of cardiovascular events since it links atherosclerosis and inflammation (Kajitani et 
al., 2010).  In the present study, acute effects of exercise resulted in an increase in the level 
of CRP which then decrease after 6 weeks of exercise in both groups and the change was 
significant in T2D.  This finding correlate with that published by Balducci et al., (2010) and 
(Kim, 2014) suggesting that exercise decrease the level of CRP in T2D. 
The function of IL-6 in insulin resistance in T2D has been emphasized in the field of research 
over the years  (Glund and Krook, 2007; Glund et al., 2007; Jiang et al., 2013; Kim, 2014), this 
is because proinflammatory cytokines, for example, resistin and IL-6 were shown to be 
associated with certain metabolic disorders including T2D (Hotamisligil, 2006). The study of 
Ellingsgaard et al., (2011) proposed that IL-6 plays a positive role in improving IS via exercise, 
consequently improving the functions of β-cells and the presence/circulation of GLP-1.  In the 
present study, both acute and chronic effect of exercise resulted in the elevation of IL-6 in 
both T2D and ND participants, however, the increment still insignificant. However, the study 
of Kim, (2014) reported a significant decrease in the level of IL-6 among participants exposed 
to circuit training when compared to aerobic exercise. Combination exercise is reported to 
greatly decrease IL-6 levels (Hopps, Canino and Caimi, 2011), however, the levels were 
increased in the present study. This observation on IL-6 mentioned in this study could be due 
to different reasons one of which is the type/mode of exercise used. 
Furthermore, the variable TNF-α was observed in the present study, and literature shows that 
intense exercise results in increased level of TNF-α which subsequently increases the level of 
anti-inflammatory cytokines including the TNF-α in ND individuals (Pedersen and Febbraio, 
2005; Petersen and Pedersen, 2005). However, in T2D the level of TNF-α is increased 
(Thomsen et al., 2010) and some research look into how this increased level can be decreased 
with exercise. In the present study, there was an insignificant reduction in the level of TNF in 
T2D while ND shows slight elevation. However, Hopps, Canino and Caimi, (2011) reported 
that the use of combined exercise greatly decrease the level of TNF-α which was supported 
by studies conducted by (You and Nicklas, 2006; Balducci et al., 2010; de Salles et al., 2010). 
 254 
 
Another fluctuating variable observed in the present study is leptin. The role of leptin in 
regulating energy balance has made it an important research variable and in the present study 
its level was observed where the levels decreased after acute effects, then decreased more 
after the last exercise sessions in T2D.  Moreover, leptin decreased in ND after acute effect 
and the 12th exercise sessions. Likewise, a decrease in leptin level was reported by Ishii et al., 
(2001) and Hayashino et al., (2014).   
Another variable studied in the present study is resistin, a protein known for its ability to 
increase insulin resistance. Research has shown that the stimulation of resistin is in 
concomitant with inflammatory molecules such as IL-6 and TNF-α, and has an important 
function in endothelial cells and macrovascular diseases (Schwartz and Lazar, 2011; Codoñer-
Franch and Alonso-Iglesias, 2015).  Another vital role of resistin is its correlation to insulin 
resistance in T2D (McTernan et al., 2003; Kusminski, McTernan and Kumar, 2005; Tokuyama 
et al., 2007), and its level was observed in the present study. In the present study, resistin 
increased in T2D and didn’t change in ND after 1st exercise session, however, it was increased 
in both groups after 12th exercise sessions although the increment is not significantly. Most 
studies reported a decreased level of resistin after exercise training (Kadoglou et al., 2007; 
Balducci et al., 2010; Wenning et al., 2013), however the study by Giannopoulou et al., (2005) 
reported that resistin level increased after exercise which correlates with the present study, 
while Hayashino et al., (2014) reported that no changes was observed in the levels of resistin. 
Marcelino-Rodríguez et al., (2017) deduced an inverse association of resistin with exercise.  
Moreover, the level of CysC prior to exercise training in T2D was increased and decreased 
after 1st session and also after 6 weeks in T2D, but the level was observed to increase in ND, 
yet this was not significant. When the result was analysed in T2D according to medication 
type all these results have no significant changes comparing the three group only CysC in 
metformin and DPP4-I group represents significant reduction after 6 weeks of combination 
exercise with P < 0.05. Various studies reported that exercise lowers the levels of 
inflammatory markers. However, results are inconsistent, representing different modes, 
durations and intensities of exercise which might have different effects on inflammatory 
markers. Furthermore, underlying chronic disease such as arthritis, hypertension or acute 
infection as well as obesity might interfere in the improvement of these markers, and also the 
medication types as well might play a role in the changes of these inflammatory markers. 
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7.8.1 Limitations: 
 
1- Only few volunteers were recruited for both T2D and ND. 
2- No data for control group. 
3-  No specific diet has been followed.  
   
7.8.2 Future work: 
Conduct another study with larger sample size and control group of both T2D and ND. 
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Chapter 8 
8.1 Previous studies which used ELISA in the analysis: 
 
ELISA 
 
No ELISA 
Shaabani et al., (2016) 
 
Prior et al., (2015)   
Eshghi et al., (2017) 
 
Fenicchia et al., (2004) 
Verheggen et al., (2016) Tura et al., (2017) 
 
Jorge et al., (2011) 
 
Bongers et al., (2017)   
(Kawano et al., 2013).   
 
 
Whyte et al., (2013) 
 
 
Hallworth et al., (2017) 
 
 
Holliday and Blannin, (2017) 
 
 
Herder et al., (2009)  
Mendham et al., (2011)  
 
 
(Nuri et al., 2016)    
Nygaard et al., (2017)  
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8.2 General conclusion: 
 
It is well known that exercise is beneficial for the human health and literature showed that it 
plays vital role in the management of diabetes to control BG and improve HbA1c to avoid any 
serious complication. In this study, the reduction in HbA1c was significant in both group as 
represented above in chapter 5. Furthermore, it has been found a significant effect on the 
anthropometric variables (weight, waist, BMI and lung capacity) in T2D group. In ND, the 
significant results was on in lung capacity.  Resting HR improved significantly in T2D after 12th 
sessions of exercise.  However, SBP, DBP and lipid profile show insignificant reduction 
especially in T2D.   Moreover, exercise is useful to strength the muscle thus improving insulin 
sensitivity as stated above in chapter 6. T2D participants show some insulin resistance at 
baseline which improved after six. It was significant when using Matsuda and HOMA indices. 
While ND have no IR before starting exercise program thus the improvement in IR was only 
significant in QUICKI after six weeks of exercise comparing to T2D.  It is also important to 
improve the secretion of GLP-1 which is recommended for future trials.  In the present study, 
GLP-1 was seen to have improved only in metformin and SGT2-I group (chapter 7). SGLT2 
inhibitors and metformin has been found affecting the body weight and it might be the reason 
behind the improvement of GLP-1 level.  Finally, there is insignificant effect of exercise on the 
inflammatory markers in both groups only in T2D IL-6 shows significant elevation after S12 
and CRP represent significant reduction after S12.  However, within T2D group (metformin 
and DDP4-I) there was a significant reduction in CysC after S12.  In general, combination 
exercise shows improvements in the human health but that need more comparison with AE 
alone or RE alone to prove that it is superior.  
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11. Appendices: 
 
 11.1 Appendix 1 (Consent form for T2D) 
 
 
                                 Leicester School of Pharmacy 
Faculty of Health & Life Sciences 
 
CONSENT FORM   Patient Identification 
Number:……………………………………………………………………….…………. 
Title of Project: The Use of a Cardio and Resistance Exercise Programme to Assess Immunological 
and Physiological Parameters in Type 2 Diabetes Mellitus Volunteers. 
Name of Principal Investigator: Prof M J Taylor, Dr T Sahota, Dr P Tomlins, Mr K Chauhan, Dr R 
Furmonaviciene, Mr B Alharbi, Mrs N Alsubaie and Mr A Hill. 
               PLEASE SIGN INITIALS IN BOX 
1. I confirm that I have read and understood the Participant Information Sheet dated (01/07/2017) 
for the above study. I have had the opportunity to consider the information, ask questions and had 
these answered satisfactorily. I understand that agreeing to take part means that I am willing to 
undertake some exercise and giving samples in the above study. 
 
2. I understand that my participation is voluntary and that I am free to withdraw at any time without 
giving any reason, without my legal rights being affected. 
 
3. I understand that any information I provide is confidential, and that no information that could 
lead to the identification of any individual will be disclosed in any reports on the project, or to any 
other party. No identifiable personal data will be published. The identifiable data will not be shared 
with any other organisation.   
 
4. I understand that confidentiality can be guaranteed for information which I might disclose in any 
session or visit I attend. I understand that this information will be used only for the purpose(s) set 
out in this statement and my consent is conditional on the University complying with its duties and 
obligations under the Data Protection Act 1998.  
 
5. I agree to take part in the above study. 
_______________    ________________   _________________ 
Name of Participant            Date     Signature 
 
_______________    ________________   __________________ 
Name of Researcher                        Date     Signature 
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11.2 Appendix 2 (Consent form for ND) 
 
                              Leicester School of Pharmacy 
Faculty of Health & Life Sciences 
 
 
CONSENT FORM   Patient Identification Number for this trial:…………………………………………….……..….. 
Title of Project: The Use of a Cardio and Resistance Exercise Programme to Assess Immunological 
and Physiological Parameters in Volunteers. 
Name of Principal Investigator: Prof M J Taylor, Dr T Sahota, Dr P Tomlins, Mr K Chauhan, Dr R Furmonaviciene,  
 Mr B Alharbi, Mrs N Alsubaie and Mr A Hill. 
               PLEASE SIGN INITIALS IN BOX 
1. I confirm that I have read and understood the Participant Information Sheet dated (01/07/2017) 
for the above study. I have had the opportunity to consider the information, ask questions and had 
these answered satisfactorily. I understand that agreeing to take part means that I am willing to 
undertake some exercise and giving samples in the above study. 
 
2. I understand that my participation is voluntary and that I am free to withdraw at any time without 
giving any reason, without my legal rights being affected. 
 
3. I understand that any information I provide is confidential, and that no information that could 
lead to the identification of any individual will be disclosed in any reports on the project, or to any 
other party. No identifiable personal data will be published. The identifiable data will not be shared 
with any other organisation.   
 
4. I understand that confidentiality can be guaranteed for information which I might disclose in any 
session or visit I attend. I understand that this information will be used only for the purpose(s) set 
out in this statement and my consent is conditional on the University complying with its duties and 
obligations under the Data Protection Act 1998.  
 
5. I agree to take part in the above study. 
_______________    ________________   _________________ 
Name of Participant            Date     Signature 
 
_______________    ________________   __________________ 
Name of researcher                        Date     Signature 
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11.3 Appendix 3 (information sheet for T2D) 
 
                                                                         Leicester School of Pharmacy 
Faculty of Health & Life Sciences 
                                                                                                        
 
Participant Information Sheet                                            Date:01/07/2017 
Title of Project: The Use of a Cardio and Resistance Exercise Programme to Assess 
Immunological and Physiological Parameters in Type 2 Diabetes Mellitus Volunteers. 
 
Principal Investigators: Prof M J Taylor, Dr T Sahota, Dr P Tomlins, Dr R Furmonaviciene, 
Mr K Chauhan, Mr B Alharbi, Mrs N Alsubaie and Mr A Hill. 
 
We would like to invite you to take part in a research study. Before you decide you need to 
understand why the research is being done and what it would involve for you. Please take 
time to read the following information carefully. Talk to others about the study if you wish. 
 
Ask us if there is anything that is not clear or if you would like more information. Please take 
time to decide whether or not you wish to take part. If you do wish to take part please 
complete the slip at the end of this sheet.  
 
What is the purpose of the study? 
As part of the growing research into Diabetes Mellitus the School of Pharmacy at De 
Montfort University are working to investigate the effects of a combined exercise programme 
(cardio and resistance) on blood glucose, metabolic and immunological parameters that 
could help you with the management of diabetes and increase your insulin sensitivity. 
 
This research involves a combination of two types of exercises and this is where we need 
your help. We would like to invite you to take part in this study which will help us to 
understand the role of exercise and how it can help people with diabetes to maintain a 
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healthy body weight, to possibly manage your blood glucose level more effectively and 
increase insulin sensitivity. 
 
We will keep your information strictly confidential and nobody other than the research team 
will have access to your personal information.  
 
Before any research goes ahead it has to be checked by De Montfort University Research 
Ethics Committee. They make sure that the research is fair.  
 
Why have I been invited? 
You have been invited to take part in this study because you are at risk or have Type 2 
Diabetes and are aged between 18 and 60. 
 
Do I have to take part? 
It is up to you to decide. We will answer any questions you have about the study and go 
through this information sheet. We will then ask you to sign a consent form to show you have 
agreed to take part. You are free to withdraw at any time, without giving a reason. This 
would not affect the standard of care you receive from your doctor or hospital. 
 
What will happen to me if I take part? 
Preliminary procedures 
Before enrolling in the study you will be asked to attend a screening visit where we will: 
 Discuss and complete confidential questionnaires regarding your health, family 
history and physical activity level. 
 Measure your blood pressure and heart rate. 
 Measure your height and weight  
 Provide an opportunity for you to ask questions. 
 Familiarise you with equipment to be used in the study and teach you how to use 
the recumbent ergometer bike and how to lift the weights safely on the multi-gym 
machine. 
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 This session will also be used to determine the intensity of exercise during 
cycling on the recumbent ergometer bike using Heart Rate Reserve (HRR). Also, 
in this orientation session we will use predicted one repetition maximum (1RM) to 
determine how much weight for different muscles you should lift in the resistance 
exercise session later. 
 
These preliminary procedures will enable us to determine whether you are suitable to safely 
participate in the study or not. 
 
Main experimental trials  
The main experimental trial will involve 2 x 2 hour exercise sessions a week for a 6 or 12 
week period, (exercise session includes rest and final observation of volunteer). We would 
conduct these trials over the duration of your degree study (3 years) so we can assess the 
impact of exercise over a longer period of time.  
Blood glucose levels will be monitored before, during and after each session, using a 
standard finger prick test.  In addition, Cholesterol, High density lipoprotein, low density 
lipoprotein and Triglyceride will be monitored before, and after each exercise programme 
using a finger prick test. 
Each exercise session will consist of a combined exercise protocol of 30 min of resistance 
exercise (3 sets of 8 -10 repetitions at 50 – 60% of predicted one-repetition maximum 
strength 1-RM ) using upper and lower muscle groups followed by 20 min moderate cycling 
at 50 – 60% of pre-determined heart rate reserve (HRR). Heart rate (HR) and rate of 
perceived exertion (RPE) will be taken in a different time points throughout the exercise trial. 
We will also perform an Oral Glucose Tolerance test to assess insulin sensitivity at the 
beginning and end of the programme and blood samples will be screened for other 
immunological parameters. If you are taking any statin medication then you may also be 
asked to provide urine samples for analysis in a parallel study. We may also ask you to 
provide a saliva sample for a further study which assesses microbes present in saliva. 
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Incentives 
We would like to offer an incentive of a subsidised gym membership at the De Montfort 
University’s QEII Leisure Centre on completion of 100% of the dates agreed. This is a thank 
you for your participation but also to help you maintain the healthy exercise regimen until the 
following year’s assessment. 
 
What are the possible benefits of taking part? 
As a result of being involved in this study you will receive health and fitness information 
about yourself including fitness tests and body measurement. You may also witness a 
decrease in your Hba1c levels and an increase in your insulin sensitivity as well as other 
general improvements to your health. 
The findings of this study will be published in scientific journals so that understanding about 
how exercise can help people with diabetes to improve their health and control their weight 
and blood glucose levels. This information may contribute towards improved exercise 
guidelines for the diabetic patients. 
We will provide you with feedback about the main study findings and also about your own 
results and would be delighted to explain our findings and discuss possible implications with 
you. 
 
What if there is a problem?  
The chance of something going wrong is small. All of the procedures involved in this study 
are low risk and our screening tests are designed to ensure that you will only participate if it 
is safe for you to do so. However, if you have any concerns at any time about any aspect of 
the way you have been approached or treated during the course of this study, you should 
ask to speak to the researchers who will do their best to answer your questions (contact 
details below), and the normal De Montfort University complaints mechanisms will be 
available to you. 
 
Will my taking part in the study be kept confidential? 
All information that is collected about you during the course of the research will be kept 
strictly confidential. Any information about you, which leaves the University, will have your 
name and address removed so that you cannot be recognised from it. 
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What will happen if I don’t want to carry on with the study? 
While we do not expect the programme to cause you to become upset if this does happen 
then you will have the option to pause or stop your participation immediately, you may 
continue only if you wanted to. If you withdraw from the study, we will destroy all your 
identifiable data, but may use the data collected up to your withdrawal.  
 
Who has reviewed the study? 
This study has been reviewed and approved by the Faculty of Health and Life Sciences 
Ethics Committee at De Montfort University. Approval does not guarantee that you will not 
come to any harm if you take part. However, approval means that the Committee is satisfied 
that your rights will be respected, that any risks have been reduced to a minimum and 
balanced against possible benefits and that you have been given sufficient information on 
which to make an informed decision. 
 
You will be given a copy of this information sheet and a signed consent form to keep 
for your records. 
 
Contact for Further Information 
Any questions about the procedures used in this study are encouraged. If you have any 
doubts or questions, please ask for further explanations by contacting 
Prof M Joan Taylor on 01162 506 317 or mjt@dmu.ac.uk, 
Dr Tarsem Sahota on 01162 506 220 or ssahota@dmu.ac.uk 
Exercise Physiology Laboratory HB1.29 Hawthorn Building Tel.No: 01162 506 220 
 
Thank you for taking the time to read this Volunteer Information Sheet 
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11.4 Appendix 4 (information sheet for ND) 
                                                    
Leicester School of Pharmacy 
Faculty of Health & Life Sciences 
                                                                                                        
 
Participant Information Sheet                                           Date:01/07/2017 
Title of Project: The Use of a Cardio and Resistance Exercise Programme to Assess 
Immunological and Physiological Parameters in Volunteers. 
 
Principal Investigators: Prof M J Taylor, Dr T Sahota, Dr P Tomlins, Dr R Furmonaviciene, 
Mr K Chauhan, Mr B Alharbi, Mrs N Alsubaie and Mr A Hill. 
  
We would like to invite you to take part in a research study. Before you decide you need to 
understand why the research is being done and what it would involve for you. Please take 
time to read the following information carefully. Talk to others about the study if you wish.  
 
Ask us if there is anything that is not clear or if you would like more information. Please take 
your time to decide whether or not you wish to take part. If you do wish to take part please 
complete the slip at the end of this sheet.  
 
What is the purpose of the study? 
As part of the growing research into Diabetes Mellitus the School of Pharmacy at De 
Montfort University are working to investigate the effects of a combined exercise programme 
(cardio and resistance) on blood glucose, metabolic and immunological parameters that 
could help you with the management of diabetes and increase your insulin sensitivity. 
 
This research involves a combination of two types of exercises and this is where we need 
your help. We would like to invite you to take part in this study which will help us to 
understand the role of exercise and how it can help people with diabetes to maintain a 
healthy body weight, to possibly manage your blood glucose level more effectively and 
increase insulin sensitivity. 
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We will keep your information strictly confidential and nobody other than the research team 
will have access to your personal information.  
 
Before any research goes ahead it has to be checked by De Montfort University Research 
Ethics Committee. They make sure that the research is fair.  
 
Why have I been invited? 
You have been invited to take part in the study as a volunteer who has no history of 
Diabetes Mellitus and are aged between 18 and 60. 
 
Do I have to take part? 
It is up to you to decide. We will answer any questions you have about the study and go 
through this information sheet. We will then ask you to sign a consent form to show you have 
agreed to take part. You are free to withdraw at any time, without giving a reason. This 
would not affect the standard of care you receive from your doctor or hospital. 
 
What will happen to me if I take part? 
Preliminary procedures 
Before enrolling in the study you will be asked to attend a screening visit where we will: 
 Discuss and complete confidential questionnaires regarding your health, family 
history and physical activity level. 
 Measure your blood pressure and heart rate. 
 Measure your height and weight  
 Provide an opportunity for you to ask questions. 
 Familiarise you with equipment to be used in the study and teach you how to use 
the recumbent ergometer bike and how to lift the weights safely on the multi-gym 
machine. 
 This session will also be used to determine the intensity of exercise during 
cycling on the recumbent ergometer bike using Heart Rate Reserve (HRR). Also, 
in this orientation session we will use predicted one repetition maximum (1RM) to 
determine how much weight for different muscles you should lift in the resistance 
exercise session later. 
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These preliminary procedures will enable us to determine whether you are suitable to safely 
participate in the study or not. 
 
Main experimental trials  
The main experimental trial will involve 2 x 2 hour exercise sessions a week for a 6 or 12 
week period, (exercise session includes rest and final observation of volunteer). We would 
conduct these trials over the duration of your degree study (3 years) so we can assess the 
impact of exercise over a longer period of time.  
Blood glucose levels will be monitored before, during and after each session, using a 
standard finger prick test.  In addition, Cholesterol, High density lipoprotein, low density 
lipoprotein and Triglyceride will be monitored before, and after each exercise programme 
using a finger prick test. 
Each exercise session will consist of a combined exercise protocol of 30 min of resistance 
exercise (3 sets of 8 -10 repetitions at 50 – 60% of predicted one-repetition maximum 
strength 1-RM ) using upper and lower muscle groups followed by 20 min moderate cycling 
at 50 – 60% of pre-determined heart rate reserve (HRR). Heart rate (HR) and rate of 
perceived exertion (RPE) will be taken in a different time points throughout the exercise trial. 
We will also perform an Oral Glucose Tolerance test to assess insulin sensitivity at the 
beginning and end of the programme and blood samples will be screened for other 
immunological parameters. If you are taking any statin medication then you may also be 
asked to provide urine samples for analysis in a parallel study. We may also ask you to 
provide a saliva sample for a further study which assesses microbes present in saliva. 
 
Incentives 
We would like to offer an incentive of a subsidised gym membership at the De Montfort 
University’s QEII Leisure Centre on completion of 100% of the dates agreed. This is a thank 
you for your participation but also to help you maintain the healthy exercise regimen until the 
following year’s assessment. 
 
 
What are the possible benefits of taking part? 
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As a result of being involved in this study you will receive health and fitness information 
about yourself including fitness tests and body measurement. You may also witness a 
decrease in your Hba1c levels and an increase in your insulin sensitivity as well as other 
general improvements to your health. 
 
The findings of this study will be published in scientific journals so that understanding about 
how exercise can help people with diabetes to improve their health and control their weight 
and blood glucose levels. This information may contribute towards improved exercise 
guidelines for the diabetic patients. 
 
We will provide you with feedback about the main study findings and also about your own 
results and would be delighted to explain our findings and discuss possible implications with 
you. 
 
What if there is a problem?  
The chance of something going wrong is small. All of the procedures involved in this study 
are low risk and our screening tests are designed to ensure that you will only participate if it 
is safe for you to do so. However, if you have any concerns at any time about any aspect of 
the way you have been approached or treated during the course of this study, you should 
ask to speak to the researchers who will do their best to answer your questions (contact 
details below), and the normal De Montfort University complaints mechanisms will be 
available to you. 
 
Will my taking part in the study be kept confidential? 
All information that is collected about you during the course of the research will be kept 
strictly confidential. Any information about you, which leaves the University, will have your 
name and address removed so that you cannot be recognised from it. 
 
What will happen if I don’t want to carry on with the study? 
While we do not expect the programme to cause you to become upset if this does happen 
then you will have the option to pause or stop your participation immediately, you may 
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continue only if you wanted to. If you withdraw from the study, we will destroy all your 
identifiable data, but may use the data collected up to your withdrawal.  
 
Who has reviewed the study? 
 
This study has been reviewed and approved by the Faculty of Health and Life Sciences 
Ethics Committee at De Montfort University. Approval does not guarantee that you will not 
come to any harm if you take part. However, approval means that the Committee is satisfied 
that your rights will be respected, that any risks have been reduced to a minimum and 
balanced against possible benefits and that you have been given sufficient information on 
which to make an informed decision. 
 
You will be given a copy of this information sheet and a signed consent form to keep 
for your records. 
 
Contact for Further Information 
Any questions about the procedures used in this study are encouraged. If you have any 
doubts or questions, please ask for further explanations by contacting 
Prof M Joan Taylor on 01162 506 317 or mjt@dmu.ac.uk, 
Dr Tarsem Sahota on 01162 506 220 or ssahota@dmu.ac.uk 
Exercise Physiology Laboratory HB1.29 Hawthorn Building Tel.No: 01162 506 220 
 
Thank you for taking the time to read this Volunteer Information Sheet 
 
 
 
